

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number

WO 2017/199036 A1

(43) International Publication Date
23 November 2017 (23.11.2017)

(51) International Patent Classification:
C07J 9/00 (2006.01) *C07J 71/00* (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/GB2017/051389

(22) International Filing Date:
18 May 2017 (18.05.2017)

Published:

— with international search report (Art. 21(3))

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
1608776.9 18 May 2016 (18.05.2016) GB

(71) Applicant: NZP UK LIMITED [GB/GB]; Science and Technology Centre, Earley Gate, Whiteknights Road, Reading Berkshire RG6 6BZ (GB).


(72) Inventors: WEYMOUTH-WILSON, Alexander Charles; c/o Dextra Laboratories Ltd, Science and Technology Centre, Earley Gate, Whiteknights Road, Reading, Berkshire RG6 6BZ (GB). KOMSTA, Zofia; c/o Dextra Laboratories Ltd, Science and Technology Centre, Earley Gate, Whiteknights Road, Reading, Berkshire RG6 6BZ (GB). WALLIS, Laura; c/o Dextra Laboratories Ltd, Science and Technology Centre, Earley Gate, Whiteknights Road, Reading, Berkshire RG6 6BZ (GB). EVANS, Timothy; c/o Dextra Laboratories Ltd, Science and Technology Centre, Earley Gate, Whiteknights Road, Reading, Berkshire RG6 6BZ (GB).

(74) Agent: O'KANE, Jessica et al.; Sagittarius IP, Three Globeside, Fieldhouse Lane, Marlow, Buckinghamshire SL7 1HZ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: PROCESS AND INTERMEDIATES FOR THE 6,7-ALPHA-EPOXIDATION OF STEROID 4,6-DIENES



(57) Abstract: The invention relates to a process for preparing a compound of general formula (Ia): wherein R², Y, R⁴ and R⁵ are as defined herein, wherein the epoxidation is conducted using an oxidant and methyltrioxorhenium as a catalyst (MeReO₃). The invention also relates to certain compounds *per se*. The compounds are intermediates in the synthesis of synthetic bile acids.

WO 2017/199036 A1

METHODS AND COMPOUNDS

Field of the invention


5 The present invention relates to methods of preparing compounds which are intermediates in the synthesis of bile acid derivatives with pharmacological activity. In particular, the invention relates to methods of preparing intermediates in the synthesis of obeticholic acid and its analogues. The invention further relates to novel intermediates *per se*.

10 Background of the invention

Bile acids are steroid acids which are found in the bile of mammals and include compounds such as cholic acid, chenodeoxycholic acid, lithocholic acid and deoxycholic acid, all of which are found in humans. Many bile acids are natural ligands of the farnesoid X receptor

15 (FXR) which is expressed in the liver and intestine of mammals, including humans.

Bile acids are derivatives of steroids and are numbered in the same way. The following shows the general numbering system for steroids and the numbering of the carbon atoms in chenodeoxycholic acid.



20

Agonists of FXR have been found to be of use in the treatment of cholestatic liver disorders including primary biliary cholangitis and non-alcoholic steatohepatitis (see review by Jonker *et al.*, in *Journal of Steroid Biochemistry & Molecular Biology*, 2012, 130, 147-158;

25 incorporated herein by reference).

Ursodeoxycholic acid (UDCA), a bile acid originally isolated from the gall bladder of bears, is currently used in the treatment of cholestatic liver disorders, although it appears to be inactive at the FXR.

30

As well as their action at the FXR, bile acids and their derivatives are also modulators of the G protein-coupled receptor TGR5. This is a member of the rhodopsin-like superfamily of G-protein coupled receptors and has an important role in the bile acid signalling network, which complements the role of the FXR.

5

Because of the importance of FXR and TGR5 agonists in the treatment of cholestatic liver disorders, efforts have been made to develop new compounds which have agonist activity at these receptors. One particularly active compound is obeticholic acid, which is a potent agonist of both FXR and TGR5. Obeticholic acid is described in WO02/072598 and 10 EP1568706 (both incorporated herein by reference), both of which describe a process for the preparation of obeticholic acid from 7-keto lithocholic acid, which is derived from cholic acid. Further processes for the production of obeticholic acid and its derivatives are described in WO2006/122977, US2009/0062256 and WO2013/192097 (all incorporated herein by reference) and all of these processes also start from 7-keto lithocholic acid.

15

It is clear from the number of patent publications directed to processes for the production of obeticholic acid that it is by no means simple to synthesise this compound and indeed the process which is currently used starts from cholic acid, has 12 steps and a low overall yield.

20


In addition to the inefficiency and high cost of this process, there are also problems with the cost and availability of the starting materials. Cholic acid, the current starting material for the production of obeticholic acid, is a natural bile acid which is usually obtained from the slaughter of cows and other animals. This means that the availability of cholic acid and 25 other bile acids is limited by the number of cattle available for slaughter. Since the incidence of cholestatic liver disease is increasing worldwide, the demand for synthetic bile acids such as obeticholic acid is also likely to increase and it is doubtful whether the supply of naturally derived bile acids will continue to be sufficient to meet demand.

30 Furthermore, the use of a starting material derived from animals means that there is the possibility of the contamination of the material with infectious agents such as viruses or prions, which can not only be hazardous to workers but could potentially contaminate the end products if steps are not taken to prevent this.

35 Although some patients with cholestatic liver disease can be treated with ursodeoxycholic acid, this is also a natural bile acid and faces the same problems of limited availability and

high cost.

In an attempt to solve the problems associated with the use of bile acids as starting materials, the present inventors have devised a process for the synthesis of synthetic bile acid derivatives, such as obeticholic acid (OCA, referred to herein as compound (XVIIIA)), which uses plant sterols as starting materials.



obeticholic acid (XVIIIA)

The inventors have developed a process for the production of synthetic bile acids which proceeds *via* novel intermediates and which provides the final product in significantly higher yield than current processes. The process is flexible and can use a variety of different starting materials including animal, fungal and plant sterols.


Suitable animal sterols which can be used as starting materials include deoxycholic acid, cholic acid, while fungal sterols include ergosterol.

Plant sterols are widely available at significantly lower cost than bile acids and, indeed, are often waste products of other processes. Suitable plant sterol and plant sterol derivatives which can be used as starting materials include 3-keto-bis-norcholenol (also known as 20-hydroxymethylpregn-4-en-3-one), androstenedione, androstadienedione, dehydroepiandrosterone, stigmasterol, brassicasterol, campesterol and β -sitosterol.

Our patent applications Nos. PCT/GB2015/053516 (WO2016/079517),
PCT/GB2015/053517 (WO2016/079518), PCT/GB2015/053518 (WO2016/079519) and
25 PCT/GB2015/053519 (WO2016/079520) (all incorporated herein by reference) relate to
intermediates in the process of synthesizing obeticholic acid (and analogues) as well as to
processes for preparing the intermediates and processes for converting them to the
desired products.

30 Summary of the invention

In a first aspect, the present invention provides a process for preparing a compound of general formula (Ia):



or a salt or isotopic variant thereof

5 wherein:

R^2 is H, halo, OH or a protected OH group;

Y is a bond, or a C_{1-20} alkylene, C_{2-20} alkenylene or C_{2-20} alkynylene linker group any of which is optionally substituted with one or more R^3 ;

wherein each R^3 is independently H, halo, OH, a protected OH group or NR^8R^9 ;

10 wherein each of R^8 and R^9 is independently H, C_{1-6} alkyl, $C(O)Ph$, benzyl, phthalimide, *tert*-butyloxycarbonyl or carboxybenzyl;

R^4 is $C(O)OR^{10}$, $OC(O)R^{10}$, $C(O)NR^{10}R^{11}$, OR^{10} , $OSi(R^{13})_3$, $S(O)R^{10}$, SO_2R^{10} , OSO_2R^{10} , SO_3R^{10} , OSO_3R^{10} , halo, CN, $C(O)R^{10}$, $NR^{10}R^{11}$, $BR^{10}R^{11}$, $C(O)CH_2N_2$, $-CH=CH_2$, $-C\equiv CH$, $CH[C(O)OR^{10}]_2$, $CH(BR^{10}R^{11})_2$, azide, NO_2 , $NR^{10}C(O)NR^{10}SO_2R^{11}$, $NR^{10}C(O)NR^{10}SO_2N$

15 $R^{10}R^{11}$, $NR^{10}SO_2R^{11}$, $C(O)NR^{10}SO_2R^{11}$, $CH(XR^{10})(XR^{11})$, $CH(R^{10})(XR^{11})$, phthalimide or a carboxylic acid mimetic group such as tetrazole;

wherein each X is independently O, S or NR^8 ;

wherein each R^{10} and R^{11} is independently:

a. hydrogen;

20 or

b. C_{1-20} alkyl, C_{3-7} cycloalkyl, C_{2-20} alkenyl or C_{2-20} alkynyl, any of which is optionally substituted with one or more substituents selected from:

C_{1-4} alkyl, C_{1-4} haloalkyl, halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$,

$C(O)N(R^{19})_2$, SO_2R^{19} , OSO_2R^{19} , SO_3R^{19} , OSO_3R^{19} , $N(R^{19})_2$ and a 6-

25 to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C_{1-6} alkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} and $N(R^{19})_2$;

or

30 c. a 6- to 14- membered aryl, 5- to 14-membered heteroaryl group or 3- to 10-membered heterocyclic ring, any of which is optionally substituted with one or more substituents selected from:

C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , $C=O$,

C(O)C₁₋₄alkyl, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹, N(R¹⁹)₂, phenyl, 5- to 14-membered heteroaryl, 3- to 10-membered heterocyclic ring, methylenedioxy and ethylenedioxy;

or

- 5 d. a polyethylene glycol residue;

or

- e. when R⁴ is C(O)NR¹⁰R¹¹, CH(XR¹⁰)(XR¹¹), CH(R¹⁰)(XR¹¹), NR¹⁰R¹¹, BR¹⁰R¹¹, CH[C(O)OR¹⁰]₂ or CH(BR¹⁰R¹¹)₂ an R¹⁰ and an R¹¹ group, together with the atom or atoms to which they are attached, may combine

10 to form a 3 to 10-membered heterocyclic ring;

wherein each R¹⁹ is independently:

H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from halo, C₁₋₆ alkyl and C₁₋₆ haloalkyl;

15

and wherein each R¹³ is independently:

- a. C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl or C₂₋₂₀ alkynyl, any of which is optionally substituted with one or more substituents selected from:

halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

or

25

- b. a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from:

C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

wherein each R¹⁹ is independently:

30

H, C₁₋₆ alkyl or C₁₋₆ haloalkyl; or


Y and R⁴ together form a =CH₂ group; and

R⁵ is H, OH or a protected OH group;

the process comprising:

35


oxidation of a compound of general formula (IIa) using an oxidant and methyltrioxorhenium as catalyst:



or a salt or isotopic variant thereof

wherein R², R⁴, R⁵ and Y are as defined for compounds of general formula (Ia).

- 5 In a second aspect, the present invention provides a process for preparing a compound of general formula (I):



or a salt or isotopic variant thereof

wherein:

- 10 R² is H, halo, OH or a protected OH group;
 Y is a bond, or a C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene linker group any of which is optionally substituted with one or more R³;

wherein each R³ is independently halo, OR⁸ or NR⁸R⁹;

wherein each of R⁸ and R⁹ is independently H or C₁₋₄ alkyl;

- 15 R⁴ is C(O)OR¹⁰, OC(O)R¹⁰, C(O)NR¹⁰R¹¹, OR¹⁰, OSi(R¹³)₃, S(O)R¹⁰, SO₂R¹⁰, OSO₂R¹⁰, SO₃R¹⁰, OSO₃R¹⁰, halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹), CH(R¹⁰)(OR¹¹), CH(SR¹⁰)(SR¹¹), NR¹⁰R¹¹, BR¹⁰R¹¹, C(O)CH₂N₂, -CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, CH(BR¹⁰R¹¹)₂, azide or a carboxylic acid mimetic group such as tetrazole;

wherein each R¹⁰ and R¹¹ is independently:

- 20 b. hydrogen;
 or
 b. C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl or C₂₋₂₀ alkynyl, any of which is optionally substituted with one or more substituents selected from:

halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹,

- 25 SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

or

- c. a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from:

C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹,

5 C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

or

- d. a polyethylene glycol residue;

or

- e. when R⁴ is C(O)NR¹⁰R¹¹, CH(OR¹⁰)(OR¹¹), CH(R¹⁰)(OR¹¹),
10 CH(SR¹⁰)(SR¹¹), NR¹⁰R¹¹, BR¹⁰R¹¹, CH[C(O)OR¹⁰]₂ or CH(BR¹⁰R¹¹)₂ an R¹⁰ and an R¹¹ group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring; wherein each R¹⁹ is independently:

H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from halo, C₁₋₆ alkyl and C₁₋₆ haloalkyl;

and wherein each R¹³ is independently:

- a. C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl or C₂₋₂₀ alkynyl, any of which is optionally substituted with one or more substituents selected from:

halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

25 or

- b. a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from:

C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹,

30 C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

wherein each R¹⁹ is independently:

H, C₁₋₆ alkyl or C₁₋₆ haloalkyl; or

Y and R⁴ together form a =CH₂ group; and


R⁵ is H, OH or a protected OH group;

35

the process comprising:

oxidation of a compound of general formula (II) using an oxidant and methyltrioxorhenium

as catalyst:



or a salt or isotopic variant thereof


wherein R², R⁴, R⁵ and Y are as defined for compounds of general formula (I).

5

Compounds of general formulae (Ia), (I), (IIa) and (II) are intermediates in the synthesis of pharmaceutically active compounds such as obeticholic acid and its derivatives.

In a third aspect, the present invention provides a process for the preparation of a

10 compound of general formula (XVIIIa):



wherein R¹ is C₁₋₄ alkyl, C₂₋₄ alkenyl or C₂₋₄ alkynyl optionally substituted with one or more substituents selected from halo, OR⁶ and NR⁶R⁷;

wherein each of R⁶ and R⁷ is independently H or C₁₋₄ alkyl;

15 R² is H, halo or OH;

R^{5a} is H or OH; and


Y¹ is a bond, or a C₁₋₂₀ alkylene linker group which is optionally substituted with one or more R³;

or Y¹ and R⁴ together form a =CH₂ group;

20 wherein R³ and R⁴ are as defined for compounds of general formula (Ia);


the process comprising:

i. preparing a compound of general formula (Ia):



25 wherein Y, R², R⁴ and R⁵ are as defined in the first aspect of the invention;


by oxidation of a compound of general formula (IIa) using an oxidant and methyltrioxorhenium as catalyst:



wherein Y, R², R⁴ and R⁵ are as defined for compounds of general formula (Ia);

5


ii. selective alkylation of a compound of general formula (Ia) with an organometallic reagent to give a compound of general formula (XIXa):



wherein R¹ is as defined for compounds of general formula (XVIIia) and Y, R², R⁴ and R⁵


10 are as defined for compounds of general formula (Ia);

iii. reducing a compound of formula (XIXa) using a suitable reducing agent to give a compound of general formula (XXa):




15 wherein R¹ and Y¹ are as defined for compounds of general formula (XVIIia) and R², R⁴ and R⁵ are as defined for compounds of general formula (Ia);

iv. oxidising the compound of general formula (XXa) using a suitable oxidizing agent to give a compound of general formula (XXIa):



20 wherein R¹ and Y¹ are as defined for compounds of general formula (XVIIia) and R², R⁴ and R⁵ are as defined for compounds of general formula (Ia);


v. epimerisation of the compound of general formula (XXIa) to give a compound of general formula (XXIIa):



- 5 wherein R¹ and Y¹ are as defined for compounds of general formula (XVIIia) and R⁴ is as defined for compounds of general formula (Ia);
 R² is H or OH or a protected OH group which is stable under basic conditions; and
 R^{5b} is H or OH or a protected OH group which is stable under basic conditions; and
- 10 (vi) reduction of the compound of general formula (XXIIa) using a suitable reducing agent and, where R² and/or R^{5b} is a protected OH, removal of the protecting group(s), to give a compound of general formula (XVIIia) as defined above, wherein removal of the protecting group can take place before or after the reduction;
- 15 wherein the process further includes one or more optional steps of converting compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) and (XVIIia) to other compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) and (XVIIia).

20 The optional steps consist of reacting the side chains of the compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) and (XVIIia) as described below to arrive at compounds with alternative Y and/or R⁴ moieties.

In a fourth aspect, the present invention provides a process for the preparation of a compound of general formula (XVIII):



- 25 wherein R¹ is C₁₋₄ alkyl optionally substituted with one or more substituents selected from halo, OR⁶ and NR⁶R⁷;
 wherein each of R⁶ and R⁷ is independently H or C₁₋₄ alkyl;
 R² is H, halo or OH;

R^{5a} is H or OH; and


Y^1 is a bond, or a C_{1-20} alkylene linker group which is optionally substituted with one or more R^3 ;

or Y^1 and R^4 together form a $=CH_2$ group;

5 wherein R^3 and R^4 are as defined for compounds of general formula (I);


the process comprising:

i. preparing a compound of general formula (I):




10 wherein Y , R^2 , R^4 and R^5 are as defined in the first aspect of the invention;

by oxidation of a compound of general formula (II) using an oxidant and methyltrioxorhenium as catalyst:




15 wherein Y , R^2 , R^4 and R^5 are as defined for compounds of general formula (I);

ii. selective alkylation of a compound of general formula (I) with an organometallic reagent to give a compound of general formula (XIX):




20 wherein R^1 is as defined for compounds of general formula (XVIII) and Y , R^2 , R^4 and R^5 are as defined for compounds of general formula (I);

iii. reducing a compound of formula (XIX) using a suitable reducing agent to give a compound of general formula (XX):



wherein R¹ and Y¹ are as defined for compounds of general formula (XVIII) and R², R⁴ and R⁵ are as defined for compounds of general formula (I);


- 5 iv. oxidising the compound of general formula (XX) using a suitable oxidizing agent to give a compound of general formula (XXI):



wherein R¹ and Y¹ are as defined for compounds of general formula (XVIII) and R², R⁴ and R⁵ are as defined for compounds of general formula (I);

10

- v. epimerisation of the compound of general formula (XXI) to give a compound of general formula (XXII):



wherein R¹ and Y¹ are as defined for compounds of general formula (XVIII) and R⁴ is as defined for compounds of general formula (I);

R² is H or OH or a protected OH group which is stable under basic conditions; and

R^{5b} is H or OH or a protected OH group which is stable under basic conditions; and

- 20 (vi) reduction of the compound of general formula (XXII) using a suitable reducing agent and, where R² and/or R^{5b} is a protected OH, removal of the protecting group(s), to give a compound of general formula (XVIII) as defined above, wherein removal of the protecting group can take place before or after the reduction;

25 wherein the process further includes one or more optional steps of converting compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) and (XVIII) to other compounds of general

formulae (I), (XIX), (XX), (XXI), (XXII) and (XVIII).

The optional steps consist of reacting the side chains of the compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) and (XVIII) as described below to arrive at 5 compounds with alternative Y and/or R⁴ moieties.

Figures

Figure 1: shows the conversion of a compound of general formula (IIa) or of general 10 formula (II) in which the side chain is -CH₂OH to other compounds of general formula (IIa) or of general formula (II), respectively, with different side chains.

Figure 2: shows the single crystal structure of (6 α , 7 α , 22E)-6,7-epoxy-3-oxo-4,22- 15 choladien-24-oic acid ethyl ester (IA) (Thermal ellipsoids drawn at the 50% probability level, see Example 10).

Detailed description of the invention

In the present specification, except where the context requires otherwise due to express 20 language or necessary implication, the word "comprises", or variations such as "comprises" or "comprising" is used in an inclusive sense i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

25 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

30 In the present application the term "C₁₋₂₀" alkyl refers to a straight or branched fully saturated hydrocarbon group having from 1 to 20 carbon atoms. The term encompasses methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl and t-butyl. Other alkyl groups, for example C₁₋₁₂ alkyl, C₁₋₁₀ alkyl, C₁₋₈ alkyl, C₁₋₆ alkyl, C₁₋₅ alkyl, C₁₋₄ alkyl, C₁₋₃ alkyl, or C₁₋₂ alkyl are as defined above but contain different numbers of carbon atoms.

35

The terms "heterocyclic" and "heterocycl" refer to a non-aromatic cyclic group having 3

to 10 ring atoms and at least one heteroatom selected from N, O, S and B and optionally substituted with one or more =O moieties. Examples of heterocyclic groups include pyrrolidine, piperidine, morpholine, piperazine, tetrahydrofuran, dioxolane (e.g. 1,3-dioxolane), dioxane (e.g. 1,3-dioxane) and cyclic thioethers. The term also includes 5 bicyclic and bridged groups such as 9-borabicyclo(3.3.1)nonane (9-BBN).

The term "halogen" refers to fluorine, chlorine, bromine or iodine and the term "halo" to fluoro, chloro, bromo or iodo groups.

10 The term "C₁₋₆ haloalkyl" refers to a straight or branched alkyl group as defined above having from 1 to 6 carbon atoms and substituted with one or more halo atoms, up to perhalo substitution. Examples include trifluoromethyl, chloroethyl and 1,1-difluoroethyl. Other haloalkyl groups, for example C₁₋₅ haloalkyl, C₁₋₄ haloalkyl, C₁₋₃ haloalkyl or C₁₋₂ haloalkyl are as defined above but contain different numbers of carbon atoms.

15 The term "C₂₋₂₀ alkenyl" refers to a straight or branched hydrocarbon group having from 2 to 20 carbon atoms and at least one carbon-carbon double bond. Examples include ethenyl (vinyl), prop-1-enyl, prop-2-enyl (allyl), hex-2-enyl etc. Other alkenyl groups, for example C₂₋₁₂ alkenyl, C₂₋₁₀ alkenyl, C₂₋₈ alkenyl, C₂₋₆ alkenyl, C₂₋₅ alkenyl, C₂₋₄ alkenyl or 20 C₂₋₃ alkenyl are as defined above but contain different numbers of carbon atoms.

The term "C₂₋₂₀ alkynyl" refers to a straight or branched hydrocarbon group having from 2 to 20 carbon atoms and at least one carbon-carbon triple bond. Examples include ethynyl, prop-1-ynyl, hex-2-ynyl etc. Other alkynyl groups, for example C₂₋₁₂ alkynyl, C₂₋₁₀ alkynyl, 25 C₂₋₈ alkynyl, C₂₋₆ alkynyl, C₂₋₅ alkynyl, C₂₋₄ alkynyl or C₂₋₃ alkynyl are as defined above but contain different numbers of carbon atoms.

The term "alkylene" refers to a straight or branched fully saturated hydrocarbon chain. Suitably alkylene is C₁₋₂₀ alkylene, C₁₋₁₂ alkylene, C₁₋₁₀ alkylene, C₁₋₈ alkylene, C₁₋₆ 30 alkylene, C₁₋₅ alkylene, C₁₋₄ alkylene, C₁₋₃ alkylene, or C₁₋₂ alkylene. Examples of alkylene groups include -CH₂-, -CH₂CH₂-, -CH(CH₃)-CH₂-, -CH₂CH(CH₃)-, -CH₂CH₂CH₂-, -CH₂CH(CH₂CH₃)- and -CH₂CH(CH₂CH₃)CH₂-.

The term "alkenylene" refers to a straight or branched hydrocarbon chain containing at 35 least one carbon-carbon double bond. Suitably alkenylene is C₂₋₂₀ alkenylene, C₂₋₁₂ alkenylene, C₂₋₁₀ alkenylene, C₂₋₈ alkenylene, C₂₋₆ alkenylene, C₂₋₅ alkenylene, C₂₋₄ alkenylene, or C₂₋₃ alkenylene. Examples of alkenylene groups include

-CH=CH-, -CH=C(CH₃)-, -CH₂CH=CH-, -CH=CHCH₂-, -CH₂CH₂CH=CH-,
-CH₂CH=C(CH₃)- and -CH₂CH=C(CH₂CH₃)-.

The term “C₂₋₂₀ alkynyl” refers to a straight or branched hydrocarbon group having from 2

5 to 20 carbon atoms and at least one carbon-carbon triple bond. Examples include ethynyl, prop-1-ynyl, hex-2-ynyl etc. Other alkynyl groups, for example C₂₋₁₂ alkynyl, C₂₋₁₀ alkynyl, C₂₋₈ alkynyl, C₂₋₆ alkynyl, C₂₋₅ alkynyl, C₂₋₄ alkynyl or C₂₋₃ alkynyl are as defined above but contain different numbers of carbon atoms.

10 The term “alkyl” refers to a straight or branched fully saturated hydrocarbon chain. Suitably alkylene is C₁₋₂₀ alkyl, C₁₋₁₂ alkyl, C₁₋₁₀ alkyl, C₁₋₈ alkyl, C₁₋₆ alkyl, C₁₋₅ alkyl, C₁₋₄ alkyl, C₁₋₃ alkyl, or C₁₋₂ alkyl. Examples of alkyl groups include -CH₃, -CH₂CH₃, -CH(CH₃)-CH₃, -CH₂CH₂CH₃, -C(CH₃)₃ and -CH₂CH₂CH₂CH₃.

15 The term “alkenyl” refers to a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond. Suitably alkenyl is C₂₋₂₀ alkenyl, C₂₋₁₂ alkenyl, C₂₋₁₀ alkenyl, C₂₋₈ alkenyl, C₂₋₆ alkenyl, C₂₋₅ alkenyl, C₂₋₄ alkenyl, or C₂₋₃ alkenyl. Examples of alkenyl groups include -CH=CH₂, -CH=CH(CH₃), -CH₂CH=CH₂, -CH=CHCH₃, -CH₂CH₂CH=CH₂, -CH₂CH=CH(CH₃)- and -CH₂CH=CH(CH₂CH₃).

20 The term “alkynylene” refers to a straight or branched hydrocarbon chain containing at least one carbon-carbon triple bond. Suitably alkynylene is C₂₋₂₀ alkynylene, C₂₋₁₂ alkynylene, C₂₋₁₀ alkynylene, C₂₋₈ alkynylene, C₂₋₆ alkynylene, C₂₋₅ alkynylene, C₂₋₄ alkynylene, or C₂₋₃ alkynylene. Examples of alkynylene groups include -C≡C-, -CH₂C≡C-, -C≡C-CH₂-, -CH₂CH₂C≡C-, -CH₂C≡CCH₂- and -CH₂C≡C-CH₂CH₂-.

25 The terms “aryl” and “aromatic” refer to a cyclic group with aromatic character having from 6 to 14 ring carbon atoms (unless otherwise specified, for example 6 to 10 ring carbon atoms) and containing up to three rings. Where an aryl group contains more than one ring, not all rings must be aromatic in character. Examples include phenyl, naphthyl and anthracenyl as well as partially saturated systems such as tetrahydronaphthyl, indanyl and indenyl. A further example of an aryl group is 1,2,3,4-tetrahydronaphthalene.

30 The terms “heteroaryl” and “heteroaromatic” refer to a cyclic group with aromatic character having from 5 to 14 ring atoms (unless otherwise specified, for example 5 to 10 ring atoms), at least one of which is a heteroatom selected from N, O and S, and containing up to three rings. Where a heteroaryl group contains more than one ring, not all rings must be aromatic

in character. Examples of heteroaryl groups include pyridine, pyrimidine, indole, benzofuran, benzimidazole and indolene. Further examples of heteroaryl groups include quinoline and isoquinoline.

5 The term “isotopic variant” refers to isotopically-labelled compounds which are identical to those recited in formula (Ia) or formula (I) but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature, or in which the proportion of an atom having an atomic mass or mass number found less commonly in nature has been
10 increased (the latter concept being referred to as “isotopic enrichment”). Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, iodine and chlorine such as ^2H (deuterium), ^3H , ^{11}C , ^{13}C , ^{14}C , ^{18}F , ^{123}I or ^{125}I (e.g. ^3H , ^{11}C , ^{14}C , ^{18}F , ^{123}I or ^{125}I), which may be naturally occurring or non-naturally occurring isotopes.

15

Polyethylene glycol (PEG) is a polyether compound, which in linear form has general formula $\text{H}-[\text{O}-\text{CH}_2-\text{CH}_2]_n-\text{OH}$. A polyethylene glycol residue is a PEG in which the terminal H is replaced by a bond linking it to the remainder of the molecule.

20 Branched versions, including hyperbranched and dendritic versions are also contemplated and are generally known in the art. Typically, a branched polymer has a central branch core moiety and a plurality of linear polymer chains linked to the central branch core. PEG is commonly used in branched forms that can be prepared by addition of ethylene oxide to various polyols, such as glycerol, glycerol oligomers, pentaerythritol and sorbitol. The
25 central branch moiety can also be derived from several amino acids, such as lysine. The branched poly (ethylene glycol) can be represented in general form as $\text{R}(-\text{PEG-OH})_m$ in which R is derived from a core moiety, such as glycerol, glycerol oligomers, or pentaerythritol, and m represents the number of arms. Multi-armed PEG molecules, such as those described in US5,932,462; US5,643,575; US5,229,490; US4,289,872;
30 US2003/0143596; WO96/21469; and WO93/21259 (all incorporated herein by reference) may also be used.

The PEG polymers may have an average molecular weight of, for example, 600-2,000,000 Da, 60,000-2,000,000 Da, 40,000-2,000,000 Da, 400,000-1,600,000 Da, 800-1,200,000 Da, 600-40,000 Da, 600-20,000 Da, 4,000-16,000 Da, or 8,000-12,000 Da.

The term “protected OH” relates to an OH group protected with any suitable protecting

group. For example, the protected OH may be a group R⁴ as defined above.

Suitable protecting groups include esters such that, for example when R² and/or R⁵ and/or R³ is a protected OH group, R² and/or R⁵ and/or R³ may independently be a group 5 OC(O)R¹⁴, where R¹⁴ is a group R¹⁰ as defined above. Silyl ethers are also suitable, and in this case, R² and/or R⁵ and/or R³ may independently be a group OSi(R¹⁶)₃, where each R¹⁶ is independently a group R¹³ as defined above.

Other suitable protecting groups for OH are well known to those of skill in the art (see

10 Wuts, PGM and Greene, TW (2006) "Greene's Protective Groups in Organic Synthesis", 4th Edition, John Wiley & Sons, Inc., Hoboken, NJ, USA, incorporated herein by reference).

Salts of the compounds of general formula (XVIIia) and (XVIII) are suitably pharmaceutically or veterinarilly acceptable salts. Salts which are not pharmaceutically or

15 veterinarilly acceptable may still be valuable as intermediates.

References to a protecting group which is stable in basic conditions mean that the protecting group cannot be removed by treatment with a base.

20 Appropriate salts of the compounds described herein include basic addition salts such as sodium, potassium, calcium, aluminium, zinc, magnesium and other metal salts as well as choline, diethanolamine, ethanolamine, ethyl diamine, meglumine and other well-known basic addition salts as summarised in Paulekuhn *et al.*, *J. Med. Chem.* **2007**, *50*, 6665-6672 (incorporated herein by reference) and/or known to those skilled in the art.

25 The term "carboxylic acid mimetic group" relates to known carboxylic acid isosteres including tetrazole, substituted tetrazole, -SO₂-NHR¹⁰, C(O)NH-SO₂R¹⁰ and NHC(O)NH-SO₂R¹⁰;

wherein R¹⁰ is as above defined for a compound of general formulae (Ia) or (I) and is 30 suitably H, C₁₋₆ alkyl, C₃₋₇ cycloalkyl or 6- to 14- membered aryl (e.g. phenyl).

Tetrazole groups include tetrazole-5-yl and tetrazole-1-yl. Substituted tetrazole includes tetrazole substituted with C₁₋₄ alkyl, halo, OH, O(C₁₋₄ alkyl), SO₂R¹⁰ (e.g. SO₂(C₁₋₄ alkyl), SO₂-phenyl or SO₂-tolyl).

35 Such carboxylic acid mimetic groups are well known in the art and are discussed, for example in "On Medicinal Chemistry"; M Stocks, L Alcaraz, E Griffen; Pub: Sci-ink Ltd

(April 2007).


Particularly suitable carboxylic acid mimetic groups include tetrazole, C(O)NH-SO₂R¹⁰ and NHC(O)NH-SO₂R¹⁰, with tetrazole being particularly suitable.

5

The epoxidation of (22E)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester (referred to herein as compound (IIA)) to form (6 α ,7 β , 22E)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester (referred to herein as compound (IA)) is described by Uekawa *et al.* in *Biosci. Biotechnol. Biochem.*, **2004**, 68, 1332-1337 (incorporated herein by reference) using either magnesium monoperoxyphthalate hydrate (MMPP) in Et₂O and CHCl₃ at ambient temperature, or *meta*-chloroperoxybenzoic acid (*m*CPBA) in CHCl₃ at reflux (Scheme 1). The reactions were performed on 19.8 mg and 200 mg scale and yields of 59.6% and 55.0% respectively were reported.

10

15 Scheme 1



When both sets of epoxidation conditions were repeated by the present inventors, conversions of 50-60 % were observed. Purified compound (IA) was isolated in yields of up to around 50 %. For both sets of conditions degradation and the formation of side products was observed during the reaction process. This was attributed to opening of the epoxide, and complex over-oxidation side reactions and/or a competing Baeyer Villager oxidation. As such, neither of the methods proposed by Uekawa *et al.* are suitable for large scale synthesis of compound (IA).

20


Furthermore, the reaction conditions described by Uekawa *et al.* require purification by preparative thin layer chromatography and column chromatography, and utilise chloroform and diethyl ether as solvent, again rendering the processes unsuitable for large scale synthesis and manufacture.

30

Regarding the observed degradation and formation of side products, the formation of compounds other than compound (IA) are not unexpected. Epoxidation at the 6,7-position of compound (IIA) must occur to form compound (IA). However, compound (IA) contains two additional double bonds at the 4,5- and 22,23-positions which are also susceptible to oxidation. Furthermore, each double bond has the potential to be oxidised on the *alpha*-

or *beta*-face of the molecule, and a single molecule may be oxidised at multiple sites. The isolated products and possible epoxides are shown in Scheme 2.

Scheme 2



5

A similar issue arises with the epoxidation of 3-oxo-4,6-choladien-24-oic acid ethyl ester (referred to herein as compound (IIB)) to form (6*a*, 7*a*)-6,7-epoxy-3-oxo-4-choladien-24-oic acid ethyl ester (referred to herein as compound (IB)).

- 10 Another consideration to be taken into account for both (IA) and (IB) is that under certain conditions e.g. acidic conditions, the epoxide product can undergo further reactions such as ring-opening and possibly polymerization, once formed.

Thus, it is an object of the present invention to provide an improved process for the 15 epoxidation of compounds of general formula (IIa) and of compounds of general formula (II), in particular an improved process for the epoxidation of a compound of formula (IIA) or formula (IIB) to form a compound of general formula (IA) or (IB), respectively. Suitably the process is regioselective and stereoselective, thereby providing higher yields of the desired epoxide. In addition, the process is suitably scalable, meaning that it is suitable for 20 use on a large scale, e.g. on an industrial scale.


As described in Example 9, the present inventors evaluated a number of alternative epoxidation conditions and found that, surprisingly, the use of an oxidant in the presence

of methyltrioxorhenium (MTO) as catalyst provided improved yields of the desired alpha epoxide compared with the Uekawa *et al.* conditions of MMPP and *m*CPBA and alternative conditions including dimethyldioxirane (DMDO). The improvement was consistently observed for various oxidants and solvents. A representative epoxidation procedure using 5 MTO is set out in Example 10.


Moreover, as shown in Example 10a, the process using MTO is also suitable for large scale synthesis, with the compound of formula (Ia) being isolated in 72% yield on a scale of 4.9 kg (based on starting compound (IIa)). Such high yields could not be achieved on 10 such a large scale using the conditions described by Uekawa *et al.*

Thus, the present invention provides an improved process for the epoxidation of compounds of general formula (IIa) to form compounds of general formula (Ia) and for the epoxidation of compounds of general formula (II) to form compounds of general 15 formula (I). In particular, the process is scalable, has improved regioselectivity, stereoselectivity, and also reduced degradation.

In a first aspect is provided a process for preparing a compound of general formula (Ia):




20 or a salt or isotopic variant thereof, wherein Y, R², R⁴ and R⁵ are as defined above, the process comprising: oxidation of a compound of general formula (IIa) using an oxidant and methyltrioxorhenium as catalyst:



25 or a salt or isotopic variant thereof, wherein Y, R², R⁴ and R⁵ and are as defined for compounds of general formula (Ia).


In a second aspect is provided a process for preparing a compound of general formula (I):



or a salt or isotopic variant thereof, wherein Y, R², R⁴ and R⁵ are as defined above, the process comprising:

oxidation of a compound of general formula (II) using an oxidant and methyltrioxorhenium

5 as catalyst:




or a salt or isotopic variant thereof.

wherein Y, R², R⁴ and R⁵ and are as defined for compounds of general formula (I).

10 The oxidation is catalysed by methyltrioxorhenium (MTO, also known as methyltrioxyrhenium and methylrhenium trioxide) which is a commercially available organometallic compound of formula CH_3ReO_3 (Scheme 3).

Scheme 3



15

The methyltrioxorhenium is typically present in the reaction at 0.1-10 mol%, such as 0.1-5 mol%, 0.2-3 mol%, 0.5-2 mol%, 0.5-1.5 mol%, about 1-2 mol % or about 1 mol%.

20 The reaction is carried out in the presence of an oxidant such as hydrogen peroxide (for example 30% hydrogen peroxide), a hydrogen peroxide adduct such as urea-hydrogen peroxide (a solid adduct of hydrogen peroxide and urea), or sodium percarbonate. In one embodiment, the oxidant is hydrogen peroxide or a hydrogen peroxide adduct. Suitably the oxidant is urea-hydrogen peroxide.


25

Up to 3 equivalents (per mole of compound of general formula (II)) of oxidant are typically

used, for example up to 2 equivalents such as up to 1.8 equivalents, up to 1.5 equivalents or up to 1.2 equivalents. At least 1 equivalent of oxidant is required.

5 A representation of two possible complexes formed between methyltrioxorhenium and hydrogen peroxide (possible active epoxidation complexes) is shown below in Scheme 4:

Scheme 4



10 The reaction is suitably carried out in the presence of a ligand which will coordinate with the active epoxidation complexes. Such ligands are well known to the skilled person (see Rudolph *et al.*, *J. Am. Chem. Soc.*, **1997**, 119(26), 6189-6190, incorporated herein by reference) and are typically Lewis bases such as N-donor ligands (including N-oxides), aromatic Schiff bases or aliphatic amines.

15

In one embodiment, the ligand is a moiety which is bound to the rhenium via 1 to 3 atoms of at least one element selected from oxygen and nitrogen, such that the 5- to 7- valency of rhenium is fulfilled. In one embodiment, the ligand is an amine e.g. a primary, secondary or tertiary aliphatic or aromatic amine, such as aniline, aminoacetone, aminoacetonitrile, 20 or ephidrine; a nitrogen-containing aliphatic heterocycle e.g. pyrrolidine, piperidine, piperazine, morpholine or quinuclidine; or a nitrogen-containing aromatic heterocycle e.g. pyridine, pyrimidine, pyrazine, imidazole, pyrazole, indole, quinoline, quinolone or isoquinoline; any of which may be optionally substituted, e.g. by C₁₋₄alkyl, or by -O⁻ (i.e. forming an N-oxide).

25

In one embodiment, the ligand is a substituted pyridine or pyrazole. Suitably the ligand is pyridine, 3-cyanopyridine, 4-cyanopyridine, 2-hydroxypyridine, 3-methyl pyridine, 1-methyl pyrazole or 3-methyl pyrazole; in particular 3-cyanopyridine, 4-cyanopyridine, 2-hydroxypyridine, 3-methyl pyridine or 3-methyl pyrazole; for example 3-methyl pyrazole.

30

If used, the ligand is typically present at 5-40 mol%, such as 5-30 mol%, 5-15 mol%, 8-15 mol% or about 12 mol%.

The presence of a ligand in the reaction mixture may provide a number of benefits including the acceleration of the reaction, the suppression of hydrolytic pathway of MTO to perrhenic acid, and buffering the reaction thereby avoiding acid catalysed opening of 5 epoxide reaction product.

The reaction is carried out in an organic solvent. Suitable organic solvents include CH₂Cl₂, CHCl₃, toluene, CH₃CN, EtOAc, IPA, MIBK, *n*BuOAc and fluorinated solvents, and mixtures thereof. In one embodiment, the organic solvent is selected from CH₂Cl₂, CH₃CN, 10 EtOAc, IPA, MIBK, *n*BuOAc, fluorinated solvents, and mixtures thereof. Suitable fluorinated solvents include HFIP (hexafluoroisopropanol), TFE (2,2,2-trifluoroethanol), hexafluorobutanol, trifluorotoluene, hexafluorobenzene and the solvents sold under the trade mark Vertrel®. In one embodiment, fluorinated solvents are selected from HFIP, TFE and the solvents sold under the trade mark Vertrel®.

15 In one embodiment, the reaction solvent comprises fluorinated solvent. In one embodiment, the reaction solvent comprises HFIP. In one embodiment the reaction solvent is a fluorinated solvent or a mixture of a fluorinated and non-fluorinated solvent. In one embodiment, the reaction solvent is a mixture of two or more different fluorinated 20 solvents. In one embodiment, the reaction solvent is a fluorinated solvent such as HFIP. In one embodiment, the reaction solvent is a mixture of a fluorinated solvent and ethyl acetate. In one embodiment, the reaction solvent is a mixture of HFIP and ethyl acetate. In one embodiment, the reaction solvent is a mixture of HFIP and toluene.

25 Suitably the reaction solvent comprises fluorinated solvent. In certain embodiments, the use of a reaction solvent comprising fluorinated solvent may be expected to lead to an improved conversion of starting material to desired epoxide product compared to the use of reaction solvent not comprising a fluorinated solvent. In certain embodiments, the use of a reaction solvent comprising fluorinated solvent may be expected to lead to higher α:β 30 epoxide ratio compared to the use of reaction solvent not comprising a fluorinated solvent. In certain embodiments, the use of a reaction solvent comprising fluorinated solvent may be expected to lead to improved selectivity for epoxidation of the 6,7 double bond in preference to the 4,5 double bond. Without wishing to be bound by theory, the present inventors believe that fluorinated solvents such as HFIP are involved in activating the 35 oxidant e.g. the peroxide, leading to improved conversion. Fluorinated solvents may also enhance solubility of the oxidant, e.g. UHP.

In one embodiment, the reaction is carried out in the temperature range of about -10 °C to about 50 °C, such as about -5 °C to about 25 °C, about 0 °C to about 10 °C, about 0 °C to about 5 °C, about 0 °C to about 4 °C, about 0 °C to about 3 °C, about 0 °C to about 2 °C, about 0 °C to about 1 °C, or about 0 °C. Another temperature range of interest is about 5 0 °C to about 15 °C e.g. about 0 °C to about 10 °C, about 2 °C to about 8 °C e.g. about 5 °C.

Once the epoxidation reaction is complete (as determined by, for example by TLC or HPLC), the extent of conversion can be determined using HPLC analysis to quantitatively 10 determine the proportion of each component in the reaction mixture. A representative set of HPLC conditions are set out in General Procedures and utilised in Example 10 to determine the relative amounts of desired *alpha*-epoxide, undesired *beta*-epoxide and unreacted starting material. Suitably the extent of conversion is such that no starting material is observed once the reaction is complete. In one embodiment, the ratio of *alpha*-epoxide:*beta*-epoxide:starting material observed following completion of the reaction using 15 the HPLC conditions described in General Procedures is between about 20:1:0 and about 10:1:0 e.g. between about 15:1:0 and 10:1:0, e.g. around 13:1:0. In one embodiment, the ratio of *alpha*-epoxide:*beta*-epoxide observed following completion of the reaction using the HPLC conditions described in General Procedures is between about 20:1 and about 20 8:1 e.g. between about 18:1 and 8:1. In one embodiment, the ratio of *alpha*-epoxide:*beta*-epoxide observed at a given time point e.g. 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 10 hours, 20 hours, or 24 hours, using the HPLC conditions described in General Procedures is between about 25:1 and about 5:1 e.g. between about 20:1 and 8:1 e.g. between about 18:1 and 8:1. In one embodiment, the ratio of *alpha*-epoxide:*beta*-epoxide observed at a 25 given time point e.g. 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 10 hours, 20 hours, or 24 hours, using the HPLC conditions described in General Procedures is at least 5:1 e.g. at least 8:1, at least 10:1, at least 12:1, at least 15:1 or at least 20:1.

Suitably, the MTO process of the invention is a batch process using a minimum quantity 30 of starting compound of general formula (IIa) or (II) of at least 1g, at least 5g, at least 100g, at least 1kg, at least 4 kg or at least 5 kg.


The process according to the invention, in at least some embodiments, is expected to have one or more advantages of:

- 35
- improved yield, in particular for large-scale synthesis;
 - being scalable i.e. consistent yields for both small and large-scale synthesis;

- reduced degradation and side product formation;
 - improved regioselectivity, i.e. selectivity for the 6,7-position of compound (IIA);
 - improved stereoselectivity, i.e. selectivity for the *alpha*-epoxide;
 - improved conversion;
 - simplified purification process;
 - suitability for large-scale synthesis compared with known processes.

Compounds of general formulae (Ia), (I), (IIa) and (II)


10 In a further aspect is provided a novel compound of general formula (IIa):



or a salt or isotopic variant thereof.

wherein, Y, R², R⁴ and R⁵ are as described above for compounds of general formula (IIa).


15 In a further aspect is provided a novel compound of general formula (II):



or a salt or isotopic variant thereof,

wherein, Y, R², R⁴ and R⁵ are as described above for compounds of general formula (II).


20 In a still further aspect is provided a novel compound of general formula (Ia):



or a salt or isotopic variant thereof

wherein, Y, R², R⁴ and R⁵ are as described above for compounds of general formula (Ia).

25 In a still further aspect is provided a novel compound of general formula (I):



or a salt or isotopic variant thereof

wherein, Y, R², R⁴ and R⁵ are as described above for compounds of general formula (I).

- 5 The following embodiments relate to compounds of general formulae (Ia), (I), (IIa) and (II) where applicable, and to methods for their preparation as described herein, unless otherwise stated. The embodiments also relate to compounds of general formulae (XVIIIa), (XVIII), (XIXa), (XIX), (XXa), (XX), (XXIa), (XXI), (XXIIa) and (XXII) where appropriate (i.e. as far as chemically sensible).

10

Embodiments relating to individual R groups, Y groups and X groups are envisaged as being fully combinable with one or more other R groups to form further embodiments of the invention.

- 15 In one embodiment, R² is H. In one embodiment, R² is halo. In one embodiment, R² is OH. In one embodiment, R² is a protected OH group. In one embodiment, R² is a protected OH group which is not stable in a basic environment such that treatment with a base converts the protected OH group to OH. Examples of such groups are well known in the art and include a group OC(O)R¹⁴, wherein R¹⁴ is a group R¹⁰ as defined above for general formula (Ia) or (I), and is suitably C₁₋₆ alkyl or benzyl, or C₁₋₆ alkyl or phenyl. In another embodiment, 20 R² is a protected OH group which is stable in a basic environment. Examples of such groups include OSi(R¹⁶)₃, where each R¹⁶ is independently a group R¹³ as defined above for general formula (Ia) or (I), and is suitably C₁₋₆ alkyl or phenyl. In one embodiment, Si(R¹⁶)₃ is selected from the group consisting of trimethylsilyl (TMS), triethylsilyl (TES), 25 triphenylsilyl (TPS), tri-isopropylsilyl (TIPS), thexyldimethylsilyl (TDS), *tert*-butyldiphenylsilyl (TBDPS), *tert*-butyldimethylsilyl (TBDMS or TBS), di-*tert*-butylmethylsilyl (DTBMS), diethylisopropylsilyl (DEIPS) and dimethylisopropylsilyl (DMIPS), in particular TMS, TES, TIPS, TBDMS and TBDPS.
- 30 In one embodiment, R² is in the “up” position i.e. is in the *beta*-configuration.

In one embodiment, Y is a bond. In one embodiment, Y is a C₁₋₂₀, C₁₋₁₂, C₁₋₁₀, C₁₋₈, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃ or C₁₋₂ alkylene or a C₂₋₁₂, C₂₋₁₀, C₂₋₈, C₂₋₆, C₂₋₅, C₂₋₄, C₂₋₃ or C₂ alkenylene

linker group either of which is optionally substituted with one or more groups R³ as defined above.

In one embodiment, Y is bond, or a C₁₋₃ alkylene or C₂₋₃ alkenylene linker group either of which is optionally substituted with one or more groups R³ as defined above. Suitably Y is a C₁₋₃ alkylene or C₂₋₃ alkenylene linker group either of which is optionally substituted with one or more groups R³ as defined above.

In one embodiment, Y is a bond, -CH₂-, -CH₂CH₂-, -CH=CH- or -CH=C(CH₃)-; suitably -CH₂-, -CH₂CH₂-, -CH=CH- or -CH=C(CH₃)-, in particular -CH₂CH₂- or -CH=CH-.

In one embodiment, Y is a bond, an unsubstituted C₁₋₃ alkylene group, a C₁₋₃ alkylene group substituted with OH, or a C₁₋₃ alkenylene group. For example, Y may be a bond, -CH₂-, -CH₂CH₂-, -CH(OH)-CH₂-, -CH=CH- or -CH=C(CH₃)-, in particular a bond, -CH₂-, -CH₂CH₂-, -CH=CH- or -CH=C(CH₃)-, especially -CH₂-, -CH₂CH₂-, -CH=CH- or -CH=C(CH₃)-.

In one embodiment, Y is an C₁₋₁₅ alkylene linker, more suitably C₁₋₁₂, C₁₋₁₀ or C₁₋₈ alkylene linker and is substituted with an OH group. In this case, the OH group may be separated from the R⁴ moiety by a single CH₂ group such that the linker Y is a group Y⁴-CH(OH)-CH₂, where Y⁴ is as defined for Y, but is shorter by two carbon atoms. For example, Y may be -CH(OH)-CH₂-.

This Y linker is particularly suitable when R⁴ is CN or R⁴ is CH(XR¹⁰)(XR¹¹) e.g. CH(OR¹⁰)(OR¹¹) wherein R¹⁰ and R¹¹ are as defined above, but particularly wherein the XR¹⁰ and XR¹¹ e.g OR¹⁰ and OR¹¹ groups together with the carbon atom to which they are attached form a cyclic group, e.g. a cyclic acetal group such as a 1,3-dioxane or 1,3-dioxolane ring.

In one embodiment, R³ is H. In one embodiment, R³ is halo. In one embodiment, R³ is OH. In one embodiment, R³ is NR⁸R⁹, wherein each of R⁸ and R⁹ are suitably independently selected from H, methyl, ethyl, benzyl and *tert*-butyloxycarbonyl. In one embodiment, R³ is a protected OH group. In one embodiment, R³ is a protected OH group which is not stable in a basic environment such that treatment with a base converts the protected OH group to OH. Examples of such groups are well known in the art and include a group OC(O)R¹⁴, wherein R¹⁴ is a group R¹⁰ as defined above for general formula (Ia) or (I), and is suitably C₁₋₆ alkyl or benzyl, or C₁₋₆ alkyl or phenyl. In another embodiment, R³ is a protected OH

group which is stable in a basic environment. Examples of such groups include $\text{OSi}(\text{R}^{16})_3$, where each R^{16} is independently a group R^{13} as defined above for general formula (Ia) or (I), and is suitably C_{1-6} alkyl or phenyl. In one embodiment, $\text{Si}(\text{R}^{16})_3$ is selected from the group consisting of trimethylsilyl (TMS), triethylsilyl (TES), triphenylsilyl (TPS), tri-5 isopropylsilyl (TIPS), thexyldimethylsilyl (TDS), *tert*-butyldiphenylsilyl (TBDPS), *tert*-butyldimethylsilyl (TBDMS or TBS), di-*tert*-butylmethylsilyl (DTBMS), diethylisopropylsilyl (DEIPS) and dimethylisopropylsilyl (DMIPS), in particular TMS, TES, TIPS, TBDMS and TBDPS.

- 10 In one embodiment R^3 is H, halo, OH, $\text{OC}(\text{O})\text{R}^{14}$, $\text{OSi}(\text{R}^{16})_3$, or NR^8R^9 ; wherein R^{14} is C_{1-6} alkyl or phenyl; each R^{16} is independently C_{1-6} alkyl or phenyl; and each R^8 and R^9 is independently H, methyl, ethyl or *tert*-butoxycarbonyl.
- 15 In one embodiment, each R^3 is independently halo, OR^8 or NR^8R^9 ; wherein each of R^8 and R^9 is independently H or C_{1-4} alkyl.

In one embodiment, each R^3 is independently halo, OR^8 or NR^8R^9 ; wherein each of R^8 and R^9 is independently selected from H, methyl or ethyl, especially H or methyl.

- 20 In one embodiment, Y and R^4 together form a $=\text{CH}_2$ group.
- In one embodiment, when present in the R_4 moiety, each R^{10} and R^{11} is independently:
- 25 a. hydrogen; or
- b. C_{1-10} alkyl, C_{2-10} alkenyl or C_{2-10} alkynyl, any of which is optionally substituted with one or more substituents as described above; or
- c. a 6- to 10- membered aryl or 5- to 10-membered heteroaryl group either of which is optionally substituted with one or more substituents as described above; or
- d. a polyethylene glycol residue; or
- 30 e. when R^4 is $\text{CH}(\text{XR}^{10})(\text{XR}^{11})$, $\text{CH}(\text{R}^{10})(\text{XR}^{11})$, $\text{NR}^{10}\text{R}^{11}$, $\text{BR}^{10}\text{R}^{11}$, $\text{CH}[\text{C}(\text{O})\text{OR}^{10}]_2$ or $\text{CH}(\text{BR}^{10}\text{R}^{11})_2$, an R^{10} and an R^{11} group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring, more suitably a 5- to 6- membered heterocyclic ring.

- 35 In one embodiment, each R^{10} and R^{11} is independently:
- a. hydrogen; or
- b. C_{1-10} alkyl, C_{2-10} alkenyl or C_{2-10} alkynyl, any of which is optionally substituted with

one or more substituents as described above; or

c. a 6- to 10- membered aryl or 5- to 10-membered heteroaryl group either of which is optionally substituted with one or more substituents as described above; or

d. a polyethylene glycol residue; or

5 e. when R^4 is $CH(OR^{10})(OR^{11})$, $CH(R^{10})(OR^{11})$, $CH(SR^{10})(SR^{11})$, $NR^{10}R^{11}$, $BR^{10}R^{11}$, $CH[C(O)OR^{10}]_2$ or $CH(BR^{10}R^{11})_2$, an R^{10} and an R^{11} group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring.

Suitably, each R^{10} and R^{11} is independently

10

a. hydrogen; or

b. C_{1-10} alkyl, C_{2-10} alkenyl or C_{2-10} alkynyl optionally substituted with one or more substituents as described above, or

c. a 6- to 10-membered aryl group or a 5- to 6-membered heteroaryl group optionally substituted with one or more substituents as described above; or

15

e. when R^4 is $C(O)NR^{10}R^{11}$ or $NR^{10}R^{11}$, an R^{10} and an R^{11} group, together with the nitrogen to which they are attached, combine to form a pyrrolidine or piperidine ring or when R^4 is $CH(XR^{10})(XR^{11})$, for example $CH(OR^{10})(OR^{11})$, the XR^{10} and XR^{11} group, together with the carbon atom to which they are attached, combine to form a ring; suitably

20

X is O and the ring is a 1,3-dioxane or 1,3-dioxolane ring; or when R^4 is $BR^{10}R^{11}$, the R^{10} and R^{11} groups, together with the boron atom to which they are attached combine to form a bridged boron-containing ring, such as 9-BBN.

Suitably, each R^{10} and R^{11} is independently:

25

a. hydrogen or

b. C_{1-10} alkyl, C_{2-10} alkenyl or C_{2-10} alkynyl optionally substituted with one or more substituents as described above or

c. a 6- to 10-membered aryl group optionally substituted with one or more substituents as described above; or

30

e. when R^4 is $C(O)NR^{10}R^{11}$ or $NR^{10}R^{11}$, an R^{10} and an R^{11} group, together with the nitrogen to which they are attached, combine to form a pyrrolidine or piperidine ring or when R^4 is $CH(OR^{10})(OR^{11})$, the OR^{10} and OR^{11} group, together with the carbon atom to which they are attached, combine to form a 1,3-dioxane or 1,3-dioxolane ring; or when R^4

35

is $BR^{10}R^{11}$, the R^{10} and R^{11} groups, together with the boron atom to which they are attached combine to form a bridged boron-containing ring such as 9-BBN.

In one embodiment, when R⁴ is NR¹⁰R¹¹, R¹⁰ is H or C₁₋₄ alkyl and R¹¹ is a 5-10 membered heteroaryl group such as tetrazole.

When R⁴ is OSi(R¹³)₃, suitably each R¹³ is independently selected from:

- 5 a. C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl optionally substituted with one or more substituents as described above; or
- b. a 6- to 10- membered aryl or 5- to 10-membered heteroaryl group optionally substituted with one or more substituents as described above.

10 More suitably, each R¹³ is independently selected from:

- a. C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl optionally substituted with one or more substituents as described above; or
- b. a 6- to 10- membered aryl group optionally substituted with one or more substituents as described above.

15

Still more suitably, each R¹³ is independently selected from C₁₋₁₀ alkyl or phenyl, either of which is optionally substituted as described above.

In one embodiment, each R¹³ is independently selected from C₁₋₆ alkyl (in particular methyl,

20 ethyl, isopropyl, *tert*-butyl, hexyl) and phenyl.

In one embodiment, Si(R¹³)₃ is selected from the group consisting of trimethylsilyl (TMS), triethylsilyl (TES), triphenylsilyl (TPS), tri-isopropylsilyl (TIPS), thexyldimethylsilyl (TDS), *tert*-butyldiphenylsilyl (TBDPS), *tert*-butyldimethylsilyl (TBDMS or TBS), di-*tert*-25 butylmethylsilyl (DTBMS), diethylisopropylsilyl (DEIPS) and dimethylisopropylsilyl (DMIPS), in particular TMS, TES, TIPS, TBDMS and TBDPS.

Suitable substituents for alkyl, alkenyl and alkynyl R¹⁰ and R¹¹ groups include halo, NO₂,

30 CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, SO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 10- membered

aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with

C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SO₂R¹⁹, SO₃R¹⁹ or N(R¹⁹)₂; where R¹⁹ is as

defined above.

Similarly, suitable substituents for alkyl, alkenyl and alkynyl R¹³ groups include halo, NO₂,

35 CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, SO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 10- membered

aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with

C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SO₂R¹⁹, SO₃R¹⁹ or N(R¹⁹)₂; where R¹⁹ is as

defined above.

More suitable substituents for these R¹⁰ and R¹¹ groups include halo, OR¹⁹, C(O)OR¹⁹, N(R¹⁹)₂, SO₃R¹⁹, OSO₃R¹⁹ or a 6- to 10-membered aryl group optionally substituted as 5 described above, and more suitable substituents for these R¹³ groups include halo, OR¹⁹, C(O)OR¹⁹, N(R¹⁹)₂, SO₃R¹⁹, OSO₃R¹⁹ or a 6- to 10-membered aryl group optionally substituted as described above.

More suitable substituents for these R¹⁰, R¹¹ and R¹³ groups include halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, C(O)OH, SO₂OH, -NH(C₁₋₄ alkyl) or -N(C₁₋₄ alkyl)₂; for example fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, C(O)OH, SO₂OH, amino, methyl amino and dimethylamino.

More suitable substituents for these R¹⁰, R¹¹ and R¹³ groups include halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, C(O)OH, SO₂OH, -NH₂, -NH(C₁₋₄ alkyl) or -N(C₁₋₄ alkyl)₂; for example fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, C(O)OH, SO₂OH, amino, methyl amino and dimethylamino.

Suitable substituents for aryl and heteroaryl R¹⁰ and R¹¹ groups include C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹ or N(R¹⁹)₂.

Similarly, suitable substituents for aryl and heteroaryl R¹³ groups include C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹ or N(R¹⁹)₂.

25 More suitable substituents for aryl and heteroaryl R¹⁰ and R¹¹ groups include C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, OR¹⁹ or N(R¹⁹)₂; and similarly, more suitable substituents for aryl and heteroaryl R¹³ groups include C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, OR¹⁹ or N(R¹⁹)₂.

Particularly suitable substituents for aryl and heteroaryl R¹⁰, R¹¹ and R¹³ groups include 30 halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, -NH(C₁₋₄ alkyl) or -N(C₁₋₄ alkyl)₂.

Specific examples of substituents for aryl and heteroaryl R¹⁰, R¹¹ and R¹³ groups include 35 fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, amino, methyl amino and dimethylamino.

As set out above, with respect to groups R¹⁰ and R¹¹, each R¹⁹ is independently H, C₁₋₆

alkyl, C₁₋₆ haloalkyl, or a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more halo substituents selected from, C₁₋₆ alkyl and C₁₋₆ haloalkyl.

5 Suitably, R¹⁹ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or a 6- to 10- membered aryl or 5 to 10-membered heteroaryl group optionally substituted with one or more substituents selected from halo, C₁₋₄ alkyl and C₁₋₄ haloalkyl.

More suitably, R¹⁹ is hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl or phenyl optionally substituted

10 with one or more substituents selected from halo, C₁₋₄ alkyl and C₁₋₄ haloalkyl.

Specific examples of R¹⁹ include H, methyl, ethyl, trifluoromethyl or phenyl optionally substituted with one or more substituents selected from fluoro, chloro, methyl, ethyl and trifluoromethyl.

15

As set out above, with respect to group R¹³, each R¹⁹ is independently H, C₁₋₆ alkyl or C₁₋₆ haloalkyl. In one embodiment, R¹⁹ is H or C₁₋₆ alkyl such as C₁₋₄ alkyl, for example, methyl or ethyl. Specific examples of R¹⁹ include H, methyl, ethyl or trifluoromethyl.

20

In some particularly suitable compounds of general formula (Ia), R⁴ is C(O)OR¹⁰, OR¹⁰, SO₃R¹⁰, OSO₃R¹⁰, halo, CN, azide, OSi(R¹³)₃, C(O)R¹⁰, NR¹⁰C(O)NR¹⁰SO₂R¹¹, NR¹⁰C(O)NR¹⁰SO₂N R¹⁰R¹¹, NR¹⁰SO₂R¹¹, CH(XR¹⁰)(XR¹¹), CH[C(O)OR¹⁰]₂, BR¹⁰R¹¹ or phthalimide.

25

In some particularly suitable compounds of general formula (Ia), R⁴ is C(O)OR¹⁰, OR¹⁰, SO₃R¹⁰, OSO₃R¹⁰, halo, CN, C(O)R¹⁰, CH(XR¹⁰)(XR¹¹), CH[C(O)OR¹⁰]₂ or BR¹⁰R¹¹, and each R¹⁰ and R¹¹ is independently H, C₁₋₆ alkyl or benzyl; or, when R⁴ is CH(XR¹⁰)(XR¹¹) or BR¹⁰R¹¹, R¹⁰ and R¹¹ together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring; or 30 R⁴ is C(O)NR¹⁰R¹¹ wherein each R¹⁰ and R¹¹ is independently substituted with C(O)OR¹⁹, OR¹⁹, SO₃R¹⁹, or OSO₃R¹⁹ and R¹⁹ is H.

35

In some particularly suitable compounds of general formula (I), R⁴ is C(O)OR¹⁰, OR¹⁰, SO₃R¹⁰, OSO₃R¹⁰, halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹), CH[C(O)OR¹⁰]₂ or BR¹⁰R¹¹, and each R¹⁰ and R¹¹ is independently H, C₁₋₆ alkyl or benzyl; or, when R⁴ is CH(OR¹⁰)(OR¹¹) or BR¹⁰R¹¹, R¹⁰ and R¹¹ together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring; or



R^4 is $C(O)NR^{10}R^{11}$ wherein each R^{10} and R^{11} is independently substituted with $C(O)OR^{19}$, OR^{19} , SO_3R^{19} , or OSO_3R^{19} and R^{19} is H.

In some particularly suitable compounds of general formula (I), R^4 is $C(O)OR^{10}$, OR^{10} ,


5 SO_3R^{10} , or OSO_3R^{10} , halo, CN, $C(O)R^{10}$, $CH(OR^{10})(OR^{11})$, $CH[C(O)OR^{10}]_2$ or $BR^{10}R^{11}$, and each R^{10} and R^{11} is independently H, C_{1-6} alkyl or benzyl; or,

when R^4 is $CH(OR^{10})(OR^{11})$ or $BR^{10}R^{11}$, R^{10} and R^{11} together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring.

10 When R^4 is $CH(XR^{10})(XR^{11})$ and R^{10} and R^{11} together with the atom or atoms to which they are attached combine to form a 3 to 10-membered heterocyclic ring, suitably R^4 is a 3-5 membered heterocyclic ring, in particular a 5-membered heterocyclic ring e.g. R^4 is selected from:




and in particular is



15 .

When R^4 is $CH(R^{10})(XR^{11})$ and R^{10} and R^{11} together with the atom or atoms to which they are attached combine to form a 3 to 10-membered heterocyclic ring, suitably R^3 is a 3-membered heterocyclic ring e.g. R^4 is selected from:



and in particular is .

Alternatively, the compound may be in the form of a salt such that:

R^4 is $C(O)O^-$, O^- , SO_3^- , or OSO_3^- ; or

R^4 is $C(O)NR^{10}R^{11}$ wherein R^{10} and R^{11} are independently substituted with $C(O)O^-$, O^- ,

25 SO_3^- , or OSO_3^- ;

and a counter ion is present as described above for basic addition salts.

In one embodiment, R^4 is $C(O)OR^{10}$, OR^{10} , $C(O)NR^{10}R^{11}$, SO_3R^{10} , or OSO_3R^{10} .

30 In one embodiment, R^4 is $OSi(R^{13})_3$.

In one embodiment, R^4 is halo, CN, $C(O)R^{10}$, $CH(XR^{10})(XR^{11})$, $NR^{10}R^{11}$, $BR^{10}R^{11}$, $-CH=CH_2$, $-C\equiv CH$, $CH[C(O)OR^{10}]_2$ or $CH(BR^{10}R^{11})_2$ or Y and R^4 together form a

=CH₂ group.

In one embodiment, R⁴ is halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹), NR¹⁰R¹¹, BR¹⁰R¹¹, -CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂ or CH(BR¹⁰R¹¹)₂ or Y and R⁴ together form a 5 =CH₂ group.

In one embodiment, R⁴ is halo, CN, C(O)R¹⁰, NR¹⁰R¹¹, BR¹⁰R¹¹, C(O)CH₂N₂, -CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, CH(BR¹⁰R¹¹)₂, azide, NO₂, NR¹⁰C(O)NR¹⁰SO₂R¹¹, C(O)NR¹⁰SO₂R¹¹, CH(XR¹⁰)(XR¹¹), CH(R¹⁰)(XR¹¹) wherein each X is independently O, S 10 or NR⁸.

When R⁴ is CH(XR¹⁰)(XR¹¹), X is suitably O or S, e.g. O. In such compounds, when R¹⁰ and R¹¹ combine to form a ring, it is suitably a 5- or 6-membered ring. More suitably, both X moieties are O and R¹⁰ and R¹¹ form a 1,3-dioxane or 1,3-dioxolane ring.

15

When R⁴ is CH(R¹⁰)(XR¹¹), X is suitably O or S, e.g. O.

In one embodiment, R⁴ is a carboxylic acid mimetic group.

20 In one embodiment, R⁴ is a carboxylic acid mimetic group selected from tetrazole, substituted tetrazole, -SO₂-NHR¹⁰, C(O)NH-SO₂R¹⁰ and NHC(O)NH-SO₂R¹⁰, wherein R¹⁰ is as above defined for a compound of general formulae (Ia) or (I) and is suitably H, C₁₋₆ alkyl, C₃₋₇ cycloalkyl or 6- to 14- membered aryl, (e.g. phenyl). Suitably, substituted tetrazole is tetrazole substituted with C₁₋₄ alkyl, halo, OH, O(C₁₋₄ alkyl) or 25 SO₂R¹⁰ (e.g. SO₂(C₁₋₄ alkyl), SO₂-phenyl or SO₂-tolyl).

When R⁴ is a carboxylic acid mimetic group, it is suitably a tetrazolyl group, for example tetrazol-1-yl or tetrazol-5-yl.

30 In one embodiment, R⁴ is halo, CN, C(O)R¹⁰, CH(XR¹⁰)(XR¹¹), CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, BR¹⁰R¹¹ or Y and R⁴ together form a =CH₂ group.

In one embodiment, R⁴ is halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹), CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, BR¹⁰R¹¹ or Y and R⁴ together form a =CH₂ group.

35

Suitably, R⁴ is C(O)OR¹⁰, C(O)NR¹⁰R¹¹, SO₃R¹⁰, or OSO₃R¹⁰.

More suitably, R⁴ is C(O)OR¹⁰, SO₃R¹⁰, or OSO₃R¹⁰ and R¹⁰ is H; or

R⁴ is C(O)NR¹⁰R¹¹ substituted with C(O)OR¹⁹, SO₃R¹⁹, or OSO₃R¹⁹ and R¹⁹ is H.

In other particularly suitable compounds R⁴ is halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹),

5 NR¹⁰R¹¹, CH[C(O)OR¹⁰]₂ or azide;

where R¹⁰ and R¹¹ are as described above but are suitably each independently H or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl optionally substituted as described above or, when R⁴ is NR¹⁰R¹¹, R¹¹ may also suitably be a heteroaryl group such as tetrazole; or when R⁴ is CH(OR¹⁰)(OR¹¹), the OR¹⁰ and OR¹¹ groups together with the carbon atom to which they

10 are attached may form a cyclic acetal group, particularly a 1,3-dioxane or 1,3-dioxolane group.

In still other particularly suitable compounds R⁴ is NR¹⁰C(O)NR¹⁰SO₂R¹¹ or

C(O)NR¹⁰SO₂R¹¹, where R¹⁰ and R¹¹ are as described above but are suitably each

15 independently H or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl optionally substituted as described above.

In one embodiment, R⁴ is C(O)OR¹⁰, OC(O)R¹⁰, OR¹⁰, OSi(R¹³)₃, OSO₂R¹⁰, halo, CN,

C(O)R¹⁰, NR¹⁰R¹¹, CH[C(O)OR¹⁰]₂, azide, C(O)NR¹⁰SO₂R¹¹ CH(XR¹⁰)(XR¹¹); phthalimide,

20 tetrazole or substituted tetrazole.

Other examples of R⁴ groups include azide and tetrazole.

In one embodiment, R⁵ is H. In one embodiment, R⁵ is OH. In one embodiment, R⁵ is a

25 protected OH group. In one embodiment, R⁵ is a protected OH group which is not stable in a basic environment such that treatment with a base converts the protected OH group to OH. Examples of such groups are well known in the art and include a group OC(O)R¹⁴

wherein R¹⁴ is a group R¹⁰ as defined above for general formula (Ia) or formula (I).

Particularly suitable R¹⁴ groups are as defined for R¹⁰ above and include C₁₋₆ alkyl such as

30 methyl, or benzyl; or C₁₋₆ alkyl such as methyl, or phenyl. In another embodiment, R⁵ is a protected OH group which is stable in a basic environment. Examples of such groups are well known in the art and include OSi(R¹⁶)₃, where each R¹⁶ is independently a group R¹³

as defined above for general formulae (Ia) and (I), and is suitably C₁₋₆ alkyl or phenyl. In

one embodiment, Si(R¹⁶)₃ is selected from the group consisting of trimethylsilyl (TMS),

35 triethylsilyl (TES), triphenylsilyl (TPS), tri-isopropylsilyl (TIPS), thexyldimethylsilyl (TDS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBDMS or TBS), di-tert-

butylmethylsilyl (DTBMS), diethylisopropylsilyl (DEIPS) and dimethylisopropylsilyl

(DMIPS), in particular TMS, TES, TIPS, TBDMS and TBDPS.

In one embodiment, the compound of general formula (Ia) or formula (I) is compound (IA): (6 α , 7 α , 22E)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester and the compound of general formula (II) is compound (IIA): (22E)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester, or the compound of general formula (I) is compound (IB): (6 α , 7 α)-6,7-epoxy-3-oxo-4-chola-ene-24-oic acid ethyl ester and the compound of general formula (II) is compound (IIB): 3-oxo-4,6-choladien-24-oic acid ethyl ester.

- 10 In one aspect of the invention is provided a compound of general formula (IIa) or formula (II) selected from:
- (20S)-20-acetoxymethyl-pregna-4,6-dien-3-one (Example 20);
(20S)-20-hydroxymethyl-pregna-4,6-dien-3-one (Example 21)
(20S)-20-tertbutyldimethylsilyloxyethyl-pregna-4,6-dien-3-one (Example 22)
- 15 (20S)-20-formyl-pregna-4,6-dien-3-one (Example 23)
(20S)-20-(ethylenedioxymethyl)-pregna-4,6-dien-3-one (Example 24)
(20S)-20-(1-mesyloxymethyl)-pregna-4,6-dien-3-one (Example 25)
(20S)-20-(1-bromomethyl)-pregna-4,6-dien-3-one (Example 26)
23-carboxy-3-oxo-4,6-choladien-24-oic acid diethyl ester (Example 27)
- 20 3-oxo-4,6-choladieno-24-nitrile (Example 28);
(20S)-20-(1-aminomethyl)-pregna-4,6-dien-3-one (Example 29);
(20R)-20-(1-cyanomethyl)-pregna-4,6-dien-3-one (Example 30);
23-carboxy-3-oxo-4,6-choladien-24-oic acid dimethyl ester (Example 31);
(22E)-3-oxo-4,6,22-cholatrien-24-oic acid (Example 32);
- 25 N-((22E)-3,24-dioxo-4,6,22-cholatrien-24-yl)cyclopropylsulfonamide (Example 33);
N-((22E)-3,24-dioxo-4,6,22-cholatrien-24-yl)-4-(trifluoromethoxy)benzenesulfonamide (Example 34);
(20S)-20-(5-tosyltetrazol-1-yl)methyl-pregna-4,6-dien-3-one (Example 35); and
(20S)-(N-phthalimidomethyl)-pregna-4,6-dien-3-one (Example 36);
- 30 or a salt or isotopic variant thereof.

In one aspect of the invention is provided a compound of general formula (Ia) or formula (I) selected from:

- (6 α , 7 α , 20S)-6,7-epoxy-20-hydroxymethyl-pregn-4-en-3-one (Example 37)
- 35 (6 α , 7 α , 20S)-20-(1-bromomethyl)-6,7-epoxy-pregn-4-en-3-one (Example 38)
(6 α , 7 α , 20S)-20-(1-mesyloxymethyl)-6,7-epoxy-pregn-4-en-3-one (Example 39)

(6 α , 7 α , 20S)-20-(1-*tert*butyldimethylsilyloxy)methyl)-6,7-epoxy-pregn-4-en-3-one (Example 40);

(6 α , 7 α , 20S)-20-acetoxymethyl-6,7-epoxy-pregn-4-en-3-one (Example 41);

(6 α , 7 α , 20S)-6,7-epoxy-20-(ethylenedioxymethyl)-pregn-4-en-3-one (Example 42);

5 (6 α , 7 α)-23-carboxy-6,7-epoxy-3-oxo-4-cholen-24-oic acid dimethyl ester (Example 43);

(6 α , 7 α)-6,7-epoxy-3-oxo-4-cholen-24-nitrile (Example 44);

(6 α , 7 α , 20R)-20-(1-cyanomethyl)-6,7-epoxy-pregn-4-en-3-one (Example 45);

(6 α , 7 α , 20S)-6,7-epoxy-20-azidomethyl-pregna-4-en-3-one (Example 46);

N-((6 α , 7 α , 22E)-3,24-dioxo-6,7-epoxy-4,22-choladien-24-yl)cyclopropylsulfonamide

10 (Example 47);

N-((6 α , 7 α , 22E)-3,24-dioxo-6,7-epoxy-4,22-choladien-24-yl)-4-

(trifluoromethoxy)benzenesulfonamide (Example 48);


(6 α , 7 α , 20S)-6,7-epoxy-20-(*N*-phthalimidomethyl)-pregna-4,6-dien-3-one (Example 49);

and

15 (6 α , 7 α , 20S)-20-(5-tosyltetrazol-1-yl)methyl-6,7-epoxy-pregna-4-en-3-one (Example 50); or a salt or isotopic variant thereof.

Preparation of compounds of general formula (IIa) and (II)

20 Compounds of general formula (IIa) or compounds of general formula (II) may be prepared from compounds of general formula (IIIa) or from compounds of general formula (III), respectively:



wherein Y, R², R⁴ and R⁵ and are as defined above for general formula (Ia) (for formula

25 (IIIa)) or are as above defined for general formula (I) (for formula (III));


by reaction with an oxidizing agent such as chloranil.

The reaction may be carried out under acidic conditions, for example in the presence of acetic acid, and in an organic solvent such as toluene. Such a reaction is described in

30 Example 8.

Some compounds of general formulae (IIa), (II), (IIIa) and (III) are known. For example Uekawa *et al.* in *Biosci. Biotechnol. Biochem.*, **2004**, 68, 1332-1337 describe the synthesis


of (22*E*)-3-oxo-4,22-choladien-24-oic acid ethyl ester (compound (IIIA)) from stigmasterol followed by its conversion to (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester (referred to herein as compound (IIA)), which has the formula:




5 This reaction is described in Example 1.

Other compounds of general formulae (IIa), (II), (IIIa) and (III) may be prepared by analogous methods from phytosterols similar to stigmasterol. Stigmasterol and other phytosterols are plant sterols and are readily available or may be prepared by known

10 routes.



Compounds of general formula (IIIa) or compounds of general formula (III) may also be prepared from compounds of general formula (IVa) or from compounds of general formula 15 (IV), respectively:




wherein Y, R², R⁴ and R⁵ are as defined in general formula (Ia) (for formula (IVa)) or are as defined in general formula (I) (for formula (IV));

by reaction with lithium bromide and a base such as lithium carbonate. The reaction may

20 be carried out in a solvent such as *N,N*-dimethylformamide (DMF) and at a temperature of about 120 to 180 °C. Such a reaction is described in Example 7.

Compounds of general formula (IVa) or compounds of general formula (IV) may be obtained by bromination of a compound of general formula (Va), or by bromination of a


25 compound of general formula (V), respectively:



wherein Y, R², R⁴ and R⁵ are as defined in general formula (Ia) (for formula (Va)) or are as defined in general formula (I) (for formula (V));
using, for example bromine in acetic acid. Such a reaction is described in Example 6.

5


Compounds of general formula (Va) or compounds of general formula (V) may be prepared from compounds of general formula (VIa) or from compounds of general formula (VI), respectively:



- 10 wherein Y, R², R⁴ and R⁵ are as defined in general formula (Ia) (for formula (VIa)) or are as defined in general formula (I) (for formula (VI));
by oxidation, typically with a chromium-based oxidizing agent or with sodium hypochlorite. Such a reaction is described in Example 5.
- 15 Compounds of general formula (VIa) and compounds of general formula (VI) in which R⁴ is C(O)OR¹⁰, where R¹⁰ is C₁₋₆ alkyl or benzyl, or C₁₋₆ alkyl or phenyl, may be prepared from compounds of general formula (VIa) and from compounds of general formula (VI), respectively, in which R⁴ is C(O)OH by esterification, typically by reaction with an appropriate alcohol under acidic conditions.

20

Compounds of general formula (VIa) and compounds of general formula (VI) in which R⁴ is C(O)OH and R⁵ is H may be prepared from compounds of general formula (VIIa) and from compounds of general formula (VII), respectively:



- 25 wherein R² and Y are as defined in general formula (Ia) (for formula (VIIa)) or are as defined in general formula (I) (for formula (VII));
R⁴ is C(O)OR¹⁰, where R¹⁰ is C₁₋₆ alkyl or benzyl; and

OR¹² is a protected OH;

by reaction with a reducing agent, typically hydrazine, under basic conditions and in an alcoholic or glycolic solvent, for example diethylene glycol.

5 Where OR^{12} is a protected OH group which is stable under basic conditions, the reaction may be followed by a reaction to remove the protecting group R^{12} to leave an OH group.

Protecting groups for OH are discussed above and, for example, R¹² may be a group C(O)R¹⁴, where R¹⁴ is as defined above, in particular, C₁₋₆ alkyl or benzyl; or C₁₋₆ alkyl or

10 phenyl. Silyl ethers are also suitable, and in this case, R¹² may be a group Si(R¹⁶)₃, where each R¹⁶ is independently a group R¹³ as defined above but is especially C₁₋₆ alkyl or phenyl. Other suitable protecting groups for OH are well known to those of skill in the art (see Wuts, PGM and Greene, TW (2006) "Greene's Protective Groups in Organic Synthesis", 4th Edition, John Wiley & Sons, Inc., Hoboken, NJ, USA).

15

Particularly suitable R^{12} groups include groups which are not stable in the presence of a base since this removes the need for the additional step of removing the protecting group. An example of a group R^{12} which is not stable in basic conditions is a group $C(O)R^{14}$, where R^{14} is as defined above, and is particularly C_{1-6} alkyl or benzyl; or C_{1-6} alkyl or phenyl.


20

Alternatively, the reaction may be carried out in 2 steps such that the compound of general formula (VIIa) or a compound of general formula (VII) is reacted with a compound of general formula (XXXII):

25

$$R^{20}-NH-NH_2 \quad (XXXII)$$

wherein R²⁰ is a leaving group such as toluene sulfonyl or methane sulfonyl; to give a compound of general formula (XXXIIIa) or a compound of general formula (XXXIII), respectively:



30

wherein R² and Y are as defined in general formula (Ia);

R^4 and R^{12} are as defined for general formula (VIIa); and

R^{20} is as defined for general formula (XXXIIa) (all for formula (XXXIIIa)); or

wherein R² and Y are as defined in general formula (I);

R⁴ and R¹² are as defined for general formula (VII); and


R²⁰ is as defined for general formula (XXXII) (all for formula (XXXIII));

followed by reduction with a suitable reducing agent. Examples of reducing agents which

5 can be used in this reaction include hydrides such as sodium borohydride, sodium cyanoborohydride, lithium aluminum hydride etc. In general formula (XXXIIIa) and in general formula (XXXIII) R²⁰ is as defined above for compounds of general formula (XXXIIa) and for compounds of general formula (XXXIII), respectively, and Y, R², R⁴ and R¹² are as defined above for compounds of general formula (VIIa) and for compounds of

10 general formula (VII), respectively.

Compounds of general formula (VIIa) or compounds of general formula (VII) may be prepared from compounds of general formula (VIIIfa) or from compounds of general formula (VIII), respectively:



wherein R² and Y are as defined in general formula (Ia) (for formula (VIIIfa)) or are as defined in general formula (I) (for formula (VIII));

R⁴ is C(O)OR¹⁰, where R¹⁰ is C₁₋₆ alkyl or benzyl; and


R¹² is as defined above for general formula (VIIa) (for formula (VIIIfa)) or is as defined

20 above for general formula (VII) (for formula VIII)); and is suitably -C(O)C₁₋₆ alkyl; by reaction with an oxidizing agent, for example sodium hypochlorite. Such a reaction is described in Example 2.

The reaction may be carried out under acidic conditions, for example in the presence of

25 acetic acid, and in an organic solvent such as ethyl acetate.

Compounds of general formula (VIIIfa) or compounds of general formula (VIII) may be prepared from compounds of general formula (IXa) or from compounds of general formula (IX), respectively:



wherein R² and Y are as defined in general formula (Ia) (for formula (IXa)) or are as defined in general formula (I) (for formula (IX));


R⁴ is C(O)OR¹⁰, where R¹⁰ is C₁₋₆ alkyl or benzyl;

by reaction with an agent suitable to introduce the protecting group R¹². For example,

5 when R¹² is C(O)R¹⁴, the compound of general formula (IXa) or a compound of general formula (IX) may be reacted with a carboxylic acid anhydride or an acid chloride in the presence of a weak base such as pyridine, suitably catalysed by 4-dimethylaminopyridine (DMAP). The reaction may be conducted in a solvent such as ethyl acetate. Such a reaction is described in Example 2.

10

Compounds of general formula (IXa) or compounds of general formula (IX) may be prepared by the esterification of compounds of general formula (Xa) or of compounds of general formula (X), respectively:




15 wherein R² and Y are as defined in general formula (Ia) and for general formula (I).

The esterification reaction may be carried out by reacting the acid of general formula (Xa) or of general formula (X) with a suitable alcohol under acidic conditions. Such a reaction is described in Example 2.

20

Compounds of general formula (Xa) and of general formula (X) are known. For example, the compound of general formula (Xa) or of general formula (X) in which Y is -CH₂CH₂- and R² is H is deoxycholic acid (referred to herein as compound (XB)), which is readily available from a number of sources.




25

An alternative route to compounds of general formula (IIIa) and to compounds of general formula (III) in which the group at the R⁴ position is an ester is as shown in Scheme 5 in which 4-androstenedione is converted to a compound of general formula (IIIa) or of general formula (III), in which R² and R⁵ are H; R⁴ is -C(O)OCH₃ and Y is either -CH₂CH₂- or -


CH=CH-.

Scheme 5




- 5 Other compounds with different values for Y and R² can be used as alternative starting materials.

- An alternative route to compounds of general formula (IIa) and to compounds of general formula (II) in which Y is an alkenylene group is by use of an olefination reaction, for example a Horner-Wadsworth-Emmons (HWE) olefination of a compound of general formula (XIa) or of a compound of general formula (XI), respectively:



wherein R² and R⁵ are as defined for general formula (Ia) and for general formula (I); using a compound of general formula (XII):



15

wherein R¹⁰ is as defined for general formula (Ia) and general formula (I).

The reaction may be carried out under standard HWE conditions, for example using a base such as sodium hydride.


Compounds of general formula (XII) are readily available or may be prepared by methods

5 known to those of skill in the art.

Other olefination reactions, such as Tebbe olefination, Wittig type olefination or a Julia-Kocienski olefination, would also give rise to compounds of general formula (IIa) and to compounds of general formula (II) in which Y is an alkenylene group. These olefination

10 reactions are familiar to a chemist of skill in the art.

Compounds of general formula (XIa) or compounds of general formula (XI) may be prepared by reaction of a compound of general formula (XIIIfa) or a compound of formula (XIIIf), respectively, with ozone




wherein R² and R⁵ are as defined for general formula (Ia) and for general formula (I) and R¹⁵ is C₁₋₆ alkyl.

An example of a reaction of this type is given in patent US2,624,748A (Levin *et al.* incorporated herein by reference).

20

Compounds of general formula (XIIIfa) or compounds of general formula (XIIIf) may be prepared by reaction of a compound of general formula (XIVa) or a compound of general formula (XIV), respectively:




25 wherein R² and R⁵ are as defined for general formula (Ia) and for general formula (I), and R¹⁵ is C₁₋₆ alkyl,

with an acid in a solvent such as methanol.

Compounds of general formula (XIVa) and compounds of general formula (XIV) may be

prepared by oxidation of a compound of general formula (XVIa) or a compound of general formula (XVI), respectively:



wherein R² and R⁵ are as defined for general formula (Ia) and for general formula (I), and

5 R¹⁵ is C₁₋₆ alkyl, using an Oppenauer oxidation.


Examples of the conversion of compounds of general formula (XVIa) to compounds of general formula (XIIIa) and of the conversion of compounds of general formula (XVI) to compounds of general formula (XIII) are taught by Shepherd *et al*, *J. Am. Chem. Soc.*

10 1955, 77, 1212-1215 and Goldstein, *J. Med. Chem.* 1996, 39, 5092-5099 (both incorporated herein by reference).

One example of a compound of general formula (XVIa) and of general formula (XVI) is ergosterol (referred to herein as (XVIa)), which is a fungal sterol and Scheme 6 below

15 shows the conversion of ergosterol to a compound of general formula (II) in which both R² and R⁵ are H, Y is CH=CH₂ and R⁴ is C(O)OR¹⁰, where R¹⁰ is ethyl.

Scheme 6




20 Compounds of general formula (Ia) and (IIa) and of general formula (I) and (II) in which R⁴ is C(O)R¹⁰, C(O)NR¹⁰R¹¹, S(O)R¹⁰, SO₃R¹⁰, or OSO₃R¹⁰ may be prepared from the

corresponding compounds in which R^4 is $C(O)OR^{10}$ by reaction with an appropriate reagents using methods well known to those of skill in the art. For example, the methods described in WO2008/002573 and WO2010/014836 or methods similar to those described by Classon *et al*, *J. Org. Chem.*, **1988**, 53, 6126-6130 and Festa *et al*, *J. Med. Chem.*, **2014**, 57, 8477-8495 (all incorporated herein by reference).

Subsequent reactions of compounds of general formula (Ia) and general formula (I)

Compounds of general formulae (Ia) and (IIa), or of general formulae (I) and (II) are 10 intermediates in the synthesis of compounds of general formula (XVIIIa) or of compounds of formula (XVIII), respectively:



or a salt or an isotopic variant thereof;

wherein,

15 R^1 is C_{1-4} alkyl, C_{2-4} alkenyl or C_{2-4} alkynyl optionally substituted with one or more substituents selected from halo, OR^6 and NR^6R^7 ;

wherein each of R^6 and R^7 is independently H or C_{1-4} alkyl;

R^2 is H, halo or OH;

R^{5a} is H or OH; and

20 Y^1 is a bond or a C_{1-20} alkylene linker group and is optionally substituted with one or more R^3 ; or

Y^1 and R^4 together form a $=CH_2$ group;

wherein R^3 and R^4 are as defined for a compound of general formula (Ia) (for formula (XVIIIa)) or are as defined for a compound of general formula (I) (for formula (XVIII)).

25

The compounds of general formula (IIa) or of general formula (II) may be converted to the compounds of general formula (XVIIIa) or of general formula (XVIII), respectively, in a 6 step process via intermediates of general formula (Ia), (I), (XIXa)-(XXIIa) and (XIX)-(XXII), as described above.

30

Compounds of general formula (XVIIIa) and of general formula (XVIII) are potent agonists of FXR and TGR5 and include, in particular, compounds in which R^1 is ethyl. Also included are the following.

- Compounds in which R^4 is $C(O)OH$, for example:
 - obeticholic acid, which is a compound of formula (XVIIIa)/(XVIII) in which R^1 is ethyl, R^2 and R^{5a} are both H, Y^1 is $-CH_2CH_2-$, and R^4 is $C(O)OH$; and
 - the compound of formula (XVIIIa)/(XVIII) in which R^1 is ethyl, R^2 and R^{5a} are both H, Y^1 is $-CH_2CH(CH_3)-$, and R^4 is $C(O)OH$; and
 - the compound of formula (XVIIIa)/(XVIII) in which R^1 is ethyl, R^2 is H, R^{5a} is OH, Y^1 is $-CH_2CH(CH_3)-$, and R^4 is $C(O)OH$.
- Compounds in which R^4 is OSO_3H or a salt thereof, for example:
 - the compound of formula (XVIIIa)/(XVIII) in which R^1 is ethyl, R^2 and R^{5a} are both H, Y^1 is $-CH_2CH_2-$, and R^4 is OSO_3H or a salt thereof; and
 - the compound of formula (XVIIIa)/(XVIII) in which R^1 is ethyl, R^2 is H, R^{5a} is OH, Y^1 is $-CH_2CH_2CH_2-$, and R^4 is OSO_3H or a salt thereof; and
 - the compound of formula (XVIIIa)/(XVIII) in which R^1 is ethyl, R^2 is OH, R^{5a} is H, Y^1 is $-CH_2CH_2-$, and R^4 is OSO_3H or a salt thereof.

5

10

15

In the compounds of general formulae (XVIIIa) to (XXIIa) and of general formula (XVIII) to (XXII), more suitable values for R^4 are as defined for general formula (Ia) and general formula (I), respectively.

20

In some compounds of general formulae (XVIIIa) to (XXIIa) or of general formulae (XVIII) to (XXII), Y^1 is a bond.

In other compounds of general formulae (XVIIIa) to (XXIIa) or of general formulae (XVIII) to (XXII), Y^1 is a C_{1-15} alkylene linker group, more suitably C_{1-12} , C_{1-10} or C_{1-8} alkylene linker group and optionally substituted with one or more R^3 as defined above. Typically each R^3 is independently halo, OR^8 or NR^8R^9 ; where each of R^8 and R^9 is independently selected from H, methyl or ethyl, especially H or methyl.

In some suitable compounds of general formulae (XVIIIa) to (XXIIa) or of general formulae (XVIII) to (XXII), Y^1 is an unsubstituted C_{1-15} alkylene or C_{2-15} alkenylene linker, more suitably C_{1-12} alkylene, C_{1-10} alkylnene or C_{1-8} alkylene, or C_{2-12} alkenylene, C_{1-10} alkenylnene or C_{1-8} alkenylene.


In suitable compounds of general formulae (XVIIIa) to (XXIIa) or of general formulae (XVIII) to (XXII), R^1 may be C_{1-4} alkyl optionally substituted with one or more substituents selected from halo, OR^6 or NR^6R^7 , where R^6 and R^7 are each independently H, methyl or ethyl,

especially H or methyl. More suitably, R¹ is unsubstituted C₁₋₄ alkyl.


Step (i)

5 Step (i) is described in detail above in the section describing the methyltrioxorhenium epoxidation. Such reactions are described in Examples 10 and 10a, and Examples 35-50.

Suitably, a compound of general formula (Ia):




10 wherein Y, R², R⁴ and R⁵ are as defined above; is prepared as described above by oxidation of a compound of general formula (IIa):




wherein Y, R², R⁴ and R⁵ are as defined for compounds of general formula (Ia).

15 Suitably, a compound of general formula (I):



wherein Y, R², R⁴ and R⁵ are as defined above; is prepared as described above by oxidation of a compound of general formula (II):




20 wherein Y, R², R⁴ and R⁵ are as defined for compounds of general formula (I).

Suitable embodiments of the reaction are described above.

Step (ii)


Compounds of general formula (XIXa) may be prepared from compounds of general formula (Ia):

5




wherein R², R⁴, R⁵ and Y are as defined above;

by selective alkylation with an organometallic reagent, to give a compound of general formula (XIXa):



10 wherein R², R⁴, R⁵ and Y are as defined for compounds of general formula (Ia).


Suitably, the compound of general formula (Ia) is



wherein R², R⁴, R⁵ and Y are as defined above.


15

Compounds of general formula (XIX) may be prepared from compounds of general formula (I):




wherein R², R⁴, R⁵ and Y are as defined above;

20 by selective alkylation with an organometallic reagent, to give a compound of general formula (XIX):



wherein R², R⁴, R⁵ and Y are as defined for compounds of general formula (I).

Suitably, the compound of general formula (I) is



wherein R^2 , R^4 , R^5 and Y are as defined above.

Suitable organometallic reagents include Gilman reagents formed by reaction of an alkyl lithium compound of formula (XXIV):

10



wherein R¹ is as defined for general formula (XVIIIa) or (XVIII);

and a copper (I) salt, particularly a copper (I) halide such as copper (I) iodide.

15

The reaction may be conducted in an organic solvent such as tetrahydrofuran, other ethers such as diethylether or a mixture thereof.

Alternatively, the addition can be carried out using Grignard reagents R^1MgX , where R^1 is as defined for general formula (XVIIa) or (XVIII), and X is a halide, for example ethylmagnesium bromide and the reaction is suitably conducted in the presence of a zinc (II) salt such as zinc chloride and a catalytic amount of a copper (I) or copper(II) salt or complex, for example copper (I) chloride, copper (II) chloride or a copper(I) or copper (II) acetylacetonate (acac) complex.

25

The reaction may be carried out in an organic solvent, for example an ether such as THF, 2-methyl THF, methyl *tert*-butyl ether (TBME) or diethyl ether. Surprisingly, the reaction temperature is not particularly significant and while in some cases the reaction may be carried out at reduced temperature, for example at about -25 to 0 °C, it has also been

successfully conducted at higher temperatures of up to about 55 °C.


The method is particularly suitable for the preparation of compounds of general formula (XIXa) or compounds of general formula (XIX) in which R⁴ is C(O)OR¹⁰ from compounds 5 of general formula (Ia) or from compounds of general formula (I), respectively, where R⁴ is also C(O)OR¹⁰, where R¹⁰ is as defined above but is especially H, C₁₋₆ alkyl or benzyl.

Compounds of general formula (XIXa) or of general formula (XIX) with other R⁴ groups may be prepared from the above compounds of general formula (XIXa) or compounds of 10 general formula (XIX), respectively, by methods which are familiar to those of skill in the art, and described below.

Representative methods of forming a compound of formula (XIXa) or a compound of formula (XIX) are described in Example 12.

15


In one embodiment, the compound of formula (XIXa) is:



wherein R¹ is as defined above for compounds of general formula (XVIIla) and Y, R², R⁴ and R⁵ are as defined above for compounds of general formula (Ia).

20


In one embodiment, the compound of formula (XIXa) is:



wherein R¹ is as defined above for compounds of general formula (XVIIla) and Y, R², R⁴ and R⁵ are as defined above for compounds of general formula (Ia).


25

In one embodiment, the compound of formula (XIXa) is:




wherein R¹ is as defined above for compounds of general formula (XVIIIa) and Y, R², R⁴ and R⁵ are as defined above for compounds of general formula (Ia).

5 In one embodiment, the compound of formula (XIX) is:




wherein R¹ is as defined above for compounds of general formula (XVIII) and Y, R², R⁴ and R⁵ are as defined above for compounds of general formula (I).

10 In one embodiment, the compound of formula (XIX) is:



wherein R¹ is as defined above for compounds of general formula (XVIII) and Y, R², R⁴ and R⁵ are as defined above for compounds of general formula (I).

15 In one embodiment, the compound of formula (XIX) is:



wherein R¹ is as defined above for compounds of general formula (XVIII) and Y, R², R⁴ and R⁵ are as defined above for compounds of general formula (I).

Step (iii)

The conversion of the compound of general formula (XIXa) or the compound of general


5 formula (XIX) to the compound of general formula (XXa) or to the compound of general

hydrogenation. Suitable catalysts for the catalytic hydrogenation include a palladium/carbon, palladium/calcium carbonate, palladium/aluminium oxide, platinum/palladium or Raney nickel catalyst. The reaction may be carried out in an organic solvent, which may be an alcoholic solvent such as methanol, ethanol or isopropanol; ethyl acetate; pyridine; acetic acid; cyclopentyl methyl ether (CPME), acetonitrile (MeCN) or


10 *N,N*-dimethylformamide (DMF). The organic solvent may optionally be mixed with a co-solvent such as acetone or water and/or a base such as triethylamine may also be added.

The choice of catalyst and solvent affects the ratio of the required product of general

15 formula (XXa) or general formula (XX):



to its isomer of general formula (XXXa) or general formula (XXX):



20 More suitably, a palladium/carbon or palladium/calcium carbonate catalyst is used. Typically, in the catalyst the palladium is present in an amount of 5-10% by weight with respect to the weight of the matrix (where the matrix is the carbon, calcium carbonate etc.).

Particularly suitable solvents and catalysts used for the reaction included a mixture of DMF

25 and MeCN with a palladium/calcium carbonate catalyst and DMF with a palladium/carbon catalyst.

Hydrogenation of a compound of formula (XIXa) or a compound of formula (XIX) will also reduce any alkene bonds, if present, in the linker Y.

Representative methods of forming a compound of general formula (XXa) or a compound of general formula (XX) are described in Examples 13 and 15.

5 Step (iv)

The oxidation reaction of a compound of general formula (XXa) to a compound of general formula (XXIa), or of a compound of general formula (XX) to a compound of general formula (XXI) may be carried out using any suitable method. One suitable method is a 10 Dess-Martin periodinane (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3-(1H)-one) oxidation, which may be carried out in a chlorinated solvent such as chloroform or dichloromethane at a temperature of about 15 to 25 °C, suitably at room temperature.

An alternative oxidation method is oxidation using a hypochlorite, for example sodium 15 hypochlorite, under acidic conditions, for example provided by acetic acid. The reaction may be carried out in an aqueous solvent and at a temperature of 0 to 15 °C, more usually at about 0 to 10 °C.

Other oxidation methods include a Jones reaction using sodium dichromate or, more 20 usually, chromic trioxide in dilute sulfuric acid. This process is known to be reliable for the clean conversion of bile acid hydroxyl groups to the corresponding keto derivatives (Bortolini *et al*, *J. Org. Chem.*, 2002, 67, 5802, incorporated herein by reference). Alternatively oxidation may be carried out using TEMPO ((2,2,6,6-tetramethyl-piperidin-1-yl)oxy) or a derivative thereof.

25 Representative examples of such a process are described in Example 16.

Step (v)

30 The epimerisation reaction of step (v) suitably comprises treating the compound of general formula (XXIa) or of general formula (XXI) with a base. The compound of general formula (XXIa) or compound of general formula (XXI) may be dissolved in an alcoholic solvent, optionally mixed with water and contacted with a base, for example sodium or potassium hydroxide or a sodium or potassium alkoxide, typically an ethoxide.

35 In the case of compounds of general formula (XXIa) or compounds of general formula (XXI) in which R⁴ is C(O)OR¹⁰, where R¹⁰ is C₁₋₆ alkyl or benzyl and where a strong base

such as sodium or potassium hydroxide is used, the epimerization reaction of step (v) may be accompanied by hydrolysis to give a compound of general formula (XXIIa) or a compound of general formula (XXII), respectively, in which R⁴ is C(O)OH.

- 5 If, in the compound of general formula (XXIa) or compound of general formula (XXI), R² and/or R⁵ is a protected OH, for example a group OC(O)R¹⁴, where R¹⁴ is as defined above but is especially C₁₋₆ alkyl or benzyl, or C₁₋₆ alkyl or phenyl, this will be removed during the epimerisation step to give a compound of general formula (XXIIa) or a compound of general formula (XXII), respectively, in which R² and/or R^{5b} is OH. Other protected OH
- 10 groups which are stable in basic conditions (for example a group OSi(R¹⁶)₃ where each R¹⁶ is independently as defined above but is especially C₁₋₆ alkyl or phenyl) may be removed before or after step (v).

Such a reaction is described in Example 17.

15

Step (vi)

- The reduction of a compound of general formula (XXIIa) or a compound of general formula (XXII) to form a compound of general formula (XVIIia) or compound of general formula (XVII), respectively, utilises a reducing agent which is typically a hydride, such as sodium borohydride which may be used in a solvent such as a mixture of tetrahydrofuran and water. Typically, this reaction is carried out under basic conditions, for example in the presence of a strong base such as sodium or potassium hydroxide and at a temperature of about 0 to 110 °C, more usually 60 to 100 °C. A compound of general formula (XVIIia) or a compound of general formula (XVII) in which R⁴ is C(O)OH may be produced by the reduction of a compound in which R⁴ is C(O)OH. Such a reaction is described in Example 18.

- 30 The process optionally further includes one or more steps of converting compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) or (XVIIia) to other compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) or (XVIIia), or one or more steps of converting compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) or (XVII) to other compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) or (XVII).

- 35 The optional steps consist of reacting the side chains of the compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) and (XVIIia) or of the compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) and (XVII) as described below to arrive at

compounds with alternative Y and/or R⁴ moieties.

It should be noted that embodiments described above with respect to different Y and R groups apply equally to the process embodiments just described.

5

Side chain conversions

The various side chain Y-R⁴ and Y¹-R⁴ groups of compounds of formulae (Ia)-(VIa) and (XVIIa)-(XXIIa) and of compounds of formulae (I)-(VI) and (XVIII)-(XXII) may be prepared using conversion steps which are well known to the skilled person e.g. by reactions involving a side chain carboxylic acid, ester, OH or protected OH group. Analogues of the compounds of formulae (XVIII), (XVIIa), (XXI), (XXIIa), (XXII), (XXIIa), (XXIII), (XXIIa) in which a saturated side chain Y¹-R⁴ is converted to an unsaturated side chain Y-R⁴ may also be prepared by these methods and are described in more detail below.

15

Figure 1 shows the conversion of a compound of general formula (IIa) or of general formula (II) in which the side chain is -CH₂OH to other compounds of general formula (IIa) or of general formula (II), respectively, with different side chains.

20


Such reactions are equally applicable to compounds of general formulae (Ia), (I), (IIIa)-(VIa), (III)-(VI), (XVIIa)-(XXIIa) and (XVIII)-(XXII), wherein appropriate (i.e. where chemically sensible).

25


As shown in Figure 1, a compound of general formula (IIa) or a compound of general formula (II) wherein Y-R⁴ is CH₂-OH may be prepared from a plant sterol such as stigmasterol (as described in Example 1).

30

As shown in Figure 1, a compound of general formula (IIa) or a compound of general formula (IIa) with the -CH₂OH side chain can be converted to compounds of general formula (IIa) or of general formula (II) with side chains including -CH₂-9-borabicyclo(3.3.1)nonyl, -CH₂CH₂CH[B(alkyl)₂]₂, -CH₂CN, -CH₂CH₂CN, -CH₂Br, -CH₂CH[C(O)OEt]₂, -CH₂C≡CH, -CH₂-CH=CH₂, =CH₂, -C(O)H, -CH₂NH₂, CH₂OTBDMS, CH₂N₃, CH₂OMs,



or



where X is O or S

alkyl may be C₁₋₆ alkyl and Et is ethyl, and also carboxylic acid mimetic groups including -C(O)NHSO₂R¹⁰ and -NHC(O)NH-SO₂R¹⁰.

Compounds of general formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) and compounds of general

5 formulae (I)-(VI), and (XVIII)-(XXII) with a side chain Y-OH (wherein Y is Y²-CH₂, and Y² is as defined above for Y except it is shorter in length by at least one carbon) can be converted to compounds in which the side chain is -Y²-C(O)H by oxidation, for example using oxalyl chloride suitably in the presence of dimethyl sulfoxide and a base such as trimethylamine. Alternatively, the oxidation may be carried out using Dess-Martin 10 periodinane as shown in Example 23.

In compounds of general formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is -Y²-C(O)H, the side chain can be extended, for example using an olefination reaction with a compound of 15 general formula (XXIII):



where Y³ is as defined for Y in general formula (Ia) and general formula (IIa) or Y in general formula (I) and general formula (II) except that it may have a shorter carbon chain such 20 that the linker Y of general formula (Ia) and general formula (IIa) or of general formula (I) and general formula (II) can be a moiety -Y²-CH₂CH₂-Y³-, wherein Y² and Y³ are as defined for Y except that they are shorter in length, wherein R²⁷ is suitably C₁₋₆ alkyl or benzyl, to give a compound in which the side chain is Y²-CH=CH-Y³-C(O)OR²⁷. An olefination reaction using (EtO)₂P(O)CH₂Y³-C(O)OR²⁷ may also be used.

25 The olefination may be carried out at about 15 to 25 °C, suitably room temperature, in a solvent such as dichloromethane.

These compounds can, in turn, be converted to compounds in which R⁴ is the carboxylic 30 acid mimetic group C(O)NHSO₂R¹⁰, wherein R¹⁰ is as defined above, by reaction with:



Wherein R¹⁰ is as defined above, in the presence of a coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI).

35 Compounds of general formula formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) and compounds of general formula formulae (I)-(VI), and (XVIII)-(XXII) in which the group at the R⁴ position is OH can be protected with a silyl protecting group. This may be achieved by reaction with

(XV) as described below, typically in an organic solvent and in the presence of a base, for example imidazole, or triethylamine. Such a reaction is shown in Example 22.



5 wherein, R^{16} is as defined above and X^1 is a leaving group, for example a halide such as chloride or a sulfonate leaving group such as trifluoromethanesulfonate (triflate), methanesulfonate (mesylate) or toluene sulfate (tosylate).

10 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is OH may also be converted to compounds in which R^4 is a sulfonate, for example methane sulfonate or toluene sulfonate, by reaction with a sulfonyl halide such as methane sulfonyl chloride, in the presence of a catalyst such as 4-dimethylaminopyridine (DMAP). Such a reaction is shown in Example 25. Alternatively, they may be converted to compounds of general formulae (Ia)-(VIa), and 15 (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is halo, for example bromo, by reaction with a halogenating agent, e.g. a brominating agent such as carbon tetrabromide as illustrated in Example 26 or *N*-bromosuccinimide, as 20 illustrated in Example 30.

25 Such sulfonate or halide compounds can then be converted to compounds of general formulae (Ia)-(VIa) and (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI) and (XVIII)-(XXII) in which R^4 is cyano by reaction with a cyanide salt, for example sodium or potassium cyanide (see Example 30). Alternatively, reaction with acetonitrile in the presence of a base such as *n*-butyllithium leads to a chain lengthening reaction so that, 30 for example, a side chain - $\text{CH}_2\text{-O-methanesulfonyl}$ or - $\text{CH}_2\text{-Br}$ is converted to a side chain - $\text{CH}_2\text{CH}_2\text{-CN}$. Such a reaction is shown in Example 28.


Compounds with a sulfonate side chain can also be converted to compounds in which R^4 35 is nitro by reaction with nitromethane in the presence of a base such as sodium or potassium carbonate.

Compounds of formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is $Y^2\text{-C(O)OH}$ or an ester thereof may be converted to compounds in which the side chain is $Y^2\text{-CH=CH}_2$ by reaction with 40 PhI(OAc)_2 in the presence of copper (II) acetate using a process similar to Hunsdiecker reaction (see *J. Org. Chem.*, 1986, 51, 404-407 and V.C. Edelsztein et al. *Tetrahedron*, 2009, 65 (2009), 3615-3623, both incorporated herein by reference). Such compounds

with side chain $-Y^2\text{-CH=CH}_2$ may in turn be oxidised using, for example, osmium tetroxide as described in *J. Org. Chem.*, 1986, 51, 404-407 (incorporated herein by reference) to give a compound in which the side chain is $-Y^2\text{-CH(OH)-CH}_2\text{-OH}$. Such compounds may be oxidised to compounds in which the side chain is $Y^2\text{-CH(OH)-C(O)H}$, which may then 5 be protected as a 1,3-dioxane or 1,3-dioxolane by reaction with 1,3-propane diol or 1,2-ethanediol in the presence of an acid catalyst such as toluene sulfonic acid. Similar reactions can be used to prepare the equivalent cyclic dithioacetals, and cyclic aminals.

Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general 10 formulae (I)-(VI), and (XVIII)-(XXII) with side chain $-Y\text{-CH=CH}_2$ may also be prepared by reduction of a compound with side chain $-Y\text{-C}\equiv\text{CH}$, typically by hydrogenation over a palladium catalyst, suitably Lindlar catalyst, as shown in Figure 1.

Compounds of formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general 15 formulae (I)-(VI), and (XVIII)-(XXII) with side chain $-Y\text{-C}\equiv\text{CH}$ may be prepared from compounds with side chain $Y\text{-X}$, where X is a halo group, particularly bromo, by reaction with an organometallic reagent, for example:



20 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain $-Y\text{-R}^4$ is $-\text{CH}_2\text{-OH}$ may also be converted to compounds in which the side chain is $=\text{CH}_2$. This can be achieved by an elimination reaction in which the compound having side chain $-Y\text{-R}^4$ is $-\text{CH}_2\text{-OH}$ is reacted with an acid such as phosphoric acid, sulphuric acid or toluene sulphonic acid as shown 25 in Figure 1. A similar reaction can be used to convert a compound with side chain $-Y^2\text{-CH}_2\text{-OH}$ to a compound with side chain $-\text{C=CH}_2$. Alternatively, compounds in which the side chain is $Y^2\text{-CH=CH}_2$ can be prepared by oxidising $-\text{Y}^2\text{-CH}_2\text{-OH}$ to $Y^2\text{-CH(O)}$ and then converting this to an alkene using an olefination reaction.

30 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) with side chain $Y\text{-C}\equiv\text{CH}$, $=\text{CH}_2$ or $-Y^2\text{-C=CH}_2$ may be reacted with a borane of formula:



35 to give compounds in which the side chain is $-Y\text{-CH}_2\text{-C}(\text{Br}^{10}\text{R}^{11})_2$, $-\text{CH}_2\text{-Br}^{10}\text{R}^{11}$ or $-Y^2\text{-CH}_2\text{-Br}^{10}\text{R}^{11}$ respectively. An example of this reaction is shown in Figure 1.

Compounds of formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general

formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is $-\text{CH}_2\text{-BR}^{10}\text{R}^{11}$ or $-\text{Y}^2\text{-CH}_2\text{-BR}^{10}\text{R}^{11}$ may be reacted with, for example phenoxyacetic acid to give a corresponding compound in which the side chain is $-\text{CH}_2\text{-C(O)OH}$ or $-\text{Y}^2\text{-CH}_2\text{-C(O)OH}$.


5 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is $-\text{CH}[\text{C(O)OR}^{10}]_2$ may be prepared from compounds in which R^4 is halo, for example bromo, by reaction with a malonate ester in the presence of a base such as sodium hydride, as shown in Figure 1. A reaction of this type is illustrated in Example 27 and Example 31.

10 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is a malonate ester $-\text{CH}[\text{C(O)OR}^{10}]_2$ may be heated under basic or acidic conditions to give compounds in which R^4 is $\text{CH}_2\text{C(O)OH}$ or, when basic conditions are used, a salt thereof.

15 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is $-\text{Y-C(O)OH}$ may also be converted to compounds in which the side chain is $-\text{Y-C(O)-CH}_2\text{-N}_2$ by reaction with phosgene to form the acid chloride, followed by reaction with diazomethane.

20 The diazomethane may be formed *in situ* using conventional methods, e.g. the treatment of *N*-nitroso-*N*-methylurea with aqueous sodium or potassium hydroxide in diethyl ether. Suitably the diazomethane is used in excess, typically in an amount of greater than 2 equivalents compared with the acid chloride. The reaction is typically conducted in an 25 organic solvent such as diethyl ether, toluene or a mixture thereof. The reaction is carried out at a temperature of about -5 to 15 °C, typically 0-10 °C.

30 The compound with side chain $-\text{Y-C(O)-CH}_2\text{-N}_2$ may be treated with an aqueous silver compound, for example silver nitrate, at an elevated temperature and in the presence of an alcohol of formula:



wherein R^{10a} is as defined for R^{10} in general formula (Ia) or in general formula (I) except that it is not H. Most suitably, R^{10a} is C_{1-6} alkyl or benzyl. Under these conditions, the compound undergoes a Wolff rearrangement to give a compound in which the side chain 35 is $-\text{Y-CH}_2\text{-C(O)OR}^{10a}$ and thus this sequence can be used to lengthen the side chain.

Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general


formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is Y-C(O)OH may be converted to compounds in which the side chain is -Y²-CH₂-CN by reaction with sodium nitrite under acidic conditions, for example in the presence of trifluoroacetic acid and trifluororoacetic anhydride (C. D. Schteingart and A. T. Hofmann, *Journal of Lipid Research*, **1988**, 29, 5 1387-1395; Valentina Sepe *et al*, *Eur. J. Org. Chem.* **2012**, 5187-5194, both incorporated herein by reference).

Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is Y-C(O)H may be converted to compounds in which the side chain is -Y-CH(XR¹⁰)(XR¹¹), for example -Y-CH(OR¹⁰)(OR¹¹) or -Y-CH(SR¹⁰)(SR¹¹) where R¹⁰ and R¹¹ together with the atoms to which they are attached join to form a cyclic group. This can be achieved by reacting the compound in which the side chain is Y-C(O)H with a compound of formula:



where X³ is O, S or NH and p is 1 to 4 but usually is 2 or 3, or with a protected version of such a compound, for example in which OH or SH groups are protected with trimethylsilyl as shown in Example 24.

20 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is Y²-C(O)H may also be converted to compounds with side chain -Y²-CH(OH)-CH₂-CH(OR¹⁰)(OR¹¹), -Y²-CH(OH)-CH₂-CH(R¹⁰)(OR¹¹) or -Y²-CH(OH)-CH₂-CH(SR¹⁰)(SR¹¹) by reaction with an appropriate 25 organometallic reagent, typically a Grignard reagent of formula:



where X is halo, typically bromo, and R^{4c} -CH(OR¹⁰)(OR¹¹), -CH(R¹⁰)(OR¹¹) or CH(SR¹⁰)(SR¹¹).

30 Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is -Y²-CH(OH)-CH₂-CH(OR¹⁰)(OR¹¹) can be converted to compounds in which the side chain is -Y²-CH=CH-C(O)H by reaction with an acid. Following this, the aldehyde can be oxidised to give a 35 carboxylic acid and/or the alkylene bond can be reduced by hydrogenation to give a saturated side chain in which Y is -Y²-CH₂CH₂-.

Compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is -N₃ may be prepared from compounds in which R⁴ is a leaving group such as toluene sulfonate, methane sulfonate or compounds of general formulae (Ia)-(IVa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII), respectively, in which R⁴ is halo (for example bromo) or a sulfonyl leaving group such as toluene sulfonate or methane sulfonate, by reaction with sodium azide. This is illustrated in Example 29.

Compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is NH₂ may be obtained by reduction of compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII), respectively, in which R⁴ is azide as illustrated in Example 29.

Compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is -NHC(O)NHSO₂R¹⁰ may be prepared from compounds in which R⁴ is NH₂ using a coupling reaction with a compound of formula:



wherein R¹⁰ is as defined above;

in the presence of a reagent such as N,N'-carbonyldiimidazole (CDI).

Compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is tetrazole-5-yl may be prepared from compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII), respectively, in which R⁴ is CN by reaction with azidotrimethylsilane/dibutylstannanone or Bu₃SnN₃ as described in US 2016/0145295. Alternatively, the compound in which R⁴ is CN may be reacted with sodium azide in the presence of acid. For example, NaN₃/NH₄Cl in toluene/DMF (*Organic and Biomolecular Chemistry*, 2008, 6, 4108) or NaN₃/NEt₃.HCl in DMF (Brown *et al*; *Bioorg Med Chem Lett*, 2002, 12, 3171). Alternatively, a compound in which R⁴ is azide may be reacted with a suitable cyanide compound, for example tosyl cyanide, under reducing conditions to give a compound in which R⁴ is tetrazol-1-yl.

Compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is amino tetrazole can be prepared from a compound in which the group at the R⁴ position is mesyl by reaction with 5-amino tetrazole.

Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) and compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which the side chain is $-Y^2-C(O)H$ may also be converted to compounds $-Y^2-CH_2-NR^{10}R^{11}$ by reductive amination, using a reducing agent such as a hydride, borohydride or cyanoborohydride (for example sodium borohydride or 5 sodium cyanoborohydride) and an amine of formula:



where R^{10} and R^{11} are as defined above.

Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general 10 formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is $C(O)OR^{10}$ may be converted to a compound of the same general formula, in which R^4 is $OC(O)R^{10}$, $C(O)NR^{10}R^{11}$, OR^{10} , $OSi(R^{13})_3$, $S(O)R^{10}$, SO_2R^{10} , OSO_2R^{10} , SO_3R^{10} , OSO_3R^{10} , halo, CN, $C(O)R^{10}$, $CH(OR^{10})(OR^{11})$, $CH(R^{10})(OR^{11})$, $CH(SR^{10})(SR^{11})$, $NR^{10}R^{11}$, $BR^{10}R^{11}$, $C(O)CH_2N_2$, - $CH=CH_2$, $-C\equiv CH$, $CH[C(O)OR^{10}]_2$ or $CH(BR^{10}R^{11})_2$, azide or a carboxylic acid mimetic 15 group such as tetrazole.

Compounds of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is SO_3R^{10} may be synthesised from 20 compounds in which R^4 is $C(O)OH$ by the methods taught in WO2008/002573, WO2010/014836 and WO2014/066819 (all incorporated herein by reference).

Thus, a compound of general formulae (Ia)-(VIa) and (XVIIIa)-(XXIIa) or compounds of 25 general formulae (I)-(VI) and (XVIII)-(XXII) in which R^4 is $C(O)OH$ may first be reacted with a C_{1-6} alkanoyl or benzoyl chloride or with a C_{1-6} alkanoic anhydride to protect any OH groups. The protected compound may then be reacted with a reducing agent such as a hydride, suitably lithium aluminium hydride or sodium borohydride in order to reduce the carboxylic acid group to OH. The alcohol group may be replaced by a halogen, for example bromine or iodine, using the triphenyl phosphine/imidazole/halogen method described by Classon *et al*, *J. Org. Chem.*, 1988, 53, 6126-6130 (incorporated herein by 30 reference). The halogenated compound may then be reacted with sodium sulphite in an alcoholic solvent to give a compound with a $SO_3^- Na^+$ substituent.

A compound of general formulae (Ia)-(VIa), and (XVIIIa)-(XXIIa) or a compound of general 35 formulae (I)-(VI), and (XVIII)-(XXII) in which R^4 is OSO_3R^{10} can be obtained by reacting the alcohol obtained from reducing the protected carboxylic acid as described above with chlorosulfonic acid in the presence of a base such as triethylamine to yield the protected triethylamine salt. Protecting groups can be removed using base hydrolysis as described

above. Reduction of the carboxylic acid followed by reaction of the resultant alcohol with a sulfonyl chloride yields a compound of general formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) or a compound of general formula (I)-(VI), and (XVIII)-(XXII) in which R⁴ is OSO₂R¹⁰.

5 Compounds of general formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) or of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is C(O)NR¹⁰R¹¹ may be prepared from the carboxylic acid by reaction with an amine of formula H-NR¹⁰R¹¹ in a suitable solvent with heating. Compounds of general formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) or of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is C(O)NR¹⁰R¹¹ or OSO₃R¹⁰ may also be prepared by
10 methods similar to those described by Festa *et al.*, *J. Med. Chem.*, **2014**, *57*, 8477–8495 (incorporated herein by reference).

An example of this is the synthesis of compounds of general formulae (Ia)-(VIa), and (XVIIia)-(XXIIa) or compounds of general formulae (I)-(VI), and (XVIII)-(XXII) in which R⁴ is C(O)NH(CH₂)₂SO₃H or C(O)NHCH₂CO₂H or salts thereof from compounds of the same general formula in which R⁴ is C(O)OH by reaction with taurine or glycine respectively in the presence of a coupling reagent such as iso-butylchloroformate and a base such as diethylamine.

20 A compound of general formulae (Ia)-(VIa) and (XVIIia) to (XXIIa) or a compound of general formulae (I)-(VI) and (XVIII) to (XXII) in which R⁴ is C(O)R¹⁰ can be obtained by reduction of a compound in which R⁴ is C(O)OR¹⁰ using one equivalent of diisobutyl aluminium hydride (DIBAL-H) to obtain an aldehyde in which R⁴ is C(O)H (see, for example, WO2011/014661, incorporated herein by reference).

25 Alternatively, the aldehyde may be prepared by oxidation of a protected compound in which R⁴ is OH prepared as described above. The oxidation may be Swern oxidation carried out using oxalyl chloride and dimethyl sulfoxide followed by triethylamine (see, for example Xiang-Dong Zhou *et al.*, *Tetrahedron*, **2002**, *58*, 10293-10299, incorporated herein by reference). Alternatively, the oxidation may be carried out using an oxidising agent such as pyridinium chlorochromate (PCC) as described by Carnell *et al.* (*J. Med. Chem.*, **2007**, *50*, 2700-2707, incorporated herein by reference).

35 A compound of general formulae (Ia)-(VIa) and (XVIIia)-(XXIIa) or a compound of general formulae (I)-(VI) and (XVIII) to (XXII) in which R⁴ is C(O)R¹⁰ where R¹⁰ is other than hydrogen can be obtained by known methods, for example by the reaction of the aldehyde in which R⁴ is C(O)H with a suitable Grignard reagent, followed by oxidation. Such

methods are well known to those of skill in the art.

Compounds of general formulae (Ia)-(VIa), and (XVIIa)-(XXIIa) or compounds of general formulae (I)-(VI) and (XVIII) to (XXII) with other R⁴ groups may be prepared from the above 5 compounds of the same general formula, by methods which are familiar to those of skill in the art.

General information

10 The invention will now be described in greater detail with reference to the examples.

ABBREVIATIONS

Ac	acetyl
AcOH	acetic acid
<i>n</i> BuOAc	<i>n</i> -butyl acetate
9-BBN	9-borabicyclo[3.3.1]nonane
<i>n</i> BuLi	<i>n</i> -butyllithium
CDCA	chenodeoxycholic acid
CDI	<i>N,N</i> -carbonyldiimidazole
CPME	cyclopentyl methyl ether
DCM	dichloromethane
DEIPS	diethylisopropylsilyl
DIBAL-H	diisobutyl aluminium hydride
DMAP	4-dimethylaminopyridine
DMDO	dimethyldioxirane
DMF	<i>N,N</i> -dimethylformamide
DMIPS	dimethylisopropylsilyl
DMP	Dess–Martin periodinane
DTBMS	di- <i>tert</i> -butylmethylsilyl
EDCI	1-ethyl-3(3-dimethylaminopropyl)carbodiimide
EtOAc	ethyl acetate
EtOH	ethanol
Et ₂ O	diethyl ether
FXR	farnesoid X receptor
HFIP	1,1,1,3,3,3-hexafluoro-2-propanol/hexafluoroisopropanol

HMPO	(20S)-20-hydroxymethyl-pregna-4-en-3-one also known as 20-hydroxymethylpregn-4-en-3-one and 3-keto-bis-norcholenol
HPLC	high performance liquid chromatography
HWE	Horner-Wadsworth-Emmons
IPC	in process control
IPA	isopropyl alcohol
<i>m</i> CPBA	<i>meta</i> -chloroperoxybenzoic acid
MeCN	acetonitrile
MeOH	methanol
MIBK	methyl isobutyl ketone
MMPP	magnesium bis(monoperoxyphthalate)
Ms	methanesulfonyl
MsCl	methanesulfonyl chloride
MTO	methyltrioxorhenium (VII)
NEt ₃	triethylamine
OCA	obeticholic acid
PCC	pyridinium chlorochromate
PEG	polyethylene glycol
PhMe	toluene
RRT	relative retention time
pTSA.H ₂ O	<i>p</i> -toluenesulfonic acid monohydrate
TBDMS	<i>tert</i> -butyldimethylsilyl
TBDPS	<i>tert</i> -butyldiphenylsilyl
TBME	<i>tert</i> -butyl methyl ether
TDS	thexyldimethylsilyl
TEMPO	(2,2,6,6-tetramethyl-piperidin-1-yl)oxy
TEPA	triethyl phosphonoacetate
TES	triethylsilyl
TFE	2,2,2-trifluoroethanol
THF	tetrahydrofuran
TIPS	tri-isopropylsilyl
TLC	thin layer chromatography
TMS	trimethylsilyl
TMSOTf	trimethylsilyl trifluoromethanesulfonate
TPS	triphenylsilyl

Ts	toluenesulfonyl/tosyl
UDCA	ursodeoxycholic acid
UHP	urea hydrogen peroxide

EXAMPLES

GENERAL PROCEDURES


5

HPLC conditions for monitoring the reaction and assessing conversion, for example, conversion of (22E)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester to (6 α , 7 α) and (6 β , 7 β) isomers of (22E)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester.

10 *Chromatographic Conditions*

Instrument	Agilent 1200 series HPLC fitted with RI detector
Column	ACE, C18, 250 mm x 4.6 mm, 5 μ m
Column Temperature	40 °C
Eluent	30:70, 25 mM Ammonium acetate pH6 : Acetonitrile
Flow Rate	1.25 mL/min
Injection Volume	10 μ L
RID Conditions	40 °C
Run Time	60 minutes

Example 1 – Synthesis of (22E)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester (IIA) from stigmasterol




15 The starting material, (22E)-3-oxo-4,22-choladien-24-oic acid ethyl ester (compound (IIIA)), was prepared from stigmasterol according to the method described by Uekawa *et al* in *Biosci, Biotechnol, Biochem.*, **2004**, 68, 1332-1337.

20 Compound (IIIA) (1.00 kg, 2.509 mol; 1 eq) was charged to a reaction vessel, followed by AcOH (3 vol, 3.0 L) and toluene (1 vol, 1.0 L) with stirring. Chloranil (0.68 kg, 2.766 mol; 1.1 eq) was then charged and the reaction mixture heated to 100 °C and maintained at this temperature for 1-2 h (IPC by TLC on silica, eluent 3:7 EtOAc: Heptane; Starting Material: R_f 0.50, Product: R_f 0.46; visualise with anisaldehyde stain). The mixture was then cooled in an ice/water bath to 10 °C and the resulting solid was filtered off. The filter-


cake was washed with premixed 3:1 AcOH : Toluene (4 x 0.5 vol) at 5 °C ± 4 °C and the filtrate concentrated *in vacuo* at up to 70 °C. The residue was dissolved in acetone (3 vol), then 3% w/w aq. NaOH (10 vol) was charged dropwise with stirring, maintaining the temperature below 30 °C (exothermic). The resulting suspension was cooled to 10-15 °C 5 and stirred for 30 mins. The solids were collected by filtration and the filter cake was washed with premixed 1:1 acetone : water (1 x 2 vol then 3 x 1 vol). The filter cake (tan solid) was dried under vacuum at 70-75 °C, resulting in 672 g of the title compound (68% yield). Characterisation of the compound agrees with the data published in the literature.

10 **Examples 2-8 - Synthesis of 3-oxo-4,6-choladien-24-oic acid ethyl ester (IIB) from deoxycholic acid**

Example 2 – Synthesis of (3 α , 5 β)-3-acetoxy-12-oxo-cholan-24-oic acid methyl ester (VIIB)



To a solution of deoxycholic acid (referred to herein as compound (XB), 500 g, 1.27 mol) in MeOH (1.5 L) was charged H₂SO₄ (0.68 mL, 12.7 mmol) and the reaction heated to 64 °C until complete. The reaction was cooled to 55 °C and pyridine (2.06mL, 25.4 mmol) was charged. MeOH (800 mL) was removed by distillation and the reaction cooled to 50 20 °C. EtOAc (500 mL) was charged and the distillation continued. This co-evaporation was repeated until the MeOH content was <0.5%. The reaction was cooled to 40 °C and EtOAc (1.0 L) was charged followed by pyridine (134 mL, 1.65 mol) and DMAP (1.1 g, 8.89 mmol). Acetic anhydride (150 mL, 1.58 mmol) was added dropwise and the reaction vessel stirred at 40 °C until complete. The reaction was cooled to 22 °C and 2M aq. H₂SO₄ (1500 mL) 25 added maintaining the temperature below 25 °C. The aqueous phase was removed and the organic phase washed with water (1.2 L), sat. aq. NaHCO₃ solution (1.2 L x 2) and water (1.2 L). AcOH (1.0 L) was charged to the organic layer, followed by NaBr (6.6 g, 63.5 mmol). Aq. 16.4% NaOCl solution (958 mL, 2.54 mol) was charged dropwise maintaining the reaction temperature below 25 °C. The reaction was stirred until complete, 30 then cooled to 10 °C and stirred for 90 mins. The resulting solids were collected by filtration, washed with water (3 x 500 mL) and the filter cake dried under vacuum at 40 °C. The solids were crystallised from MeOH (10 vol) to give the title compound as an off white solid (268 g).

Example 3 – Synthesis of (3 α , 5 β)-3-acetoxy-cholan-24-oic acid methyl ester


(3 α , 5 β)-3-acetoxy-12-oxo-cholan-24-oic acid methyl ester (compound (VII B), 268 g, 0.6 mol) was charged to the reaction vessel under argon, followed by AcOH (1.8 L).

5 Tosyl hydrazide (190 g, 1.02 mol) was then added maintaining the reaction temperature at 25 °C. The reaction was stirred until complete and then NaBH₄ (113.5 g, 3.00 mol) was charged

10 portion-wise maintaining the temperature below 25 °C. The reaction mixture was stirred until complete and then quenched by the dropwise addition of water (1.34 L) maintaining the temperature below 25 °C. The reaction mixture was stirred for 30 mins, the resulting

15 solids collected by filtration, washed with water (3 x 270 mL) and the solid dried under vacuum at 40 °C. The solids were crystallised from MeOH (3 vol) to give the title compound as an off white solid (214.5 g).

15 **Example 4 – Synthesis of (3 α , 5 β)-3-hydroxy-cholan-24-oic acid (Lithocholic Acid) (VIB)**




To a solution of (3 α , 5 β)-3-acetoxy-cholan-24-oic acid methyl ester (214.5 g, 0.50 mol) in

20 IPA (536 mL) was charged water (536 mL) and 50% w/w NaOH (99 g, 1.24 mol). The reaction was heated to 50 °C and stirred until complete. 2M H₂SO₄ was charged slowly


with vigorous stirring until pH 2-3 was obtained and then the reaction cooled to 20 °C. The resulting solids were collected by filtration, washed with water (3 x 215 mL) and the resultant solid dried under vacuum at 40 °C to give the title compound (176.53 g)

25 **Example 5 – Synthesis of (5 β)-3-oxocholan-24-oic acid ethyl ester (VB)**



To a solution of ($3\alpha, 5\beta$)-3-hydroxy-cholan-24-oic acid (compound (VIB), 10 g, 26.5 mmol) in EtOH (50 mL) was charged H_2SO_4 96% (14 μ L, 0.27 mmol) and the reaction mixture then heated to reflux for 16 h. Pyridine was then charged, the mixture stirred for 30 mins and concentrated *in vacuo* at 40 °C. The residue was dissolved in EtOAc (30 mL) and 5 AcOH (10 mL) and NaBr (136 mg, 1.33 mmol) was then charged. The solution was cooled to 5 °C and NaOCl 9% (27 mL, 39.8 mmol) was charged dropwise maintaining the temperature below 10 °C. The resulting suspension was warmed to ambient temperature and stirred for 1 h. The reaction mixture was cooled to 0 °C for 10 mins, the solids collected by filtration and washed with water (3 x 3 vol). The resultant solid was dried under vacuum 10 at 40 °C to give the title compound (7.83 g).


Example 6 – Synthesis of (5β)-3-oxo-4-bromo-cholan-24-oic acid ethyl ester (IVB)




To a solution of (5β)-3-oxocholan-24-oic acid ethyl ester (compound (VB), 8.0 g, 19.9 mmol) in AcOH (84 mL) was added Br_2 in AcOH (16 mL, 21.9 mmol) dropwise over 15 mins. The reaction mixture was stirred for 10 mins, then diluted with EtOAc (250 mL), washed with water (2 x 200 mL) and concentrated *in vacuo* at 40 °C. The crude material 15 was purified by column chromatography (30% Heptane: EtOAc) and concentrated *in vacuo* at 40 °C to give the title compound a pale crystalline solid (7.49 g).

20

Example 7 – Synthesis of (5β)-3-oxo-4-cholene-24-oic acid ethyl ester (IIIB)



To a solution of ($4\alpha, 5\beta$)-3-oxo-4-bromo-cholan-24-oic acid ethyl ester (compound (IVB), 4.0 g, 8.33 mmol) in DMF (40 mL) was charged Li_2CO_3 (4.0 g, 1 mass eq) and LiBr (2.0 g, 25 0.5 mass eq). The mixture was heated to 150 °C for 2 h then allowed to cool to ambient temperature and poured onto a mixture of water and ice (200 g, 50 volumes) and AcOH (8 mL). The resulting suspension was stirred for 15 mins, the solids collected by filtration and then purified by column chromatography (30% Heptane: EtOAc) to give the title compound as a pale crystalline solid (1.68 g).

Example 8 - Synthesis of 3-oxo-4,6-choladien-24-oic acid ethyl ester (IIB)

3-oxo-4-cholene-24-oic acid ethyl ester (compound (IIIB), 2.23 g, 5.57 mmol) was charged

- 5 to a reaction vessel, followed by AcOH (6.7 mL) and toluene (2.23 mL). Chloranil (1.5 g, 6.13 mmol) was charged and the reaction mixture heated to 100 °C for 2 h (IPC by TLC, 3:7 EtOAc: Heptane; visualized with Anisaldehyde stain). The reaction mixture was cooled to 10 °C for 10 mins and the resulting solid removed by filtration. The filter cake was washed with DCM (9 vol) and the resulting filtrate then concentrated *in vacuo* at 40 °C.
- 10 The residue was dissolved in acetone (9 vol) then 3% w/w aq. NaOH (27 vol) was added dropwise maintaining the temperature below 30 °C. The resulting mixture was cooled in an ice bath for 10 mins and the solids collected by filtration. The filter cake was washed with water (2 x 9 vol) and acetone: water 2:1 (4 vol). Purification by column chromatography (0-30% Heptane: EtOAc) gave the title compound as a pale crystalline
- 15 solid (1.45 g)

Examples 9-11 – Epoxidation reactions**Example 9 – Various epoxidation reactions for (22E)-3-oxo-4,6,22-cholatrien-24-oic**

20 **acid ethyl ester (IIA)**

A series of trials were carried out to evaluate alternative epoxidation conditions for the epoxidation of compound (IIA) to form compound (IA) to those described in Uekawa *et al.* in *Biosci. Biotechnol. Biochem.*, 2004, 68, 1332-1337 of magnesium monoperoxyphthalate

25 hydrate (MMPP) in Et₂O and CHCl₃ at ambient temperature, or *meta*-chloroperoxybenzoic acid (*m*CPBA) in CHCl₃ at reflux. The starting material used was compound (IIA) prepared according to Example 1, ultimately deriving from stigmasterol.

Firstly, the use of alternative reaction conditions using MMPP and *m*CPBA as oxidant were

30 investigated.

A series of trials was performed using *m*CPBA in various solvents and temperatures. The temperatures ranged from 0 to 80 °C (or reflux for lower boiling solvents) and the solvents

screened were CH_2Cl_2 , CHCl_3 , EtOAc , nBuOAc , CH_3CN and PhMe . The reactions were performed with and without H_2O as a co-solvent and with and without a catalytic amount of BHT (butylated hydroxytoluene). The equivalents of oxidant varied from 1-3 equivalents, often with further addition over the course of the reaction to drive completion. Compound 5 (IA) yields of up to about 45% were observed, with moderate selectivity. There were also concerns about decomposition pathways and work-up conditions.

Trials using magnesium monoperoxyphthalate hexahydrate (MMPP) in range of solvents and temperatures were also carried out. MMPP epoxidations proved inconsistent, with 10 crude yields (recovery of the product) ranging between 30% and 70%. However, isolated yields were seldom higher than 50%. It was established that the low and inconsistent yields obtained from the reaction were due to quick decomposition of the epoxide to further products, which are soluble in aqueous, especially in basic media.

15 Furthermore, when both the *m*CPBA and MMPP reactions were repeated on a larger scale (than used in the Uekawa reference), the yields were observed to decrease, and were inconsistent between batches.

Alternative oxidations systems were investigated. Experiments using various dioxiranes 20 were performed. Initial experiments focussed on dimethyldioxirane (DMDO) and were performed in a range of solvents: CH_2Cl_2 , CH_3CN , EtOAc and THF . In comparison to *m*CPBA and MMPP, DMDO gave a reduced selectivity towards the desired epoxide, with other by-products e.g. 4,5-epoxide forming in a higher proportion. Other substituted dioxiranes were also investigated, among them those formed from: trifluoroacetone, 25 trifluoroacetophenone, cyclohexanone, menthone, 4'-methoxyacetophenone, methyl isobutyl ketone and 2,4-dimethylpentanone. None of these have proven to be more successful than *m*CPBA or MMPP.

The following oxidation systems were also investigated but were found to be inferior to 30 *m*CPBA and MMPP: Jacobsen catalyst, oxo-vanadium, iron oxycatalysts and perborate.


Methyltrioxorhenium (VII) (MTO) was then evaluated as a potential catalyst for the epoxidation reaction. The reactions were screened in various solvents using H_2O_2 and urea hydrogen peroxide as oxidant, using various ligands. The reactions were conducted 35 at 0 to 10 °C. Good selectivity and yields were consistently observed, with HFIP as solvent, urea hydrogen peroxide as oxidant and 3-methyl pyrazole as ligand providing yields of up to 85% of compound (IA). The high yields and selectivity compared with the other oxidation

conditions evaluated were surprising. Optimum quantities of MTO required for the reactions were established at about 1 mol% with 12 mol% of ligand and up to 2 equivalents of the oxidant. A full representative procedure is described in Example 10.

5 Moreover, as shown in Example 10a, this reaction using MTO could be scaled-up considerably without a reduction in the yield, unlike the prior art conditions. Thus, the process of the present invention is scalable.

Example 10 – Epoxidation of (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester

10 **(IIA) using methyltrioxorhenium to form (6 α , 7 α , 22*E*)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester (IA)**



To a solution of (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester (compound (IIA) prepared according to Example 1, ultimately derived from stigmasterol, 5.00 g, 12.6 mmol)

15 in HFIP (20 mL, 4 volumes) and EtOAc (10 mL, 2 volumes) was added MTO (37 mg, 0.126 mmol) and 3-methylpyrazole (122 μ L, 1.51 mmol) and the mixture was cooled to 5 °C. Urea hydrogen peroxide (UHP, 1.30 g, 13.9 mmol) was added portion-wise and the mixture was stirred at 5 °C for 24 h. After 24 h, a second addition of MTO (37 mg, 0.126 mmol) and UHP (1.30 g, 13.9 mmol) was conducted and the reaction was stirred at 5 °C for 18 h. The 20 reaction was then quenched with the addition of 12% aqueous NaHSO₃ (15 mL, 3 volumes) which was added portion-wise to keep internal temperature <25 °C. The chiller was then set to ambient and the mixture stirred for 0.5 h to ensure all peroxide was quenched (tested with peroxide paper). Water (12.5 mL, 2.5 volumes) and EtOAc (5 mL, 1 volume) were added and the layers were separated. The organic was washed with 5% 25 aqueous NaHCO₃ (20 mL, 4 volumes) and water (20 mL, 4 volumes) and was concentrated under reduced pressure. The crude material (5.72 g) was crystallised from EtOAc (15 mL, 3 volumes) to give the desired product (3.1 g, 60% yield) as an off white crystalline solid.

The conversion from starting material to desired alpha epoxide and other undesired products (e.g. the beta-epoxide) can be assessed using HPLC, (see chromatographic

30 conditions in General Procedures), with the following retention times.

Compound	Approximate Retention Time (min)	RRT
----------	----------------------------------	-----

α epoxide (Compound (IA))	7.2	1.0
Starting material (Compound (IIA))	13.7	1.9
β epoxide	8.6	1.2

Crystal data and Experimental

The single crystal structure of the title compound is shown in Figure 2 (Thermal ellipsoids drawn at the 50% probability level).

Experimental. Single clear colourless fragment-shaped crystals of (2015sot0055-S-100K) were recrystallised from EtOAc by slow evaporation. A suitable crystal ($0.60 \times 0.32 \times 0.12$) was selected and mounted on a MITIGEN holder in perfluoroether oil on a Rigaku R-AXIS SPIDER IP diffractometer. The crystal was kept at $T = 100(2)$ K during data collection. Using **Olex2** (Dolomanov et al., 2009), the structure was solved with the **olex2.solve** (Bourhis et al., 2015) structure solution program, using the Charge Flipping solution method. The model was refined with version of **ShelXL** (Sheldrick, 2008) using Least Squares minimisation.


Crystal Data. $C_{26}H_{36}O_4$, $M_r = 412.55$, orthorhombic, $P2_12_12_1$ (No. 19), $a = 10.3271(7)$ Å, $b = 10.6793(10)$ Å, $c = 20.3570(18)$ Å, $\alpha = \beta = \gamma = 90^\circ$, $V = 2245.1(3)$ Å 3 , $T = 100(2)$ K, $Z = 4$, $Z' = 1$, $\mu(\text{CuK}_\alpha) = 0.637$, 17551 reflections measured, 4187 unique ($R_{int} = 0.0982$) which were used in all calculations. The final wR_2 was 0.0852 (all data) and R_1 was 0.0473 ($I > 2(I)$).

Table 1: Fractional Atomic Coordinates ($\times 10^4$) and Equivalent Isotropic Displacement Parameters ($\text{\AA}^2 \times 10^3$) for 2015sot0055_S_100K. U_{eq} is defined as 1/3 of the trace of the orthogonalised U_{ij} .

Atom	x	y	z	U_{eq}
O1	3852(2)	6518.8(19)	-1709.3(10)	43.1(6)
O2	5224(2)	5457(2)	930.5(10)	43.3(6)
O3	4093(2)	7837(2)	5524(1)	46.8(6)
O4	2179.8(19)	8068(2)	6028.6(9)	41.8(6)
C1	1343(3)	5740(3)	233.1(15)	44.8(9)
C2	2583(3)	6537(3)	253.3(14)	34.0(8)
C3	2431(3)	7694(3)	-189.5(13)	39.5(8)
C4	2381(3)	7372(3)	-921.3(14)	43.8(9)
C5	3477(3)	6539(3)	-1139.7(15)	36.7(8)

Atom	x	y	z	U_{eq}
C6	4052(3)	5728(3)	-635.9(14)	37.0(8)
C7	3689(3)	5733(3)	-6.2(15)	34.2(8)
C8	4340(3)	4864(3)	458.5(15)	38.2(9)
C9	4047(3)	4910(3)	1162.8(14)	35.9(8)
C10	3062(3)	5801(3)	1427.4(13)	33.4(8)
C11	2914(3)	6947(3)	970.0(13)	33.6(8)
C12	1987(3)	7917(3)	1248.6(13)	37.9(8)
C13	2283(3)	8279(3)	1962.3(14)	37.2(8)
C14	2348(3)	7128(3)	2412.6(14)	32.8(8)
C15	3381(3)	6254(3)	2125.5(14)	33.6(8)
C16	3593(3)	5272(3)	2661.3(13)	34.8(8)
C17	3453(3)	6032(3)	3303.5(14)	36.1(8)
C18	2908(3)	7336(3)	3112.6(13)	35.1(8)
C19	1019(3)	6503(3)	2463.5(14)	36.3(8)
C20	1525(4)	9199(3)	3500.4(15)	49.9(10)
C21	2020(3)	7875(3)	3651.8(13)	36.5(8)
C22	2711(3)	7885(3)	4298.3(14)	38.3(8)
C23	2162(3)	7926(3)	4887.4(14)	37.4(8)
C24	2930(3)	7940(3)	5491.6(15)	33.9(8)
C25	2864(3)	8060(3)	6651.0(13)	39.6(8)
C26	1902(3)	8245(3)	7187.8(13)	41.7(9)

Example 10a – Large scale epoxidation of (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester (IIA) using methyltrioxorhenium to form (6 α , 7 α , 22*E*)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester (IA)




5

To a stirred mixture of hexafluoroisopropanol (20 L, 4 vol) and EtOAc (10 L, 2 vol) at 10 °C (± 2 °C) was charged solid (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester (compound (IIA) (4.9 kg)) followed by MTO (15.0 g) and 3-methylpyrazole (31 mL). Solid urea hydrogen peroxide (1.3 kg) was then charged in three equal portions at 20 min intervals and the mixture was stirred at 10 °C (± 2 °C). After 7 h a further portion of MTO (15.0 g) and 3-methylpyrazole (31 mL) was added. The mixture was maintained for 15 h

10


at 10 °C (± 2 °C) and a further portion of MTO (15.0 g), 3-methylpyrazole (31 mL) and urea hydrogen peroxide (0.47 kg) were charged. After 24 h at 10 °C (± 2 °C) HPLC analysis indicated completion of the reaction and the reaction was quenched by the addition of 5% aq. NaHSO₃ (20 L, 4 vol), maintaining the temperature between 5.5 and 9.5 °C. After 5 complete quench the phases were separated and the organic phase (bottom) was returned to the reaction vessel and washed with 5% aq. NaHCO₃ (20 L, 4 vol) and then H₂O (20 L, 4 vol). The volume of the organic phase was concentrated to 1.8 vol (9 L) under reduced pressure at 47 (± 2 °C). Two EtOAc (10 L, 2 vol) co-evaporations were then performed under reduced pressure with the total reaction volume reduced to 2 vol (10 L) each time. 10 EtOAc (10 L, bringing the total volume of the reaction to 20 L = 4 vol) was charged to the vessel and the mixture was heated at 80 °C until complete dissolution of the product. The solution was then cooled gradually to 0 °C over 4 h and then held at this temperature for further 16 h. The precipitated solid was filtered and rinsed with cold EtOAc (2 L, 0.4 vol, at 5 °C) to give (6 α , 7 α , 22E)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester (Compound (IA), 3.17 kg, 62% yield) after drying. The second crop of crystals was obtained by further reducing the solvent volume to give 527g to give a total yield of compound (IA) of 3.7kg (72%). 15

Example 11 – Epoxidation of 3-oxo-4,6-choladien-24-oic acid ethyl ester (IIB) using mCPBA to form (6 α , 7 α)-6,7-epoxy-3-oxo-4-chola-ene-24-oic acid ethyl ester (IB)



3-oxo-4,6-choladien-24-oic acid ethyl ester (Compound (IIB), 1.37 g, 4.27 mmol) was charged to a reaction vessel, followed by BHT (23 mg, 0.13 mmol), EtOAc (11mL) and water (3.4 mL) with stirring. The solution was heated to 80 °C and then a solution of mCPBA 70% (1.5 g, 7.51 mmol) in EtOAc (7.5 mL) was added dropwise over 15 mins.


25 The reaction mixture was stirred at 70 °C for 2 h (IPC by TLC, 3:7 EtOAc: Heptane; visualized with Anisaldehyde stain), cooled to ambient temperature and then washed with 1M aq. NaOH (2 x 20 mL) followed by 10% aq. Na₂S₂O₃: 2% NaHCO₃ (3 x 20 mL). The organic phases were dried over Na₂SO₄ and concentrated *in vacuo* at 40 °C. The crude solids were crystallized from EtOAc (3 vol) at 60 °C to give an off white solid which was 30 dried under vacuum at 40 °C to give the title compound (0.90 g).

Examples 12-18 – Subsequent reactions of compounds (IA) and (IB)**Example 12 – Synthesis of (6 β , 7 α , 22E)-6-ethyl-7-hydroxy-3-oxo-4,22-choladien-24-oic acid ethyl ester (XIXA)**

5

Method 1:

To a suspension of CuI (1.40 g, 7.35 mmol) in diethyl ether (10 mL), cooled to -78 °C under an argon blanket was charged EtLi (28.8 mL, 14.4 mmol, 0.5 M solution in benzene / cyclohexane). The thick white suspension formed was allowed to warm to 0 °C, stirred for 10 5 mins (forming a dark solution) and cooled to -78 °C. A solution of (6 α , 7 α , 22E)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester (compound (IA) prepared according to Example 1, ultimately deriving from stigmasterol, 1.00 g, 2.42 mmol) in diethyl ether / THF (24 mL, 3:1) was prepared and charged to the vessel containing the organocuprate. THF (1 mL) was used to rinse the vessel that contained the solution of the epoxide and this was 15 also charged to the organocuprate. The reaction mixture was allowed to warm to -4 °C over 30 mins after which time the reaction was complete by TLC (silica, 1:1 EtOAc : heptane). After a further 30 mins of stirring at c.a. -4 °C a solution of aq. sat. NH₄Cl was charged and the mixture was stirred over 30 mins. The mixture was transferred to a separating funnel and the aqueous phase was removed, along with solid material present 20 at the interface. The organic phase was washed with 5 wt % aq NaHCO₃ (2 x 50 mL,.) and water (1 x 50 mL). TBME (50 mL) was used to extract the original aqueous phase from the reaction and the combined washes. The combined organic phases were concentrated and the residue was purified by chromatography using silica (25 g) as the stationary phase (gradient elution with 0-30 % EtOAc in heptane) to give the title compound (0.63 g, 59 %).



¹H NMR (400 MHz, CDCl₃): δ = 6.82 (1H, dd, *J* = 15.6, 8.9, C22H), 5.75 (1H, s, C4H), 5.74 (1H, d, *J* = 15.6, C23H), 4.17 (2H, q, *J* = 7.1, OCH₂CH₃), 3.72 (1H, br s, C7H), 2.52-2.25 (5H, m), 2.05-1.98 (2H, m), 1.82-1.10 (23H, m), 0.91 (3H, t, *J* = 7.4, CH₃), 0.77 (3H, s, CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 199.2, 171.2, 167.1, 154.5, 128.4, 119.0, 71.9, 60.1, 55.3, 54.9, 49.9, 44.3, 42.7, 39.6, 39.1, 38.3, 37.4, 35.6, 34.0, 28.0, 26.3, 23.6, 20.8, 19.7, 19.2, 14.2, 12.8, 12.0; (IR) $\nu_{\text{max}}(\text{cm}^{-1})$: 3467, 2939, 2870, 1716, 1651, 1457, 1268, 1229, 1034; HRMS (ESI-TOF) *m/z*: (M+H)⁺ calcd for C₂₈H₄₃O₄ 443.3161; found: 443.3156. mp = 59.4 - 62.9 °C

10

Method 2

ZnCl₂ (32.84 g, 240.9 mmol) was dried under vacuum with slow stirring at 180 °C for 2 h. The flask was cooled to room temperature under an argon atmosphere and the residue was dissolved in THF (520 mL) and transferred via cannula into a three neck reaction flask 15 equipped with mechanical stirrer and temperature probe. The solution was cooled in an ice bath to 0-3 °C and a 3M solution of EtMgBr in Et₂O (80 mL, 240.0 mmol) was added dropwise over 20 mins, maintaining the internal temperature below 10 °C. Formation of a white precipitate (active zincate species) was observed after addition of ca. 1/3 of the Grignard solution. The mixture was stirred for 1.2 h at 0 °C before a solution of the epoxide 20 (IA) prepared according to Example 1, ultimately deriving from stigmasterol (43.0 g, 104.2 mmol) in THF (300 mL) was added dropwise, maintaining the internal temperature below 10 °C. Solid CuCl (1.03 g, 0.104 mmol) was then added in two equal portions with vigorous stirring. After 10 mins the cooling bath was removed and stirring continued at ambient 25 temperature for an additional 1.2 h. The reaction was quenched by dropwise addition of sat. aq. NH₄Cl (800 mL) at < 15 °C and stirred for 0.5 h. The mixture was filtered and the solid rinsed with TBME (150 mL). The phases were separated and the aqueous phase extracted with TBME 2×250 mL. The combined organic extracts were washed with 10%

aq. NaCl (2×200 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo* to give 43.7 g of the crude title compound as a yellow foam.

Method 3

5 To a solution of ZnCl₂ in THF (0.5 M, 8.7 mL, 4.85 mmol, 0.9 eq) was charged anhydrous THF (8.0 mL) and the contents then cooled to -25 °C. A solution of EtMgBr in TBME (1.0 M, 8.7 mL, 8.70 mmol, 1.8 eq) was added over 30 mins and the mixture stirred for 45 mins at -25 °C. Solid CuCl (24 mg, 0.49 mmol, 0.05 eq) was added in one portion and a solution of compound (IA) prepared according to Example 1, ultimately deriving from stigmasterol
10 (2.0 g, 4.85 mmol) in THF (8.0 mL) was added dropwise over 30 mins. The remaining solid CuCl (24 mg, 0.49 mmol, 0.05 eq) was added half way through the addition of compound (IA). The reaction was stirred for 1 h at -25 °C, (TLC 1:1 Heptane:EtOAc, visualised by UV and developed using Ceric Ammonium Molybdate stain) and then additional of EtMgBr in TBME (1.0 M, 2.9 mL, 2.91 mmol, 0.6 eq) was added over 10 mins. The reaction was
15 stirred for 0.5 h at -25 °C and then quenched by the addition of sat. aq. NH₄Cl (5 mL), maintaining the temperature below -5 °C. The inorganic salts were filtered off, rinsed with TBME and the filtrate phases were separated. The aqueous layer extracted with TBME and then the combined organic extracts were washed with sat. aq. NH₄Cl (3 × 5 mL) and 10% brine (3 × 6 mL). The organic phase was concentrated *in vacuo* at 40 °C to give crude
20 title compound as a yellow foam (1.91 g).

Method 4

To a solution of ZnCl₂ in THF (0.5 M, 8.7 mL, 4.85 mmol, 0.9 eq) was charged anhydrous THF (8.0mL) and the contents then heated to 40 °C. A solution of EtMgBr in TBME (1.0 M, 8.7 mL, 8.70 mmol, 1.8 eq) was added over 30 mins and the mixture stirred for 45 mins at 40 °C. Solid CuCl (24 mg, 0.49 mmol, 0.05 eq) was added in one portion and a solution of compound (IA) prepared according to Example 1, ultimately deriving from stigmasterol (2.0 g, 4.85 mmol) in THF (8.0 mL) was added dropwise over 30 mins. The remaining solid CuCl (24 mg, 0.49 mmol, 0.05 eq) was added half way through the addition of compound (IA). The reaction was stirred for 1 h at 40 °C, (TLC 1:1 Heptane:EtOAc, visualised by UV and developed using Ceric Ammonium Molybdate stain) and then quenched by the dropwise addition of sat. aq. NH₄Cl (5 mL). The inorganic salts were filtered off, rinsed with TBME and the filtrate phases were separated. The aqueous layer was extracted with TBME and then the combined organic extracts were washed with sat. aq. NH₄Cl (3 × 5 mL) and 10% brine (3 × 6 mL). The organic phase was concentrated *in vacuo* at 40 °C to give crude title compound as a yellow foam (2.08 g).

Method 5

To a solution of $ZnCl_2$ in THF (0.5 M, 8.7 mL, 4.85 mmol, 0.9 eq) was charged anhydrous

THF (8.0 mL) and the contents then cooled to -15 °C. A solution of $EtMgBr$ in THF (1.0 M,

5 8.7 mL, 8.70 mmol, 1.8 eq) was added over 30 mins and the mixture stirred for 45 mins at

-15 °C. Solid $CuCl$ (24 mg, 0.49 mmol, 0.05 eq) was added in one portion and a solution

of compound (IA) prepared according to Example 1, ultimately deriving from stigmasterol

in THF (8.0 mL) was added dropwise over 30 mins. The remaining solid $CuCl$ (24 mg, 0.49

mmol, 0.05 eq) was added half way through the addition of compound (IA). The reaction

10 stirred for 1 h at -15 °C, (TLC 1:1 Heptane:EtOAc, visualised by UV and developed using

Ceric Ammonium Molybdate stain) and then additional $EtMgBr$ in THF (1.0 M, 4.35 mL,

4.36 mmol, 0.9 eq) was added over 15 mins and then quenched by the dropwise addition

of sat. aq. NH_4Cl (5 mL). The inorganic salts were filtered off, rinsed with TBME and the

15 filtrate phases were separated. The aqueous phase was extracted with TBME and then


the combined organic extracts were washed with sat. aq. NH_4Cl (3×5 mL) and 10% brine

(3×6 mL). The organic phase was concentrated *in vacuo* at 40 °C to give crude title

15 compound as a yellow foam (1.94 g).

Example 13 – Synthesis of (5β , 6β , 7α)-6-ethyl-7-hydroxy-3-oxo-cholan-24-oic acid

20 **ethyl ester (XXA)**

Method 1

To a suspension of 10 wt. % Pd/C (50% wet, 20 mg, 8.6 mol%) in DMF (2 mL) was added

a solution of (6β , 7α , $22E$)-6-ethyl-7-hydroxy-3-oxo-4,22-choladien-24-oic acid ethyl ester

25 (compound (XIXA), prepared according to Example 12, ultimately deriving from

stigmasterol, 50 mg, 0.11 mmol) in DMF (3 mL) and the reaction mixture was cooled to 0

°C. The flask was evacuated then filled with hydrogen three times with vigorous stirring.

After 3 h the flask was evacuated then filled with argon and the mixture filtered *via* syringe

filter. The mixture was partitioned between TBME (30 mL) and H_2O (20 mL). The organic

30 phase was dried (Na_2SO_4) and concentrated *in vacuo*. The crude product (50 mg) was a

14:1 mixture of 5β to 5α isomers (analysed by 1H NMR) of title compound, yield 92%.

1H NMR (700 MHz, $CDCl_3$): δ = 4.12 (2H, q, J = 7.1, OCH_2CH_3), 3.71 (1H, br s, C7H), 3.34

(1H, dd, J = 15.5, 13.6, C4H), 2.39-2.32 (2H, m), 2.24-2.20 (1H, m), 2.14-2.09 (2H, m), 2.03-1.91 (4H, m), 1.83-1.79 (2H, m), 1.68-1.63 (2H, m), 1.58 (1H, s), 1.55-1.12 (19H, m), 1.04 (3H, s), 0.95-0.93 (6H, m), 0.88 (1H, J = 7.0), 0.71 (3H, s). ^{13}C NMR (100 MHz, CDCl_3): δ = 213.5, 174.2, 72.1, 60.2, 55.9, 50.2, 49.8, 47.0, 46.7, 42.7, 39.5, 37.7, 36.3, 36.0, 35.7, 35.3, 34.2, 31.3, 31.0, 28.1, 27.7, 24.4, 23.8, 20.8, 18.3, 14.2, 13.9, 11.8. (IR) $\nu_{\text{max}}(\text{cm}^{-1})$: 3514, 2939, 2870, 1710, 1462, 1377, 1159, 1099, 1032; HRMS (ESI-TOF) m/z : (M-H₂O+H)⁺ calcd for C₂₈H₄₅O₃ 429.3369; found: 429.3363.

Method 2

10 Compound (XIXA) prepared according to Example 12, ultimately deriving from stigmasterol (20.0 g) was dissolved in DMF (400 mL) and added under argon to solid 10 wt. % Pd/C (50% wet, 10.0 g). The mixture was cooled in an ice-salt bath to approximately -15 °C and the flask was evacuated then filled with hydrogen three times with vigorous stirring. The mixture was stirred under an atmosphere of hydrogen for 6 h then the flask 15 was evacuated, filled with argon and filtered through a pad of celite. The catalyst was rinsed with 400 mL of TBME. The filtrate was washed with 10% aq. NaCl (400 mL) and the aqueous phase extracted with TBME (400 mL). The combined organic phases were washed with 10% aq. NaCl (3 × 200 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo* to give crude title compound (20.0 g, ca. 28:1 5H β :5H α ratio) as pale yellow oil.

20


Method 3

10% Pd/C was charged to a stainless steel jacketed reaction vessel under an argon atmosphere; DMF was added (20 mL), followed by a solution of crude compound (XIXA) prepared according to Example 12, ultimately deriving from stigmasterol from Example 3 (approximately 72.6 mmol) in DMF (130 mL). The reaction mixture was cooled to -25 °C (over approximately 40 mins) with vigorous stirring (1200 rpm). The reaction vessel was evacuated and charged with hydrogen (10-12 bar) three times. The mixture was stirred for 16 h under an atmosphere of hydrogen (10-12 bar). The vessel was evacuated, purged with argon and warmed to 20 °C with stirring. TLC of the reaction mixture (1:1 25 Heptane:EtOAc, developed using Ceric Ammonium Molybdate or vanillin dip, R_f values: starting material = 0.42, product = 0.67) indicated complete consumption of the starting material. The suspension was diluted with CH₃CN (120 mL) and H₂O (30 mL) and the suspension filtered *via* a double GFA filter paper and the filter cake rinsed with CH₃CN (60 mL). The mixture was telescoped to the next step without further purification. The mixture 30 contained approximately 5% of the 5H- α isomer.

35

Optimisation

The hydrogenation reaction of this example proceeds *via* the intermediate shown below and produces both the required 5H β compound and its 5H α isomer. A solvent and catalyst screen was carried out to determine reaction conditions which led to the highest yield and 5 the highest ratios of 5H β isomer to 5H α isomer.



The solvent screen was performed using 10 wt. % Pd/C catalyst and the reactions were run at room temperature under atmospheric pressure of hydrogen. The reaction run in 10 MeOH in the presence of NEt₃ was more selective than the one run in neat MeOH, whilst the addition of 10% of H₂O decreased the 5 β H selectivity. The reaction in DMF provided the best β : α ratio. The reaction in pyridine gave poor conversion to the required product with mainly starting material and intermediate present in the mixture.

	Solvent	5H β : α ratio
A	MeOH	4 : 1
B	MeOH:H ₂ O	2 : 1
C	MeOH:NEt ₃	7 : 1
D	EtOH	3 : 1
E	IPA	2 : 1
F	EtOAc	2 : 1
G	Pyridine	2 : 1
H	AcOH	1 : 1
I	CPME	1 : 1
J	DMF	9 : 1

15


Reactions in DMF and MeOH were tested at a range of temperatures. For reactions run in DMF temperature has substantial impact on selectivity (the selectivity decreases with increasing temperature), while little difference was observed for reactions in MeOH.

Reactions in DMF and MeOH were tested at a range of commercially available 5 and 10 wt. % Pd catalysts, on carbon, calcium carbonate, barium sulfate and aluminium oxide support.

5 The reactions were run in 10 volumes of solvent at -15 °C under atmospheric pressure of hydrogen gas. For reactions run in DMF pressure has lower impact on the selectivity than the temperature. The effect of dilution on the selectivity is negligible.


Example 14 – Synthesis of (6 β ,7 α)-6-ethyl-7-hydroxy-3-oxo-4-cholen-24-oic acid

10 **ethyl ester (XIXB)**



ZnCl₂ (600 mg, 4.25 mmol) was charged to a reaction vessel and dried under vacuum at 180 °C for 1 h. The reaction vessel was cooled to ambient temperature, THF (15 mL) charged and the contents of the reaction vessel cooled to 3 °C. A solution of 3M EtMgBr in Et₂O (1.5 mL, 4.25 mmol) was charged to the reaction vessel over 40 mins maintaining the temperature below 5 °C. The reaction mixture was then stirred for 1 h. (6 α , 7 α)-6,7-epoxy-3-oxo-4-chola-ene-24-oic acid ethyl ester (compound (IB), prepared according to Example 11, 0.80 g, 1.93 mmol) in THF (6 mL) was charged to the reaction vessel over 40 mins, maintaining the temperature below 5 °C. CuCl (20 mg, 0.19 mmol) was charged 15 in one portion and the reaction stirred at ambient temperature for 16 h (IPC by TLC, 3:7 EtOAc: Heptane; visualized with Anisaldehyde stain). The reaction mixture was cooled in an ice bath and sat. aq.NH₄Cl was added dropwise, maintaining the temperature below 10 °C. The reaction mixture was filtered and the filter cake washed with TBME (12.5 vol). The organic phase of the filtrate was separated and the aqueous phase extracted with TBME 20 (2 x 12.5 vol). The combined organic phases were washed with 5% NaCl (3 x 12.5 vol) and concentrated *in vacuo* at 40 °C.

Example 15 – Synthesis of (5 β , 6 β , 7 α)-6-ethyl-7-hydroxy-3-oxo-cholan-24-oic acid ethyl ester (XXB)



10% Pd/C (70 mg) was charged to a reaction vessel under an argon atmosphere followed by the crude material from Example 14 (compound (XIXB) ultimately deriving from deoxycholic acid) in DMF (14.6 mL). The mixture was cooled to -10 °C and the reaction


5 vessel was evacuated then filled with hydrogen three times with vigorous stirring. The mixture was stirred under an atmosphere of hydrogen for 24 h while maintaining the temperature at -10 °C (IPC by TLC, eluent 1:1 EtOAc: Heptane; visualized with Anisaldehyde stain) then the flask was evacuated, filled with argon and filtered through a pad of celite and rinsed with DMF (7 mL). 10% Pd/C (70 mg) was recharged to the reaction

10 vessel under an argon atmosphere followed by the DMF reaction mixture. The mixture was cooled to approximately -10 °C and the reaction vessel was evacuated then filled with hydrogen three times with vigorous stirring. The mixture was stirred under an atmosphere of hydrogen for 24 h at -10 °C (IPC by TLC, 1:1 EtOAc: Heptane; visualized with Anisaldehyde stain) then the flask was evacuated, filled with argon and filtered through a

15 pad of celite and washed with TBME (62.5 vol, 50 mL). The filtrate was washed with 10% aq. NaCl (4 x 25 vol), dried over Na₂SO₄, filtered and concentrated *in vacuo* at 40 °C. Purification by column chromatography (SiO₂, 0-30% Heptane: EtOAc) gave the title compound (0.17 g). The product was identical to the material (compound (XXA), see Example 13) obtained from (6 β , 7 α , 22E)-6-ethyl-7-hydroxy-3-oxo-4,22-choladien-24-oic

20 acid ethyl ester (derived from stigmasterol i.e. of plant origin)

Example 16 – Synthesis of (5 β , 6 β)-3,7-dioxo-6-ethyl-cholan-24-oic acid ethyl ester (XXIA)



25 Method 1

A solution of Jones's reagent prepared from CrO₃ (1.10 g, 11 mmol) in H₂SO₄ (1.4 mL) and made to 5 mL with water was charged dropwise to a solution of (6 β , 5 β , 7 α)-6-ethyl-7-hydroxy-3-oxo-cholan-24-oic acid ethyl ester (compound (XXA)) prepared according to Example 15, 0.18 g, 0.40 mmol) in acetone (10 mL) until an orange colour persisted. The

reaction mixture was quenched with IPA (1 mL), filtered through a 0.45 μ m nylon syringe filter and the filter was washed with acetone (10 mL). The combined filtrate and wash was concentrated, the residue was dissolved in EtOAc (20 mL) and washed with water (2 x 10 mL). The aqueous phase was extracted with EtOAc (20 mL), the combined EtOAc phases were concentrated and the residue was dissolved and concentrated from toluene (20 mL) then acetone (20 mL) to give a clear oil containing the title compound (185 mg).

5 1 H NMR (700 MHz, CDCl₃): δ = 4.12 (2H, q, *J* = 7.1), 2.42 (1H, t, *J* = 11.4), 2.38-2.17 (6H, m), 2.09-1.74 (9H, m), 1.68-1.11 (17H, m), 0.93 (3H, d, *J* = 6.5), 0.85 (3H, t, *J* = 7.4), 0.72 (3H, s). 13 C NMR (100 MHz, CDCl₃): δ = 214.5, 211.4, 174.0, 60.1, 57.1, 55.1, 50.3, 48.4, 10 47.3, 44.9, 43.6, 43.1, 39.2, 35.8, 35.2 (\times 2), 34.9, 31.3, 30.9, 28.1, 24.6, 23.7, 23.4, 21.7, 18.3, 14.2, 12.6, 12.2. (IR) ν_{max} (cm⁻¹): 2950, 2872, 1709, 1461, 1377, 1304, 1250, 1177, 1097, 1034; HRMS (ESI-TOF) *m/z*: (M+H)⁺ calcd for C₂₈H₄₅O₄ 445.3318; found: 445.3312;

Method 2

15 To a solution of compound (XXA) prepared according to Example 15 (41.0 g crude mass) in anhydrous CH₂Cl₂ (600 mL) at 0 °C was added solid DMP (34.0 g, 80.2 mmol) portion-wise over 20 mins (exothermic). The mixture was stirred at 0-5 °C for 2 h, then a further portion of DMP (4.0 g, 9.4 mmol) was added and reaction stirred at 0-5 °C for 1 h. The mixture was filtered through a GFA filter and the solid rinsed with CH₂Cl₂ (50 mL), the 20 filtrate was stirred vigorously with 10% aq. Na₂S₂O₃ and 2% aq. NaHCO₃ (100 mL) for 20 mins. The phases were separated and the aq. extracted with CH₂Cl₂ (2 \times 100 mL). The combined organic extracts were washed with 1M NaOH (100 mL). The mixture was diluted with CH₂Cl₂ (300 mL) and phases separated. The organic layer was concentrated under reduced pressure and the residue (cloudy brown oil) was dissolved in TBME (600 mL) and 25 washed with 1M NaOH (100 mL) and NaCl (3 \times 100 mL). The organic phase was concentrated *in vacuo* to give a dark yellow runny oil, crude mass 38.1 g. The oil was dissolved in EtOH (400 mL) and stirred with activated charcoal (10 g) at 50 °C, the mixture was then filtered, the charcoal rinsed with EtOH (200 mL) and the filtrate concentrated *in vacuo* to give the title compound as a yellow oil (35.9 g).


30

Method 3


A solution of compound (XXA) prepared according to Example 15 (218 mmol) in DMF (450 ml), CH₃CN (540 mL) and H₂O (90 mL) was charged into a 2 L vessel and cooled to 9 °C, then AcOH (180 mL) was charged, followed by NaBr (4.1 g). A solution of sodium 35 hypochlorite (~10.5% w/v, 450 mL) was added dropwise over 1.5 h, maintaining the internal temperature at 5–6 °C, then the mixture was stirred for 5 h at 7 °C. TLC of the

reaction mixture indicated complete consumption of the starting material (IPC by TLC, eluent EtOAc/heptane 3:7, R_f for (5 β , 6 β , 7 α)-6-ethyl-7-hydroxy-3-oxo-cholan-24-oic acid ethyl ester (compound (XXA) = 0.34; (5 β , 6 β)-3,7-dioxo-6-ethyl-cholan-24-oic acid ethyl ester (compound (XXIA) = 0.45). A solution of aq. 10% w/v Na₂SO₃ (360 mL) was charged 5 dropwise with vigorous stirring, maintaining the internal temperature at 8–10 °C, then H₂O (270 mL) was added dropwise and the mixture stirred at 5 °C for 16 h. The solid was filtered and washed with H₂O (720 mL). The solid was then dissolved in TBME (1.1 L) and subsequently washed with an aq. NaHCO₃ (300 mL) and 10% brine (300 mL). The organic phase was then stirred with activated charcoal (10 g) for 20 mins at 40 °C, treated with 10 anhydrous MgSO₄ (5 g) and filtered *via* GFA filter paper, the filter cake was rinsed with TBME (50 mL) and the filtrate concentrated *in vacuo* to give the title compound as light brown oil which solidifies on standing (82.7 g).

Example 17 – Synthesis of (5 β , 6 α)-3,7-dioxo-6-ethyl-cholan-24-oic acid (XXIIA)




Into a 500 mL flask was charged 0.5 vol of 0.5 M NaOH (9 mL) followed by (5 β , 6 β)-3,7-dioxo-6-ethyl-cholan-24-oic acid ethyl ester from Example 16 (compound (XXIA), 18.00 g, 1 eq) and then IPA (180 mL, 10 vol). The mixture was warmed to 60 ± 2 °C and held until a solution was obtained (10-15 mins). The remaining 0.5 M NaOH solution (171 mL, 9.5 vol) was charged over 20 mins and then the reaction was stirred for a further 3.5 h at 60 ± 2 °C. The IPA was removed under vacuum at 60 °C and then 2M HCl (8 mL) charged to pH 9. EtOAc was charged (90 mL, 5 vol) followed by 2M HCl (54 mL) to pH 1. Vigorous mixing was followed by phase separation. The aqueous phase was back extracted with additional EtOAc (90 mL, 5 vol) and then the combined organic phases were washed with water (54 mL, 3 vol), followed by three portions of 10% aq. NaCl (3 x 54 mL, 3 x 3 vol). The organic phase was treated with activated charcoal (100 mesh powder, 3.37 g, ~0.20 mass eq) for 12 mins and then filtered through GF/B. Concentration at 50 °C *in vacuo* gave the title compound as a light yellow foam in quantitative yield.



¹H NMR (700 MHz, CDCl₃): δ = 2.74 (1H, dd, *J* = 12.8, 5.4), 2.47 (1H, t, *J* = 12.5), 2.43-0.90 (32H, m), 0.81 (3H, t, *J* = 7.4), 0.70 (3H, s). ¹³C NMR (100 MHz, CDCl₃): δ = 212.1, 210.6, 179.4, 54.9, 52.4, 52.3, 50.0, 48.9, 43.7, 42.7, 38.9, 38.3, 36.7, 36.0, 35.5, 35.2, 30.9, 30.7, 28.2, 24.6, 22.9, 22.3, 18.6, 18.3, 12.1, 11.8. (IR) ν_{max} (cm⁻¹): 2939, 2873, 1706, 1458, 1382, 1284.8. HRMS (ESI-TOF) *m/z*: (M+H)⁺ calcd for C₂₆H₄₁O₄ 417.3005; found: 417.2997; mp = 71.2-75.9 °C

Example 18 – Synthesis of (3 α , 5 β , 6 α , 7 α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid

10 (compound (XVIIIA), obeticholic acid)




To a solution of crude (5 β , 6 α)-3,7-dioxo-6-ethyl-cholan-24-oic acid (compound (XXIIA) prepared according to Example 17, 21.7 g crude mass) in H₂O (260 mL) and 50% NaOH (15.2 mL) at 90 °C was added, dropwise, a solution of NaBH₄ (4.4 g, 116.3 mmol) in aq. 15 NaOH (prepared from 25 mL of H₂O and 0.8 mL 50% NaOH). The mixture was heated to reflux and stirred for 3 h. The mixture was then cooled to 60 °C and a 2M solution of HCl (200 mL) added dropwise with vigorous stirring. *n*BuOAc (100 mL) was then charged to the reaction flask and the mixture stirred for a further 20 mins. The phases were separated and the aqueous phase (pH = 1/2) extracted with *n*BuOAc (100 mL). The combined 20 organic phases were washed with 2M HCl (50 mL) and 10% aq. NaCl (100 mL). The organic solvent was distilled off under reduced pressure at 70-80 °C. The residue (dense oil) was dissolved in *n*BuOAc (60 mL) at 70 °C and allowed to gradually cool to room temperature, then stored at 6 °C for 2 h. The solid was collected *via* filtration, rinsed with cold *n*BuOAc (20 mL), then dried under vacuum at 70 °C for 5h to give the title compound 25 as a white solid (8.2 g).

Examples 19-36 – Synthesis of further epoxidation precursors

Example 19 – Synthesis of (20S)-20-hydroxymethyl-pregna-4-en-3-one


5



(20S)-20-Hydroxymethyl-pregna-4-en-3-one (HMPO) can be prepared by chemoselective reduction of dinorcholenaldehyde ((20S)-20-formyl-pregn-4-en-3-one) with NaBH₄ in primary alcohol (Barry M. Trost, Alvin C. Lavoie *J. Am. Chem. Soc.*, **1983**, 105 (15), 5075–5090, incorporated herein by reference).


10

Example 20 – Synthesis of (20S)-20-acetoxyethyl-pregna-4,6-dien-3-one



HMPO (300 g, 0.913 mol) was charged to a reaction vessel, followed by AcOH (0.9 L) and toluene (0.3 L) with stirring. *p*-Chloranil (245 g, 1.00 mol) was then charged and the reaction mixture heated to 110 °C and maintained at this temperature for 6 h. The mixture was then cooled to 5 °C and held at that temperature for 2 h. The resulting solid was filtered and the filter-cake washed with cold, premixed 3:1 AcOH : Toluene (4 x 150 mL) and the filtrate was concentrated *in-vacuo*. The residue was dissolved in acetone (900 mL), then 3.5% w/w aqueous NaOH (3.0 L) was charged dropwise with stirring, maintaining the temperature below 30 °C. The resulting solids were collected by filtration and the filter cake was washed with premixed 1:1 acetone : water (1.5 L). The filter cake was then slurried in 1:1 acetone : water (600 mL) at 20 °C, filtered and washed with premixed 1:1 acetone : water (1.0 L). The solid was dried under vacuum at 65-70 °C to give the desired product (224 g, 67%) as a tan solid. δH (400 MHz, CDCl₃): 6.17-6.12 (1H, m, C6-CH), 6.10 (1H, dd, *J* 9.9, 2.0, C7-CH), 5.68 (1H, s, C4-CH), 4.10 (1H, dd, *J* 10.7, 3.5, C22-CH_aH_b), 3.79 (1H, dd, *J* 10.7, 7.4, C22-CH_aH_b), 2.58 (1H, ddd, *J* 17.9, 14.4, 5.4, C2-CH_aH_b), 2.49-2.39 (1H, m, C2-CH_aH_b), 2.20 (1H, brt, *J* 10.2, C8-CH), 2.10-1.97 (1H, m), 2.06 (3H, s, OC(O)CH₃), 1.96-1.66 (4H, m), 1.62-1.53 (1H, m), 1.52-1.16 (8H, m), 1.12 (3H, s, C19-CH₃), 1.04 (3H, d, *J* 6.6, C21-CH₃), 0.79 (3H, s, C18-CH₃); δC (100 MHz, CDCl₃): 199.6, 171.3, 163.8, 141.2, 127.9, 123.6, 69.4, 53.2, 52.6, 50.7, 43.6, 39.4, 37.7, 36.1, 35.8, 33.9, 33.9, 27.6, 23.8, 21.0, 20.7, 17.1, 16.3, 11.9.

Example 21 – Synthesis of (20S)-20-hydroxymethyl-pregna-4,6-dien-3-one




(20S)-20-Acetoxymethyl-pregna-4,6-dien-3-one (25 g, 67.5 mmol) was suspended in

5 MeOH (250 mL) and sodium methoxide (25% w/v solution in MeOH) was added until pH 12 was achieved. The resulting mixture was stirred at room temperature for 4 h. The pH was adjusted to pH 4 by addition of Finex CS08GH⁺ resin. The mixture was filtered and the filtrate was concentrated under reduced pressure, co-evaporating with PhMe (2 × 250 mL). The residue was dried in a vacuum oven at 30 °C for 48 h to give the desired product 10 (22.15 g, 99%) as a light brown solid. δ H (400 MHz, CDCl₃): 6.16-6.11 (1H, m, C7-CH), 6.09 (1H, dd, *J* 9.9, 2.3, C6-CH), 5.67 (1H, s, C4-CH), 3.65 (1H, dd, *J* 10.5, 3.3, C22-CH_aH_b), 3.59 (1H, dd, *J* 10.5, 6.7, C22-CH_aH_b), 2.57 (1H, ddd, *J* 18.0, 14.4, 5.5, C2-CH_aH_b), 2.45-2.38 (1H, m, C2-CH_aH_b), 2.19 (1H, brt, *J* 10.4, C8-CH), 2.11-1.76 (5H, m), 1.71 (1H, td, *J* 13.9, 5.3, C1-CH_aH_b), 1.65-1.16 (9H, m), 1.11 (3H, s, C19-CH₃), 1.06 (3H, d, *J* 6.6, C21-CH₃), 0.78 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃): 199.7, 164.0, 141.4, 15.9, 123.5, 67.8, 53.2, 52.3, 50.7, 43.5, 39.4, 38.7, 37.8, 36.1, 33.9, 33.9, 27.6, 23.8, 20.7, 16.7, 16.3, 12.0.

Example 22 – Synthesis of (20S)-20-tertbutyldimethylsilyloxymethyl-pregna-4,6-

dien-3-one




(20S)-20-Hydroxymethyl-pregna-4,6-dien-3-one (1.00 g, 3.04 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL) and the solution was cooled to 0 °C. Imidazole (414 mg, 6.09 mmol) and TBDMSCl (551 mg, 3.65 mmol) were added and the reaction was stirred at 0

25 °C for 4 h. The reaction was warmed to room temperature and CH₂Cl₂ (10 mL) and water (20 mL) were added. The layers were separated and the organic phase was washed with water (20 mL), saturated aqueous sodium chloride (20 mL), dried over sodium sulfate and was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (0-25% EtOAc in heptane) to give the desired product (890 30 mg, 66%) as a light yellow solid. δ H (400 MHz, CDCl₃): 6.14 (1H, dd, *J* 9.9, 1.3, C7-CH),

6.09 (1H, dd, *J* 9.8, 2.4, C6-CH), 5.66 (1H, s, C4-CH), 3.58 (1H, dd, *J* 9.7, 3.4, C22-CH_aH_b), 3.28 (1H, dd, *J* 9.7, 7.2, C22-CH_aH_b), 2.57 (1H, ddd, *J* 17.9, 14.4, 5.4, C2-CH_aH_b), 2.47-2.37 (1H, m, C2-CH_aH_b), 2.19 (1H, brt, *J* 10.3, C8-CH), 2.07 (1H, dt, *J* 12.9, 3.3), 2.00 (1H, dd, *J* 8.5, 2.1), 1.94-1.63 (3H, m), 1.60-1.15 (9H, m), 1.11 (3H, s, C19-CH₃), 1.00 (3H, d, *J* 6.7, C21-CH₃), 0.89 (9H, s, SiC(CH₃)₃), 0.77 (3H, s, C18-CH₃), 0.03 (6H, s, Si(CH₃)₂); δ C (100 MHz, CDCl₃): 199.6, 163.9, 141.5, 127.8, 123.5, 67.7, 53.2, 52.5, 50.7, 43.5, 39.4, 39.0, 37.8, 36.1, 34.0, 33.9, 27.6, 25.9, 25.9, 25.9, 23.9, 20.7, 18.4, 16.9, 16.3, 12.0, -5.3, -5.4; (IR) $\nu_{\text{max}}(\text{cm}^{-1})$: 3027, 2956, 2930, 2891, 2857, 1677, 1077, 753; HRMS (ESI-TOF) *m/z*: (M+H)⁺ calculated for C₂₈H₄₆O₂Si 442.3267, found 443.3338.


10

Example 23 – Synthesis of (20S)-20-formyl-pregna-4,6-dien-3-one



(20S)-20-Hydroxymethyl-pregna-4,6-dien-3-one (3.01 g, 9.16 mmol) was dissolved in anhydrous CH₂Cl₂ (60 ml) and the solution was cooled to 0 °C. Dess-Martin periodinane (5.83 g, 13.7 mmol) was added portion-wise over 10 minutes and the reaction was allowed to slowly warm to room temperature and was stirred for 22 h. The mixture was cooled to 0 °C and a 1 : 1 mixture of 10% aq. Na₂S₂O₃ and 2% aq. NaHCO₃ (75 ml) was added portionwise. CH₂Cl₂ (50 mL) was added and the layers were separated. The aqueous phase was extracted with CH₂Cl₂ (2 × 50 mL) and the combined organics were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (0-25% EtOAc in heptane) to give the desired product (1.23 g, 41%) as a pale yellow solid. δ H (400 MHz, CDCl₃): 9.59 (1H, d, *J* 3.2, CHO), 6.12 (2H, s, C6-CH and C7-CH), 5.68 (1H, s, C4-CH), 2.58 (1H, ddd, *J* 17.9, 14.4, 5.4), 2.49-2.36 (2H, m), 2.22 (1H, t, *J* 10.6, C8-CH), 2.08-1.81 (4H, m), 1.73 (1H, td, *J* 13.8, 5.1, C1-CH_aH_b), 1.65-1.20 (8H, m), 1.15 (3H, d, *J* 6.9, C21-CH₃), 1.13 (3H, s, C19-CH₃), 0.82 (3H, d, C18-CH₃); δ C (100 MHz, CDCl₃): 204.6, 199.5, 163.6, 140.8, 128.1, 123.7, 52.8, 50.8, 50.7, 49.4, 44.0, 39.2, 37.6, 36.0, 33.9, 33.9, 27.0, 24.1, 20.6, 16.3, 13.5, 12.3; (IR) $\nu_{\text{max}}(\text{cm}^{-1})$: 3030, 2934, 2706, 1717, 1655, 1615, 15811; HRMS (ESI-TOF) *m/z*: (M+H)⁺ calculated for C₂₂H₃₀O₂ 326.2246; found 327.2318.


30

Example 24 – Synthesis of (20S)-20-(ethylenedioxymethyl)-pregna-4,6-dien-3-one

To a solution of (20S)-20-formyl-pregna-4,6-dien-3-one (3.89 g, 12 mmol) in CH_2Cl_2 (5 vol, 20 mL) under an argon atmosphere was added 1,2-bis (trimethylsilyloxy) ethane (2.94 mL,

5 12 mmol). The reaction mixture was cooled to -78°C and TMSOTf (108 μL , 0.6 mmol) was added. After 2 h the reaction mixture was diluted with CH_2Cl_2 (100 mL) and washed with water (2×100 mL) and 5% aq. NaCl (100 mL). The organic phase was dried over Na_2SO_4 and was concentrated under reduced pressure. Purification by column chromatography on silica gel gave the desired product (2.42 g, 55%) as a colourless 10 crystalline solid. δH (700 MHz, CDCl_3): 6.12 (2H, m), 5.67 (1H, m), 4.86 (1H, d, *J* 2.0), 3.94 (2H, m), 3.86 (2H, m), 2.56 (1H, m), 2.43 (1H, m), 2.19 (1H, t, *J* 10.6), 2.05-1.95 (3H, m), 1.85 to 1.20 (11H, m), 1.11 (3H, s), 0.95 (3H, d, *J* 6.7), 0.77 (3H, s). δC (176 MHz, CDCl_3): 199.7, 163.9, 141.4, 127.9, 123.6, 105.6, 65.3, 65.1, 52.9, 52.2, 50.6, 43.7, 39.3, 39.3, 37.8, 36.1, 34.0, 33.9, 27.3, 23.9, 20.67, 16.3, 11.7, 11.6.

15


Example 25 – Synthesis of (20S)-20-(1-mesyloxymethyl)-pregna-4,6-dien-3-one

To a solution of (20S)-20-hydroxymethyl-pregna-4,6-dien-3-one (1.00 g, 3.05 mmol) in pyridine (10 mL) was added DMAP (19 mg, 0.15 mmol). MsCl (1.18 mL, 15.2 mmol) was

20 added dropwise and the reaction was stirred at room temperature for 18 h. The reaction was cooled in an ice bath and water (10 mL) was added dropwise. EtOAc (20 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with 2 M aq. HCl (20 mL), dried over sodium sulfate and were concentrated under reduced pressure. The residue was purified 25 by column chromatography on silica gel (0-50% EtOAc in heptane) to give the desired product (1.01 g, 82%) as an orange solid. δH (400 MHz, CDCl_3): 6.12 (2H, brs, C6-CH and C7-CH), 5.68 (1H, s, C4-CH), 4.21 (1H, dd, *J* 9.4, 3.2, C22- CH_aH_b), 4.01 (1H, dd, *J* 9.4, 6.6, C22- CH_aH_b), 3.01 (3H, s, OS(O₂)CH₃), 2.58 (1H, ddd, *J* 18.0, 14.4, 5.5, C2- CH_aH_b), 2.49-2.39 (1H, m, C2- CH_aH_b), 2.21 (1H, brt, *J* 10.5, C8-CH), 2.09-1.80 (5H, m), 1.73 (1H, td, *J* 13.8, 5.2, C1- CH_aH_b), 1.63-1.53 (1H, m), 1.52-1.18 (7H, m), 1.13 (3H, s, C19-CH₃), 30

1.12 (3H, d, *J* 6.1, C21-CH₃), 0.80 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃); 199.5, 163.6, 140.9, 128.0, 123.7, 74.8, 53.1, 51.8, 50.6, 43.6, 39.3, 37.7, 37.2, 36.3, 36.0, 33.9, 33.9, 27.5, 23.8, 20.6, 16.9, 16.3, 12.0.

5 **Example 26 – Synthesis of (20S)-20-(1-bromomethyl)-pregna-4,6-dien-3-one**




To a solution of (20S)-20-hydroxymethyl-pregna-4,6-dien-3-one (1.00 g, 3.05 mmol) in anhydrous CH₂Cl₂ (10 mL) was added carbon tetrabromide (1.52 g, 4.57 mmol).

Triphenylphosphine (1.20 g, 4.57 mmol) was added and the mixture was heated at reflux

10 for 2 h. The reaction was allowed to cool to room temperature and water (20 mL) was added. The layers were separated and the organic layer was washed with 5% aq. NaHCO₃ (20 mL), 10% aq NaCl (20 mL) and was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (0-25% acetone in heptane) to give the desired product (980 mg, 82%) as a light yellow crystalline solid. δ H (400 MHz, CDCl₃); 6.09-6.00 (2H, m, C6-CH and C7 CH), 5.59 (1H, s, C4-CH), 3.43 (1H, dd, *J* 9.8, 2.7, C22-CH_aH_b), 3.29 (1H, dd, *J* 9.8, 5.8, C22-CH_aH_b), 2.50 (1H, ddd, *J* 17.9, 14.4, 5.4, C2-CH_aH_b), 2.40-2.30 (1H, m, C2-CH_aH_b), 2.13 (1H, brt, *J* 9.8, C8-CH), 2.01-1.57 (5H, m), 1.55-1.45 (1H, m), 1.44-1.10 (8H, m), 1.05 (3H, s, C19-CH₃), 1.03 (3H, d, *J* 6.5, C21-CH₃), 0.72 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃); 199.2, 163.6, 141.0, 127.9, 123.6, 53.5,

15 53.1, 50.6, 43.4, 43.3, 39.2, 37.7, 37.6, 36.0, 33.9, 33.9, 27.4, 23.6, 20.6, 18.6, 16.3, 12.3.

20 **Example 27 – Synthesis of 23-carboxy-3-oxo-4,6-choldien-24-oic acid diethyl ester**



Sodium hydride (60% dispersion in mineral oil, 226 mg, 5.64 mmol) was suspended in

25 anhydrous THF (10 mL) and the mixture was cooled to 0 °C. Diethyl malonate (1.17 mL, 7.68 mmol) was added drop-wise and the mixture was stirred at 0 °C for 15 minutes. A solution of (20S)-20-(bromomethyl)-pregna-4,6-dien-3-one (1.00 g, 2.56 mmol) in anhydrous THF (10 mL) was added drop-wise and the reaction was heated at reflux for 18 h. The reaction was allowed to cool to room temperature and water (10 mL) was added.


30 EtOAc (25 mL) was added and the layers were separated. The aqueous layer was

extracted with EtOAc (3x 50 mL) and the combined organics were washed with 10% aq. NaCl (50 mL), dried over sodium sulfate and were concentrated under reduced pressure.

The residue was purified by column chromatography on silica gel (0-25% acetone in heptane) to give the desired product (1.00 g, 83%) as a clear oil. δ H (400 MHz, CDCl₃);


5 6.17-6.07 (2H, m, C6-CH and C7-CH), 5.67 (1H, s, C4-CH), 4.29-4.14 (4H, m, 2x C(O)OCH₂), 3.44 (1H, dd, *J* 10.9, 3.7, EtO₂CCH), 2.57 (1H, ddd, *J* 17.9, 14.4, 5.4, C2-CH_aH_b), 2.43 (1H, dddd, *J* 17.8, 5.1, 2.0, 0.8, C2-CH_aH_b), 2.24-2.12 (2H, m), 2.10-1.93 (3H, m), 1.87-1.77 (1H, m), 1.71 (1H, td, *J* 16.2, 5.2, C1-CH_aH_b), 1.59-1.35 (4H, m), 1.34-1.14 (12H, m), 1.11 (3H, s, C18-CH₃), 0.96 (3H, d, *J* 6.2, C21-CH₃), 0.75 (3H, s, C19-CH₃);
10 δ C (100 MHz, CDCl₃); 199.5, 170.0, 169.6, 163.8, 141.3, 127.9, 123.6, 61.4, 61.2, 56.2, 53.4, 50.6, 49.8, 43.5, 39.5, 37.7, 36.1, 35.0, 34.3, 34.0, 33.9, 28.0, 23.7, 20.7, 18.2, 16.3, 14.2, 14.1, 11.9.

Example 28 – Synthesis of 3-oxo-4,6-choladieno-24-nitrile



15

Synthesis of (20S)-20-bromomethyl-3,3-ethylenedioxy-4-pregnene and (20S)-20-bromomethyl-3,3-ethylenedioxy-5-pregnene



To a solution of (20S)-20-bromomethyl-4-pregnene-3-one (1.00 g, 2.59 mmol) and ethylene


20 glycol (2.0 mL, 36.25 mmol) in toluene (30 mL) was added *p*TSA.H₂O (9.86 mg, 0.05 mmol) and the mixture was heated to reflux using a Dean Stark apparatus for 5 h. The reaction mixture was allowed to cool to room temperature before being poured onto 5% aq. NaHCO₃ (30 mL). The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (2 x 30 mL). The combined organics were dried over sodium sulfate and were

25 concentrated under reduced pressure. The residue was used in the next step without purification. A sample was purified by column chromatography (heptane/EtOAc) to give a mixture of (20S)-20-bromomethyl-3,3-ethylenedioxy-4-pregnene and (20S)-20-

bromomethyl-3,3-ethylenedioxy-5-pregnene in 68 % yield (the ratio of Δ^5 : Δ^4 was approximately 3.6:1). δ H (700 MHz, CDCl₃); 5.35 (0.8H, dt, *J* = 4.4, 2.2), 5.23 (0.2H, s),

4.02-3.96 (4H, m, CH_2O), 3.51 (0.8H, dd, J 9.7, 2.7), 3.51-3.49 (0.2H, m), 3.34 (0.8H, dd, J 9.7, 6.0), 3.33 (0.2H, dd, J 9.7, 6.1), 2.56 (0.8H, dq, J 14.1, 2.9), 2.20 (0.2H, td, J 13.9, 4.9, 1.8), 2.12 (0.8H, dd, J 14.2, 2.9), 2.05 (0.2H, ddd, J 14.0, 4.2, 2.4), 1.99-1.93 (2H, m), 1.91-1.83 (1H, m), 1.81-1.75 (2H, m), 1.74-1.62 (4H, m), 1.60 (0.8H, s), 1.56-1.51 (1H, m), 5 1.50-1.41 (2H, m), 1.37-1.25 (3H, m), 1.21 (1H, td, J 6.5, 4.2), 1.17-1.04 (3H, m), 1.09 (3H, d, J 6.4), 1.03 (3H, s), 1.01-0.84 (0.8H, m), 0.71 (2.4H, s), 0.70 (0.6H, s); δ C (176 MHz, $CDCl_3$); 151.6, 140.2, 122.1, 119.65, 109.5, 106.2, 64.6, 64.5, 64.2, 64.2, 56.4, 55.7, 53.8, 53.7, 53.7, 49.6, 43.6, 43.5, 42.5, 42.4, 41.8, 39.5, 39.5, 37.9, 37.8, 37.4, 36.6, 36.3, 35.8, 34.9, 32.4, 32.1, 31.9, 31.9, 31.7, 31.1, 30.0, 27.6, 27.6, 24.2, 24.1, 21.0, 18.9, 18.7, 18.6, 10 17.6, 12.3, 12.2.

Synthesis of 3,3-ethylenedioxy-4-choleno-24-nitrile and 3,3-Ethylenedioxy-5-choleno-24-nitrile



Procedure A


15 A solution containing MeCN (26.0 mg, 0.63 mmol) in THF (1.85 mL) was cooled to -78 °C under argon and *n*BuLi (0.32 mL, 2 M in cyclohexane, 0.63 mmol) was charged dropwise over 2 min. To this mixture, a solution containing (20*S*)-20-bromomethyl-3,3-ethylenedioxy-4-pregnene and (20*S*)-20-bromomethyl-3,3-ethylenedioxy-5-pregnene (185 mg, 0.423 mmol) in THF (2.15 mL) was charged dropwise over 30 min. The reaction mixture was allowed to warm to 0 °C over 4 h, cooled to -78 °C and quenched with 10% aq. NH₄Cl (3 mL). The reaction mixture was diluted with EtOAc (20 mL) and 10% aq. NH₄Cl (20 mL) and the organic phase was separated. The aqueous phase was extracted with EtOAc (20 mL), and the combined organic phases were washed with 5% aq. NaCl (20 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue 20 was purified by column chromatography on silica gel using heptane: EtOAc (5:1) as the eluent. A fraction containing 3,3-ethylenedioxy-4-choleno-24-nitrile and 3,3-ethylenedioxy-5-choleno-24-nitrile was obtained in 49% yield (the ratio of Δ^5 : Δ^4 was approximately 7:1). δ H (700 MHz, $CDCl_3$); 5.35 (0.9H, dt, J 4.5, 2.2), 5.2 (0.1H, br s), 4.02-3.86 (4H, m), 2.56 (0.9H, dq, J 14.2, 2.9), 2.39-2.34 (0.1H, m), 2.34 (0.9H, ddd, J 16.9, 8.6, 5.1), 2.27 (0.9H, dt, J 16.8, 8.4), 2.27 (0.1H, dt, J 16.8, 8.4), 2.20 (0.1H, td, J 13.9, 5.0, 1.8), 2.12 (0.9H, dd, J 14.2, 3.0), 2.05 (0.1H, ddd, J 13.8, 4.4, 2.2), 2.01-1.95 (2H, m), 1.87-1.75 (4H, m), 1.73- 25 1.72 (0.1H, ddd, J 13.8, 4.4, 2.2), 1.72 (0.1H, ddd, J 13.8, 4.4, 2.2), 1.60 (0.8H, s), 1.56-1.51 (1H, m), 1.50-1.41 (2H, m), 1.37-1.25 (3H, m), 1.21 (1H, td, J 6.5, 4.2), 1.17-1.04 (3H, m), 1.09 (3H, d, J 6.4), 1.03 (3H, s), 1.01-0.84 (0.8H, m), 0.71 (2.4H, s), 0.70 (0.6H, s); δ C (176 MHz, $CDCl_3$); 151.6, 140.2, 122.1, 119.65, 109.5, 106.2, 64.6, 64.5, 64.2, 64.2, 56.4, 55.7, 53.8, 53.7, 53.7, 49.6, 43.6, 43.5, 42.5, 42.4, 41.8, 39.5, 39.5, 37.9, 37.8, 37.4, 36.6, 36.3, 35.8, 34.9, 32.4, 32.1, 31.9, 31.9, 31.7, 31.1, 30.0, 27.6, 27.6, 24.2, 24.1, 21.0, 18.9, 18.7, 18.6, 17.6, 12.3, 12.2.

1.70 (0.3H, m), 1.69-1.59 (3.4H, m), 1.58-1.52 (2H, m), 1.50-1.43 (2H, m), 1.39-1.25 (4.6H, m), 1.18 (1H, td, *J* 6.5, 4.2), 1.14-0.99 (4H, m), 1.03 (3H, s), 0.96 (2.7H, d, *J* 6.6), 0.94 (0.3H, d, *J* 6.7), 0.88 (0.9H, t, *J* 14.3), 0.70 (2.7H, s), 0.70 (0.3H, s); δ C (176 MHz, CDCl₃); 151.6, 140.1, 122.1, 120.2, 119.6, 109.5, 106.2, 64.6, 64.4, 64.2, 56.7, 56.0, 55.5, 55.5, 53.8, 49.6, 42.6, 42.5, 41.8, 39.8, 39.7, 37.4, 36.6, 36.3, 35.7, 35.2, 35.2, 34.9, 32.4, 32.1, 31.9, 31.7, 31.6, 31.5, 31.1, 30.0, 29.7, 28.1, 28.1, 24.2, 24.1, 21.0, 18.9, 17.9, 17.9, 17.6, 14.3, 14.2, 14.1, 12.0, 11.9.

Procedure B

A solution of MeCN (2.06 mL, 39.43 mmol) in THF (34 mL) was charged dropwise over 10 1.2 h to a solution of *n*BuLi (19.72 mL, 2 M in cyclohexane, 39.43 mmol) in THF (69 mL) at -60 °C under argon. To the resulting white suspension, a solution containing (20*S*)-20-bromomethyl-3,3-ethylenedioxy-4-pregnene and (20*S*)-20-bromomethyl-3,3-ethylenedioxy-5-pregnene (6.9 g, 15.77 mmol) in THF (69 mL) was charged dropwise over 1.2 h. The thick suspension that formed was warmed to 0 °C over 15 min and water 15 (69 mL) was charged dropwise. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 100 mL). The combined organic phases were washed with 5% aq. NaCl (2 x 100 mL) and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient of EtOAc in heptane as the eluent. A fraction containing 3,3-ethylenedioxy-4-choleno-24-nitrile and 3,3-ethylenedioxy-5-choleno-24-nitrile was obtained which also contained the product from 20 double-alkylation of MeCN (mass 3.88 g).


Synthesis of 3-oxo-4-choleno-24-nitrile



To a solution of 3,3-ethylenedioxy-4-choleno-24-nitrile and 3,3-ethylenedioxy-5-choleno-24-nitrile (3.75 g, 9.43 mmol) in EtOH (75 mL) was added a solution of H₂SO₄ (1 mL, conc, 18.86 mmol) in water (7.5 mL). The reaction mixture was heated at reflux for 30 min and cooled to room temperature. A white solid was removed by filtration and the filter-cake was washed with EtOH (2 x 20 mL). Pyridine (3 mL) was added to the combined wash and filtrate and the mixture was concentrated under reduced pressure. The residue was 25 dissolved in EtOAc (100 mL), washed with 1 M aq. H₂SO₄ (100 mL), 5% aq. NaHCO₃ (100 mL), 5% aq. NaCl (2 x 100 mL), dried over sodium sulfate and was concentrated 30


under reduced pressure to give the desired product (2.36 g). ^1H NMR (700 MHz, CDCl_3): δ = 5.72 (1H, s, C4-CH), 2.45-2.25 (6H, m), 2.04-2.00 (2H, m), 1.89-1.82 (3H, m), 1.69 (1H, td, J 7.0, 4.6), 1.67-1.62 (1H, m), 1.59-1.51 (3H, m), 1.44 (1H, qd, J 13.1, 4.0), 1.39-1.25 (2H, m), 1.20-1.10 (3H, m), 1.18 (3H, s), 1.05-0.99 (2H, m), 0.96 (3H, d, J 6.6), 0.95-0.91 (1H, m), 0.73 (3H, s); ^{13}C NMR (176 MHz, CDCl_3): δ = 199.6 (C=O), 171.4 (C=CH), 123.8 (C=CH), 120.2 (CN), 55.8, 55.5, 53.7, 42.6, 39.6, 38.6, 35.7, 35.6, 35.1, 34.0, 32.9, 32.0, 31.5, 28.1, 24.1, 21.0, 17.9, 17.4, 14.3, 12.0.

Synthesis of 3-oxo-4,6-choladieno-24-nitrile




10 To a solution of 3-oxo-4-choleno-24-nitrile (2.25 g, 0.64 mmol) in toluene (2.25 mL) and AcOH (6.75 mL) was added chloranil (1.72 g, 0.70 mmol). The mixture was heated at 100 °C for 45 min and was then allow to cool to room temperature. The mixture was filtered, washing with AcOH : toluene (3 : 1, 20 mL) and the combined filtrates were concentrated under reduced pressure. The residue was concentrated from toluene (3 x 40 mL) and acetone (3 x 40 mL) and was then dissolved in acetone (6.75 mL). The solution was charged to an aqueous solution of NaOH (22.5 mL, 3% w/v) and the sticky solid that formed was collected by filtration and washed with water: acetone (2 x 20 mL, 2 : 1). The solid was purified by chromatography on silica gel using a gradient of EtOAc in heptane as the eluent to give the desired product as a yellow solid (1.33 g, 59% yield). ^1H NMR (700 MHz, CDCl_3): δ = 6.13 (1H, d, J 11.0), 6.10 (1H, dd, J 9.8, 2.3), 5.67 (1H, s), 2.57 (1H, ddd, J 17.9, 14.5, 5.4), 2.45-2.41 (1H, m), 2.39 (1H, ddd, J 17.0, 8.3, 5.1), 2.29 (1H, dt, J 16.8, 8.4), 2.20 (1H, t, J 10.6), 2.05 (1H, dt, J 12.9, 3.4), 2.00 (1H, ddd, J 13.2, 5.3, 2.0), 1.95-1.89 (1H, m), 1.88-1.80 (2H, m), 1.71 (1H, td, J 9.7, 1.3), 1.62-1.54 (2H, m), 1.44 (1H, qd, J 9.7, 1.3), 1.41-1.34 (2H, m), 1.30 (1H, ddd, J 24.0, 11.7, 5.8), 1.25-1.19 (3H, m), 1.17 (1H, q, J 9.5), 1.11 (3H, s), 0.97 (3H, d, J 6.7), 0.78 (3H, s); ^{13}C NMR (176 MHz, CDCl_3): δ = 199.6, 163.8, 141.1, 127.9, 123.6, 120.1, 55.4, 53.4, 50.6, 43.6, 39.5, 37.7, 36.0, 35.2, 34.0, 33.9, 31.4, 28.1, 23.7, 20.6, 17.9, 16.3, 14.4, 11.9.

Example 29 – Synthesis of (20S)-20-(1-aminomethyl)-pregna-4,6-dien-3-one




Synthesis of (20S)-tosyloxymethyl-pregna-4,6-dien-3-one

5



To a solution of (20S)-hydroxymethyl-pregna-4,6-dien-3-one (1.50 g, 4.58 mmol) in pyridine (50 mL) at 0 °C was added *p*-toluenesulfonyl chloride (1.79 g, 9.39 mmol). The reaction was stirred at 0 °C for 1 h and ambient for 17 h. The reaction was quenched with 1 M aq. HCl (75 mL) and was diluted with ethyl acetate (150 mL). The organic phase was separated and washed with water (50 mL), 5% aq. sodium bicarbonate (75 mL), 5% aq. NaCl (50 mL) and was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (heptane-EtOAc) to give the desired product (1.59 g, 72%) as a yellow powder. R_f : 0.36 (3:2, heptane:ethyl acetate); ^1H NMR (700 MHz, CDCl_3): δ = 7.78 (2H, d, J 8.2, Ar-H), 7.35 (2H, d, J 8.2, Ar-H), 6.10 (2H, br. s, C6H and C7H), 5.67 (1H, s, C4H), 3.97 (1H, dd, J 9.3, 3.2, C22H), 3.80 (1H, dd, J 9.3, 6.4, C22H), 2.56 (1H, ddd, J 17.6, 14.6, 5.6, C2H), 2.45-2.41 (4H, m, C2H and Ts- CH_3), 2.17 (1H, t, J 10.5), 2.01-1.96 (2H, m), 1.80-1.67 (4H, m), 1.54 (1H, dq, J 13.5, 3.1), 1.41 (1H, qd, J 13.1, 3.9), 1.30-1.23 (3H, m), 1.23-1.17 (3H, m), 1.10 (3H, s, C19H), 1.00 (3H, d, J 6.7, C21H), 0.73 (3H, s, C18H). ^{13}C NMR (176 MHz, CDCl_3): δ = 197.9, 162.0, 142.9, 139.2, 131.3, 128.0, 126.2, 126.1, 121.9, 73.6, 51.3, 49.9, 48.8, 41.7, 37.4, 35.9, 34.4, 34.3, 32.2, 32.1, 25.6, 21.9, 20.0, 18.8, 15.1, 14.5, 10.1.


Synthesis of (20S)-azidomethyl-pregna-4,6-dien-3-one



25 To a suspension of (20S)-tosyloxymethyl-pregna-4,6-dien-3-one (1.58 g, 3.27 mmol) in DMF (24 mL) and water (59 μL) was added sodium azide (273 mg, 4.20 mmol). The reaction was heated to 70 °C and stirred for 1 h. The reaction was quenched with 2%


aq. sodium bicarbonate solution (50 mL) at 40 °C, and was diluted with ethyl acetate (100 mL). The layers were separated and the organic layer was washed with 2% aq. sodium bicarbonate (50 mL), 5% aq. NaCl (50 mL) and was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (heptane-EtOAc) to give the desired product (1.01 g, 91% yield) as a colourless crystalline solid. R_f : 0.54 (3:2, heptane:ethyl acetate); ^1H NMR (700 MHz, CDCl_3): δ = 6.12 (1H, d, J 9.9, C6H), 6.10 (1H, dd, J 9.9, 2.1, C7H), 5.67 (1H, s, C4H), 3.38 (1H, dd, J 11.9, 3.3, C22H), 3.07 (1H, dd, J 11.9, 7.3, C22H), 2.57 (1H, ddd, J 17.8, 14.7, 5.4, C2H), 2.46-2.41 (1H, m, C2H), 2.17 (1H, t, J 10.6), 2.04 (1H, dt, J 12.8, 3.3), 2.00 (1H, ddd, J 13.2, 5.4, 2.1), 1.93-1.86 (1H, m), 1.86 -1.81 (1H, m), 1.75-1.65 (2H, m), 1.56 (1H, dq, J 13.4, 3.7), 1.44 (1H, qd, J 13.0, 4.0), 1.40-1.28 (6H, m), 1.11 (3H, s, C19H), 1.06 (3H, d, J 6.7, C21H), 0.77 (3H, s, C18H). ^{13}C NMR (176 MHz, CDCl_3): δ = 199.9, 163.8, 141.1, 128.0, 123.6, 57.9, 53.2, 53.0, 50.6, 43.6, 39.3, 37.7, 36.9, 36.0, 34.0, 33.9, 27.8, 23.8, 20.6, 17.8, 16.3, 12.0.

15 (iii) Synthesis of (20S)-aminomethyl-pregna-4,6-dien-3-one




To a solution of (20S)-azidomethyl-pregna-4,6-dien-3-one (99 mg, 0.292 mmol) and triphenylphosphine (106 mg, 0.404 mmol) in THF (1.1 mL) under argon atmosphere was added acetone (300 μL). The reaction was stirred at room temperature for 64 h. The reaction was diluted with ethyl acetate (10 mL) and 2 M aq. hydrochloric acid solution (10 mL). The layers were separated and the aqueous phase was basified with 2 M aq. sodium hydroxide (6.5 mL) to pH 11, and was then extracted with ethyl acetate (10 mL). The organic phase was separated and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (DCM-MeOH) to give the desired product (28 mg, 30% yield) as an off-white powder. R_f 0.23 (4:1, CH_2Cl_2 :MeOH); ^1H NMR (700 MHz, CDCl_3): δ = 6.12-6.07 (2H, m, C6H and C7H), 5.67 (1H, s, C4H), 3.05 (1H, dd, J 12.7, 3.1, C22H_aH_b), 2.74 (1H, dd, J 12.7, 8.3, C22H_aH_b), 2.58 (1H, ddd, J 17.9, 14.5, 5.4, C2H_aH_b), 2.46-2.41 (1H, m, C2H_aH_b), 2.18 (1H, t, J 10.5), 2.05-1.94 (3H, m), 1.90-1.81 (2H, m), 1.68 (1H, td, J 13.9, 5.6), 1.55 (1H, dq, J 13.4, 3.4), 1.45-1.17 (9H, m), 1.20 (3H, obscured d, J 6.7, C21H), 1.11 (3H, s, C18H), 0.78 (3H, s, C19H). ^{13}C NMR (140 MHz, CDCl_3): δ = 199.5, 163.6, 140.8, 128.0, 123.7, 53.2, 52.8, 50.6, 45.3, 43.6, 39.3, 37.6, 36.0, 36.0, 35.1, 34.0, 33.9, 27.8, 23.7, 20.7, 17.3, 16.3.

Example 30 – Synthesis of (20R)-20-(1-cyanomethyl)-pregna-4,6-dien-3-one




Synthesis of (20S)-20-bromomethyl-4-pregnen-3-one

5



To a solution of (20S)-hydroxymethyl-4-pregnen-3-one (50 g, 0.15 mol) in CH_2Cl_2 (350 mL) at 0 °C was added triphenylphosphine (43.6 g, 0.17 mol). *N*-bromosuccinimide (29.6 g, 0.17 mol) was added portionwise and the reaction mixture was stirred at 18 °C. After 18 h, the reaction mixture was cooled to 0 °C and triphenylphosphine (19.8 g, 0.08 mol) was added, followed by *N*-bromosuccinimide (13.5 g, 0.08 mol) portionwise. The mixture was warmed to 18 °C. After 2 h the reaction mixture was washed with water (350 mL) and the aqueous phase extracted with CH_2Cl_2 (350 mL). The combined organic phases were washed with 5% aq. sodium bicarbonate (350 mL), and the aqueous phase extracted with CH_2Cl_2 (100 mL). The combined organic phases were washed with 5% aq. sodium chloride (150 mL), dried over sodium sulfate and were concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (heptane-EtOAc) to give the desired product (47.1 g, 79%) as a yellow solid. ^1H NMR (700 MHz, CDCl_3): δ = 5.72 (1H, s), 3.50 (1H, dd, J = 9.8, 2.7, C22- CH_aH_b), 3.35 (1H, dd, J = 9.8, 5.9, C22- CH_aH_b), 2.45-2.32 (3H, m), 2.27 (1H, ddd, J = 14.6, 4.1, 2.5), 2.04-1.98 (2H, m), 1.91-1.82 (2H, m), 1.72-1.64 (3H, m), 1.56-1.50 (2H, m), 1.43 (1H, qd, J = 13.1, 4.1), 1.33-1.27 (2H, m), 1.22 (1H, dd, J = 13.0, 4.2), 1.20-1.13 (1H, m), 1.18 (3H, s), 1.09 (3H, d, J = 6.4), 1.09-1.00 (2H, m), 0.94 (1H, ddd, J = 12.3, 10.9, 4.1), 0.74 (3H, s); ^{13}C NMR (176 MHz, CDCl_3): δ = 197.5, 169.3, 121.8, 53.5, 51.6, 51.6, 41.4, 40.4, 37.3, 36.5, 35.7, 33.6, 33.6, 31.9, 30.8, 29.9, 25.5, 22.0, 18.9, 16.6, 15.3, 10.3.


Synthesis of (20*R*)-cyanomethyl-4-pregnen-3-one



To a suspension of (20*S*)-20-bromomethyl-4-pregnen-3-one (15 g, 38.1 mmol) in DMF (225 mL) was added potassium cyanide (7.5 g, 114 mmol). The suspension was stirred at

5 80 °C for 41 h before cooling to room temperature. EtOAc (250 mL) and water (500 mL) were added and the layers were separated. The aqueous layer was extracted with EtOAc (2 x 250 mL) and the combined organic phases were washed with 5% aq. NaCl (250 mL) and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (heptane/EtOAc) to afford the desired product (9.7 g, 75%) as a white solid. δ H (700 MHz, CDCl₃): 5.73 (1H, s, C4-CH), 2.45-2.32 (4H, m), 2.27 (1H, ddd, J = 14.6, 4.2, 2.7), 2.24 (1H, dd, J = 16.8, 7.1), 2.04-1.99 (2H, m), 1.89-1.78 (3H, m), 1.72-1.65 (2H, m), 1.57-1.51 (2H, m), 1.43 (1H, qd, J = 13.2, 4.0), 1.31-1.16 (4H, m), 1.18 (3H, s), 1.17 (3H, d, J = 6.7), 1.11-1.01 (2H, m), 0.94 (1H, ddd, J = 12.3, 10.7, 4.1), 0.74 (3H, s); δ C (176 MHz, CDCl₃): 199.5, 171.2, 123.9, 118.9, 55.7, 54.7, 53.6, 42.5, 39.2, 38.5, 35.7, 35.6, 34.0, 33.6, 32.8, 31.9, 28.0, 24.8, 24.1, 20.9, 19.3, 17.4, 12.1.

Synthesis of (20*R*)-cyanomethyl-4,6-pregnadien-3-one




To a suspension of (20*R*)-cyanomethyl-4-pregnen-3-one (9.1 g, 26.8 mmol) in toluene (36

20 mL) and acetic acid (0.15 mL) was added *p*-chloranil (7.2 g, 29.5 mmol). The mixture was heated at reflux for 90 minutes before allowing to cool to room temperature. The suspension was filtered, washing with toluene (25 mL). The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (heptane/EtOAc). The material was then dissolved in acetone (35 mL) and methanol (23 mL) and 0.5 M aq. NaOH (200 mL) was added dropwise. Water (100 mL) was added and the resulting solid was filtered, washing with water (2 x 50 mL) and 2 : 1 acetone : water (2 x 20 mL). The solid was dried *in vacuo* to afford the desired product (5.4 g, 60%) as a pale brown solid. δ H (700 MHz, CDCl₃): 6.11 (2H, s), 5.67 (1H, s), 2.57 (1H, ddd, J = 18.0, 14.4, 5.4), 2.45-2.42 (1H, m), 2.37 (1H, dd, J = 16.7, 3.7), 2.25 (1H, dd, J = 16.7, 7.2), 2.01 (1H, t, J = 10.4), 2.03 (1H, dt, J = 12.8, 3.3), 2.00 (1H, ddd, J = 13.2, 5.4, 2.1), 1.96-1.91


(1H, m), 1.88-1.81 (1H, m), 1.74-1.70 (1H, m), 1.58 (1H, dq, $J = 13.4, 3.6$), 1.44 (1H, qd, $J = 4.4, 3.9$), 1.36-1.20 (7H, m), 1.18 (3H, d, $J = 6.7$), 1.11 (3H, s), 0.79 (3H, s); ^3C (176 MHz, CDCl_3): 199.6, 163.67, 140.8, 128.1, 123.7, 118.8, 54.6, 53.2, 50.5, 43.5, 39.1, 37.6, 36.0, 33.9, 33.9, 33.5, 28.0, 24.8, 23.6, 20.6, 19.3, 16.3, 12.0.

5

Example 31 – Synthesis of 23-carboxy-3-oxo-4,6-choladien-24-oic acid dimethyl ester




10 **Synthesis of 23-carboxy-3-oxo-4-cholen-24-oic acid dimethyl ester**



To a suspension of (20S)-20-bromomethyl-4-pregn-3-one (15 g, 38.1 mmol), tetrabutylammonium bromide (1.2 g, 3.8 mmol) and potassium carbonate (26.3 g, 191 mmol) in toluene (150 mL) was added dimethylmalonate (13.1 mL, 114 mmol) and the reaction mixture was stirred at 80 °C for 91 h. The reaction mixture was then cooled to room temperature and was poured onto water (150 mL). The layers were separated and the aqueous phase was extracted with EtOAc (2 × 100 mL). The combined organic phases were washed with 5% aq. sodium chloride (100 mL) and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (heptane-EtOAc) to give the desired product (14.8 g, 87%) as a yellow solid. ^1H NMR (700 MHz, CDCl_3): $\delta = 5.72$ (1H, s), 3.75 (3H, s), 3.72 (3H, s), 3.48 (1H, dd, $J = 11.0, 4.0$), 2.44-2.36 (2H, m), 2.33 (1H, dt, $J = 17.0, 3.6$), 2.27 (1H, ddd, $J = 14.6, 4.1, 2.4$), 2.18 (1H, ddd, $J = 13.7, 11.1, 2.5$), 2.03-2.00 (2H, m), 1.95-1.89 (1H, m), 1.85-1.82 (1H, m), 1.71-1.67 (1H, m), 1.64-1.60 (1H, m), 1.54-1.39 (4H, m), 1.37-1.30 (2H, m), 1.19-1.09 (3H, m), 1.18 (3H, s), 1.05-0.99 (2H, m), 0.94-0.90 (1H, m), 0.93 (3H, d, $J = 6.5$), 0.70 (3H, s); ^{13}C NMR (176 MHz, CDCl_3): $\delta = 199.6, 171.5, 170.4, 170.0, 123.8, 56.3, 55.8, 53.7, 52.6, 52.4, 49.4, 42.5, 39.6, 38.6, 35.7, 35.6, 35.1, 34.3, 34.0, 32.9, 32.0, 28.0, 24.1, 21.0, 18.1, 17.4, 11.9$.


Synthesis of 23-carboxy-3-oxo-4,6-choladien-24-oic acid dimethyl ester



23-Carboxy-3-oxo-4-cholen-24-oic acid dimethyl ester (14.5 g, 32.7 mmol) was suspended in toluene (60 mL) and acetic acid (0.19 mL, 3.3 mmol). *p*-Chloranil (8.8 g, 35.9 mmol) was

5 added and the mixture stirred at reflux for 65 min. The reaction mixture was cooled to room
 temperature and filtered. The filter cake was washed with toluene (45 mL) and the filtrate
 concentrated under reduced pressure. The residue (21.6 g) was used without further
 purification. A small portion was purified by column chromatography on silica gel (heptane-
 EtOAc) to give the product. ^1H NMR (700 MHz, CDCl_3): δ = 6.12 (1H, d, J = 10.8), 6.08
 10 (1H, dd, J = 9.8, 2.2), 5.65 (1H, s), 3.74 (3H, s), 3.71 (3H, s), 3.47 (1H, dd, J = 11.0, 3.9),
 2.58 (1H, dd, J = 14.3, 5.3), 2.53 (1H, dd, J = 14.3, 5.3), 2.44-2.38 (1H, m), 2.21-2.15 (2H,
 m), 2.05-1.92 (3H, m), 1.83-1.77 (1H, m), 1.69 (1H, td, J = 13.9, 5.2), 1.55-1.34 (5H, m),
 1.31-1.11 (5H, m), 1.10 (3H, s), 0.93 (3H, d, J = 6.3), 0.73 (3H, s); ^{13}C NMR (176 MHz,
 15 CDCl_3): δ = 199.6, 170.4, 170.0, 163.9, 141.4, 127.8, 123.5, 56.1, 53.4, 52.6, 52.4, 50.6,
 49.4, 43.5, 39.5, 37.7, 36.0, 35.1, 34.3, 33.9, 33.9, 28.0, 23.7, 20.6, 18.1, 16.3, 11.9.

Example 32 – Synthesis of (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid




(22E)-3-Oxo-4,6,22-cholatrien-24-oic acid ethyl ester (10 g, 25.2 mmol) was suspended in

20 IPA (100 mL) and the mixture was heated to 60 °C. 0.5 M aq. NaOH (60 mL, 30 mmol) was added and the mixture was stirred at 60 °C for 3 h. The volatiles were removed under reduced pressure and EtOAc (250 mL) was added. The mixture was acidified to pH 1 using 2 M aq. HCl, and further EtOAc (100 mL) was added. The layers were separated and the organic layer was washed with water (3 x 100 mL) and concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL) with heating and was then cooled to -20 °C for 18 h. The solid formed was filtered, washing with EtOAc (20 mL). The solid was then dried under reduced pressure to give the desired product (4.55 g, 49%) as a tan solid. δ H (400 MHz, CDCl₃): 6.94 (1H, dd, *J* 15.6, 9.0, C23-CH), 6.11 (2H, brs, C6-CH and C7-CH), 5.77 (1H, dd, *J* 15.6, 0.6, C22-CH), 5.68 (1H, s, C4-CH), 2.58 (1H, ddd, *J* 18.0, 14.4, 5.4, C2-CH_aH_b), 2.51-2.40 (1H, m, C2-CH_aH_b), 2.40-2.28 (1H, m), 2.21 (1H,

appt, J 10.1), 2.10-1.95 (2H, m), 1.89-1.65 (3H, m), 1.64-1.53 (1H, m), 1.53-1.39 (1H, m), 1.38-1.18 (7H, m), 1.12 (3H, s, C19-CH₃), 1.12 (3H, d, J 6.6, C21-CH₃), 0.81 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃) 199.7, 171.8, 163.9, 156.9, 141.1, 128.0, 123.6, 118.6, 54.7, 53.2, 50.7, 43.7, 39.7, 39.3, 37.7, 36.1, 33.9, 33.9, 27.8, 23.7, 20.6, 19.1, 16.3, 12.1.

5

Example 33 – Synthesis of *N*-(*(22E*)-3,24-dioxo-4,6,22-cholatrien-24-yl)cyclopropylsulfonamide




To a solution of (*22E*)-3-oxo-4,6,22-cholatrien-24-oic acid (2.00 g, 5.43 mmol) in CH₂Cl₂

10 (40 mL) was added EDCI (1.69 g, 10.9 mmol) and DMAP (1.33 g, 10.9 mmol). Cyclopropane sulfonamide (1.97 g, 16.3 mmol) was added and the reaction was stirred at room temperature for 22 h. Water (25 mL) was added and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (2 x 25 mL) and the combined organics were washed with 2 M aq HCl (20 mL), 10% aq. NaCl (10 mL), dried over sodium sulfate and 15 concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (0-10% acetone in toluene) to give the desired product (1.68 g, 66%) as an off-white solid. δ H (400 MHz, CDCl₃) 8.90 (1H, s, NH), 6.95 (1H, dd, J 15.5, 9.0, C23-CH), 6.11 (2H, brs, C6-CH and C7-CH), 5.86 (1H, dd, J 15.5, 0.5, C22-CH), 5.68 (1H, s, C4-CH), 3.00 (1H, dddd, J 12.8, 9.5, 8.1, 4.8, SO₂CH), 2.64 (1H, ddd, J 18.1, 14.4, 20 5.4, C2-CH_aH_b), 2.51-2.41 (1H, m, C2-CH_aH_b), 2.40-2.28 (1H, m), 2.25-2.15 (1H, m), 2.09-1.96 (2H, m), 1.85-1.64 (3H, m), 1.63-1.52 (1H, m), 1.51-1.17 (9H, m), 1.17-1.07 (5H, m), 1.12 (3H, s, C19-CH₃), 0.80 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃) 200.0, 164.2, 164.1, 155.5, 141.3, 127.9, 123.6, 119.4, 54.7, 53.2, 50.6, 43.8, 39.8, 39.3, 37.8, 36.1, 33.9, 33.9, 31.5, 28.1, 23.7, 20.6, 19.1, 16.3, 12.2, 6.3, 6.3.

25

Example 34 – Synthesis of *N*-(*(22E*)-3,24-dioxo-4,6,22-cholatrien-24-yl)-4-(trifluoromethoxy)benzenesulfonamide




To a solution of (*22E*)-3-oxo-4,6,22-cholatrien-24-oic acid (2.00 g, 5.43 mmol) in CH₂Cl₂

30 (40 mL) was added EDCI (1.69 g, 10.9 mmol) and DMAP (1.33 g, 10.9 mmol). 4-

(Trifluoromethoxy)benzene sulfonamide (3.93 g, 16.3 mmol) was added and the reaction was stirred at room temperature for 22 h. Water (25 mL) was added and the layers were separated. The aqueous layer was extracted with CH_2Cl_2 (2 x 25 mL) and the combined organics were washed with 2 M aq HCl (20 mL), 10% aq. NaCl (10 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was used in the next step without purification. A portion was purified by column chromatography on silica gel (0-50% EtOAc in heptane) to give the desired product as an off-white solid. δH (400 MHz, MeOD); 8.16-8.11 (2H, m, ArH), 7.52-7.46 (2H, m, ArH), 6.82 (1H, dd, *J* 15.4, 9.0, C23-CH), 6.20 (1H, brdd, *J* 9.8, 1.4, C6-CH), 6.15 (1H, dd, *J* 9.9, 1.4, C7-CH), 5.82 (1H, dd, *J* 15.4, 0.7, C22-CH), 5.64 (1H, s, C4-CH), 2.62 (1H, ddd, *J* 18.2, 14.5, 5.4, C2-CH_aH_b), 2.42-2.20 (3H, m), 2.12-1.98 (2H, m), 1.88-1.63 (3H, m), 1.63-1.55 (1H, m), 1.49 (1H, dd, *J* 12.6, 3.8), 1.40-1.18 (7H, m), 1.14 (3H, s, C19-CH₃), 1.08 (3H, d, *J* 6.6, C21-CH₃), 0.81 (3H, s, C18-CH₃); δC (100 MHz, MeOD); 202.3, 167.2, 165.9, 156.7, 154.0, 143.3, 139.7, 131.8, 128.8, 123.9, 123.0 (q, *J* 254), 121.9, 120.6, 56.0, 54.6, 52.2, 44.9, 40.9, 40.6, 39.1, 37.4, 35.0, 34.7, 30.2, 29.0, 24.7, 21.7, 19.5, 16.6, 12.5.


Example 35 – Synthesis of (20S)-20-(5-tosyltetrazol-1-yl)methyl-pregna-4,6-dien-3-one



20 To a solution of (20S)-azidomethyl-pregna-4,6-dien-3-one (500 mg, 1.41 mmol) in CH_2Cl_2 (5 mL) was added *p*-toluenesulfonyl cyanide (282 mg, 1.55 mmol). Copper(I) trifluoromethanesulfonate benzene complex (71 mg, 0.141 mmol) was added and the mixture was stirred at room temperature for 18 h. Toluene (5 mL), added *p*-toluenesulfonyl cyanide (128 mg, 0.708 mmol) and copper(I) trifluoromethanesulfonate benzene complex (71 mg, 0.141 mmol) were added and the mixture was heated to 60 °C for 24 h. Water (10 mL) and CH_2Cl_2 (30 mL) were added and the layers were separated. The organic layer was washed with 10% aq. $\text{Na}_2\text{S}_2\text{O}_3$ /2% aq. NaHCO_3 (2 x 20 mL), 10% aq. NaCl (20 mL), was dried over sodium sulfate and was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (0-50% EtOAc in heptane) to give the desired product (381 mg, 50%) as a light yellow solid. δH (400 MHz, CDCl_3); 8.03-7.97 (2H, m, ArH), 7.46 (2H, m, ArH), 6.14 (2H, brs, C6-CH and C7-CH), 5.69 (1H, s, C4-CH), 4.80 (1H, dd, *J* 13.4, 3.9, C22-CH_aH_b), 4.45 (1H, dd, *J* 13.4, 10.5, C22-CH_aH_b), 2.26-2.53 (1H, m), 2.51 (3H, s, ArCH₃), 2.49-2.28 (2H, m), 2.24 (1H, appt, *J*, 10.5), 2.13-1.97 (2H, m), 1.96-1.87 (1H, m), 1.79-1.63 (2H, m), 1.53-1.18 (8H, m), 1.13 (3H, s, C19-CH₃), 0.89

(3H, d, J 6.6, C21- CH_3), 0.86 (3H, s, C18- CH_3); δ C (100 MHz, $CDCl_3$): 199.5, 163.6, 147.5, 140.8, 134.3, 130.4, 129.3, 128.1, 123.7, 55.1, 53.9, 53.2, 50.7, 44.0, 39.4, 37.8, 37.6, 36.0, 33.9, 33.9, 31.9, 27.5, 23.8, 22.7, 21.9, 20.6, 16.5, 16.3, 12.0.

5 **Example 36 – Synthesis of (20S)-(N-phthalimidomethyl)-pregna-4,6-dien-3-one**



(20S)-Bromomethyl-pregna-4,6-dien-3-one (1.25 g, 3.2 mmol) was dissolved in DMF (25 mL, 20 vol) and potassium phthalimide (0.65 g, 1.1 eq) was added. The mixture was stirred at 50°C under argon for 65 h and cooled to 25 °C. TBME (80 mL, 64 vol) was added and the reaction mixture was washed with water (80 mL, 64 vol). The aqueous phase was separated, extracted with TBME (80 mL) and the organic phases were combined, washed with aqueous NaOH (0.2 M, 80 mL), aqueous 5% w/v NaCl (80 mL) and concentrated to give (20S)-(N-phthalimidomethyl)-pregna-4,6-dien-3-one (0.97 g, 66%). R_f : 0.30 (3:7, EtOAc:Heptane); 1 H NMR (700 MHz, $CDCl_3$): 7.84 (2H, m), 7.72 (2H, m), 6.15 (1H, dd, J 9.7, 1.4), 6.11 (1H, dd, J 9.8, 2.7), 5.67 (1H, s), 3.65 (1H, dd, J 13.3, 3.8), 3.44 (1H, dd, J 13.6, 10.5), 2.57 (1H, ddd, J 17.8, 14.4, 5.4), 2.43 (1H, m), 2.21 (1H, t, J 10.6), 2.11–2.03 (2H, m), 2.02–1.96 (2H, m), 1.87 (1H, m), 1.72 (1H, td, J 13.9, 5.1), 1.66, (1H, m), 1.55 (1H, m), 1.43 (1H, qd, J 13.1, 4.0), 1.36 (1H, m), 1.29–1.20 (4H, m) 1.11 (3H, s), 0.91 (3H, d, J 6.63), 0.80, (3H, s); 13 C NMR (175 MHz, $CDCl_3$): 199.7, 168.8, 163.9, 141.3, 133.9, 132.1, 127.9, 123.6, 123.2, 54.5, 53.2, 50.6, 43.8, 43.7, 39.4, 37.7, 36.2, 36.1, 34.0, 33.9, 27.8, 23.9, 20.6, 17.0, 16.3, 12.0.

Examples 37-50 – Further epoxidation reactions of compounds of formula (II)


25 **General Procedure A: MTO catalyzed epoxidation**

To a solution of dienone of general formula (II) (1 eq.) and MTO (1 mol%) in EtOAc (2 vol) and HFIP (4 vol) was added 3-methylpyrazole (0.12 eq.) and the mixture was cooled to 5 °C. UHP (1.1 eq) was added and the mixture was stirred for 18-50 h until deemed complete by TLC analysis. The reaction mixture was then quenched with the addition of 12% aq. NaHSO₃ (3 vol) then partitioned between water (2.5 vol) and EtOAc (1 vol). Phases were separated and the organic washed with 5% aq NaHCO₃ (4 vol) and water (4 vol). After

concentration under reduced pressure the crude residue was purified by column chromatography (SiO_2 , eluting with heptane : EtOAc gradient).

Example 37 – Epoxidation of (20S)-20-hydroxymethyl-pregna-4,6-dien-3-one to form

5 **(6 α , 7 α , 20S)-6,7-epoxy-20-hydroxymethyl-pregn-4-en-3-one**




The product was prepared according to the general procedure for MTO catalysed epoxidation on 500 mg scale, isolated in 40% yield (210 mg) as a light yellow solid.

δH (400 MHz, CDCl_3) ; 6.11 (1H, s, C4-CH), 3.66 (1H, dd, J 10.4, 3.3, C22- CH_aH_b), 3.45

10 (1H, d, J 3.7, C6-CH), 3.42-3.32 (2H, m, C7-CH and C22- CH_aH_b), 2.56 (1H, ddd, J 18.2, 14.1, 5.5, C2- CH_aH_b), 2.45 (1H, dddd, J 18.0, 5.3, 2.0, 0.8, C2- CH_aH_b), 2.02 (1H, dt, J 12.8, 2.7, C12- CH_aH_b), 1.98-1.83 (4H, m), 1.71 (1H, td, J 13.6, 5.5, C1- CH_aH_b), 1.65-1.16 (10H, m), 1.10 (3H, s, C19- CH_3), 1.06 (3H, d, J 6.6, C21- CH_3), 0.77 (3H, s, C18- CH_3); δC (100 MHz, CDCl_3) ; 198.3, 162.7, 131.1, 67.8, 54.6, 52.5, 52.5, 51.1, 43.2, 40.6, 39.2, 38.8, 15 35.6, 34.7, 34.1, 33.9, 27.8, 23.8, 19.9, 17.2, 16.7, 11.9.

Example 38 – Epoxidation of (20S)-20-(1-bromomethyl)-pregna-4,6-dien-3-one to

form (6 α , 7 α , 20S)-20-(1-bromomethyl)-6,7-epoxy-pregn-4-en-3-one




20 The product was prepared according to the general procedure for MTO catalysed epoxidation on 500 mg scale, isolated in 56% yield (290 mg) as a light brown solid.

δH (400 MHz, CDCl_3) ; 6.12 (1H, s, C4-CH), 3.52 (1H, dd, J 9.8, 2.6, C22- CH_aH_b), 3.46

(1H, d, J 3.7, C6-CH), 3.39-3.17 (2H, m, C7-CH and C22- CH_aH_b), 2.56 (1H, ddd, J 18.1, 14.0, 5.4, C2- CH_aH_b), 2.47 (1H, dddd, J 18.0, 5.5, 2.2, 0.9, C2- CH_aH_b), 2.05-1.84 (5H, m), 1.79-1.66 (2H, m), 1.58-1.46 (1H, m), 1.44-1.19 (7H, m), 1.11 (3H, d, J 6.3, C21- CH_3), 1.10 (3H, s, C19- CH_3), 0.78 (3H, s, C18- CH_3); δC (100 MHz, CDCl_3) ; 198.2, 162.6, 131.2,

54.5, 53.5, 52.5, 51.2, 43.1, 43.0, 40.6, 39.0, 37.8, 35.6, 34.7, 34.1, 33.9, 27.6, 34.6, 19.9, 18.6, 17.2, 12.2.


5 **Example 39 – Epoxidation of (20S)-20-(1-mesyloxymethyl)-pregna-4,6-dien-3-one to form (6 α , 7 α , 20S)-20-(1- mesyloxymethyl)-6,7-epoxy-pregn-4-en-3-one**



The product was prepared according to the general procedure for MTO catalysed epoxidation on 500 mg scale, isolated in 88% yield (460 mg) as a light yellow solid.

δ H (400 MHz, CDCl₃); 6.12 (1H, s, C4-CH), 4.22 (1H, dd, J 9.4, 3.2, C22-CH_aH_b), 3.99 (1H, dd, J 9.4, 6.9, C22-CH_aH_b), 3.46 (1H, brd, J 3.7, C6-CH), 3.34 (1H, brd, J 3.6, C7-CH), 3.01 (3H, s, OS(O₂)CH₃), 2.56 (1H, ddd, J 18.2, 14.1, 5.5, C2-CH_aH_b), 2.50-2.41 (1H, m), 2.05-1.80 (6H, m), 1.72 (1H, td, J 13.6, 5.6, C1-CH_aH_b), 1.65-1.17 (8H, m), 1.11 (3H, d, J 6.5, C21-CH₃), 1.10 (3H, s, C19-CH₃), 0.76 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃); 198.2, 162.5, 131.2.

15 **Example 40 – Epoxidation of (20S)-20-(1-tertbutyldimethylsilyloxymethyl)-pregna-4,6-dien-3-one to form (6 α , 7 α , 20S)-20-(1-tertbutyldimethylsilyloxymethyl)-6,7-epoxy-pregn-4-en-3-one**




The product was prepared according to the general procedure for MTO catalysed epoxidation on 500 mg scale, isolated in 19% yield (100 mg) as a light brown solid.

δ H (400 MHz, CDCl₃); 6.11 (1H, s, C4-CH), 3.58 (1H, dd, J 9.6, 3.3, C22-CH_aH_b), 3.45 (1H, d, J 3.7, C6-CH), 3.42 (1H, brd, J 3.5, C7-CH), 3.28 (1H, dd, J 9.6, 7.2, C22-CH_aH_b), 2.55 (1H, ddd, J 18.2, 14.1, 5.5, C2-CH_aH_b), 2.49-2.40 (1H, m, C2-CH_aH_b), 2.02 (1H, td, J 12.8, 3.0, C12-CH_aH_b), 1.98-1.82 (4H, m), 1.71 (1H, td, J 13.6, 5.5, C1-CH_aH_b), 1.61-1.14 (9H, m), 1.10 (3H, s, C19-CH₃), 1.00 (3H, d, J 6.6, C21-CH₃), 0.89 (9H, s, SiC(CH₃)₃), 0.75 (3H, s, C18-CH₃), 0.06 (6H, d, J 0.6, 2x SiCH₃); δ C (100 MHz, CDCl₃); 198.3, 162.8, 131.1,

67.7, 54.7, 52.6, 52.3, 51.1, 43.1, 40.7, 39.2, 39.0, 35.6, 34.7, 34.1, 33.9, 27.8, 26.0, 26.0, 23.8, 19.9, 18.4, 17.2, 16.9, 11.9, -5.3, -5.4.

Example 41 – Epoxidation of (20S)-20-acetoxymethyl-pregna-4,6-dien-3-one to

5 **form (6 α , 7 α , 20S)-20-acetoxymethyl-6,7-epoxy-pregn-4-en-3-one**




The product was prepared according to the general procedure for MTO catalysed epoxidation on 200 g scale, isolated in 50% yield (105 g) as a tan solid.¹H NMR (700 MHz,

10 CDCl₃): δ = 6.11 (1H, s), 4.09 (1H, dd, *J* 10.7, 3.4), 3.79 (1H, dd, *J* 10.7, 7.4), 3.45 (1H, d, *J* 3.7), 3.34 (1H, d, *J* 3.5), 2.55 (1H, m), 2.46 (1H, m), 2.05 (3H, s), 2.02–1.85 (5H, m), 1.78–1.68 (2H, m), 1.55–1.20 (8H, m), 1.10 (3H, s), 1.02 (3H, d, *J* 6.6), 0.76 (3H, s); ¹³C NMR (175 MHz, CDCl₃): δ = 198.3, 171.3, 162.7, 131.1, 69.3, 54.6, 52.5, 52.4, 51.1, 43.2, 40.6, 39.1, 35.8, 35.6, 34.6, 34.1, 33.9, 27.7, 23.7, 21.0, 19.9, 17.2, 17.1, 11.8.

15

Example 42 – Epoxidation of (20S)-20-(ethylenedioxymethyl)-pregna-4,6-dien-3-one (Example 1F) to form (6 α , 7 α , 20S)-6,7-epoxy-20-(ethylenedioxymethyl)-pregn-4-en-3-one




20

The product was prepared according to the general procedure for MTO catalysed epoxidation and was obtained as a crude colourless solid in a 7.6 : 1 ratio of α : β epoxides.

¹H NMR (700 MHz, CDCl₃): δ = 6.31 (1H, s), 4.85 (1H, d, *J* = 2.0), 4.0–3.8 (2H, m), 3.45 (1H, d, *J* = 3.7), 3.35 (1H, d, *J* = 3.6), 2.59–2.43 (2H, m), 2.05–1.68 (8H, m), 1.55 – 1.20 (9H, m), 1.10 (3H, s), 0.93 (3H, d, *J* = 6.6), 0.75 (3H, s). ¹³C NMR (176 MHz, CDCl₃): δ = 198.6, 163.0, 131.0, 105.9, 65.2, 65.0, 54.7, 52.5, 51.9, 50.8, 43.4, 40.6, 39.3, 39.0, 35.6, 34.6, 34.1, 33.8, 27.4, 23.8, 19.9, 17.2, 11.6, 11.6.


Example 43 – Epoxidation of 23-carboxy-3-oxo-4,6-choladien-24-oic acid dimethyl ester to form (6 α , 7 α)-23-carboxy-6,7-epoxy-3-oxo-4-cholen-24-oic acid dimethyl ester



5

23-Carboxy-3-oxo-4,6-choladien-24-oic acid dimethyl ester (8.94 g, 19.5 mmol) was dissolved in HFIP (35.8 mL) and EtOAc (17.9mL) and the solution was cooled to 10 °C. MTO (51mg, 0.195 mmol) and 3-methylpyrazole (97 μ L, 1.17 mmol) were charged to the solution followed by UHP (2.08g, 21.4 mmol) in 2 portions over 5 minutes. After 2 h further MTO (51mg, 0.195 mmol) and 3-methylpyrazole (97 μ L, 1.17 mmol) were charged and the solution stirred for 16 h. Further MTO (51mg, 0.195 mmol), 3 methylpyrazole (97 μ L, 1.17 mmol) and UHP (0.38g, 3.90 mmol) were charged and the solution stirred for 2 h. The reaction was quenched by addition of 5% aq. NaHSO₃ (36 mL) over 5 minutes. The phases were separated and the organic phase washed with 5% aq. NaHSO₃ until a negative test for peroxides was observed. The organic phase was washed with 5% aq. NaHCO₃ (40 mL) and water (40 mL), then dried over sodium sulfate and was concentrated *in vacuo*. The residue was purified by column chromatography on silica gel to give the desired product (7.07g, 76%) as a white crystalline solid. ¹H NMR (700 MHz, CDCl₃): δ = 6.10 (1H, s), 5.31 (2H, s), 3.75 (3H, s), 3.73 (3H, s), 3.48 (1H, dd, J = 11.1, 4.0), 3.45 (1H, d, J = 4.0 Hz), 3.34 (1H, d, J = 3.6 Hz), 2.55 (1H, ddd, J = 18.1, 14.4, 5.6), 2.45 (1H, m), 2.19 (1H, ddd, J = 13.6, 11.1, 2.4), 2.05 – 1.85 (5H, m), 1.70 (1H, td, J = 13.9, 5.2), 1.53 – 1.25 (6H, m), 1.22 – 1.17 (2H, m), 1.09 (3H, s), 0.49 (3H, d, J = 6.5), 0.72 (3H, s); ¹³C NMR (176 MHz, CDCl₃): δ = 198.4, 170.3, 170.0, 162.8, 131.1, 56.0, 54.6, 53.4, 52.6, 52.5, 52.4, 51.3, 49.3, 43.1, 40.6, 39.2, 35.5, 35.1, 34.5, 34.3, 34.1, 33.8, 28.1, 23.6, 19.9, 18.1, 17.2, 11.8.


Example 44 – Epoxidation of 3-oxo-4,6-choladieno-24-nitrile to form (6 α ,7 α)-6,7-epoxy-3-oxo-4-cholen-24-nitrile



A solution of 3-oxo-4,6-choladieno-24-nitrile (1.25 g, 3.56 mmol) in EtOAc (2.5 mL) and HFIP (5 mL) under argon was cooled to 10 °C. MTO (8.9 mg, 0.036 mmol), 3-methylpyrazole (0.017 mL, 0.213 mmol) and UHP (0.37 g, 3.91 mmol) were charged and the mixture was stirred for 2 h. Further portions of MTO (8.9 mg, 0.036 mmol), 3-methylpyrazole (0.017 mL, 0.213 mmol) and UHP (67 mg, 0.71 mmol) were charged and the mixture was stirred overnight at 10 °C. The reaction was quenched by addition of 5% aq. NaHSO₃ (15 mL) was charged and the mixture was extracted with EtOAc (20 mL). The aqueous phase was separated and extracted with EtOAc (20 mL). The combined organic phases were washed with 5% aq. NaCl (20 mL) and were concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient of EtOAc in heptane as the eluent to give the desired product (0.92 g, 70 %).

¹H NMR (700 MHz, CDCl₃): δ = 6.11 (1H, s), 3.46 (1H, d, J 3.7), 3.34 (1H, d, J 3.6), 2.55 (1H, ddd, J 18.1, 14.3, 5.5), 2.47-2.44 (1H, m), 2.41-2.37 (1H, ddd, J 16.9, 8.3, 5.0), 2.30 (1H, dt, J 16.8, 8.4), 2.01 (1H, dt, J 12.9, 3.3), 1.98-1.83 (5H, m), 1.71 (1H, td, J 6.9, 5.2), 1.61-1.56 (1H, m), 1.52 (1H, dq, J 12.7, 3.6), 1.46 (1H, ddd, J 12.4, 11.4, 7.0), 1.41-1.26 (5H, m), 1.22-1.17 (2H, m), 1.10 (3H, s), 0.97 (3H, d, J 6.6), 0.76 (3H, s); ¹³C NMR (176 MHz, CDCl₃): δ = 198.3, 162.6, 131.1, 120.1, 55.3, 54.6, 52.6, 51.3, 43.2, 50.6, 39.3, 35.6, 35.1, 34.6, 34.1, 33.9, 31.4, 28.2, 23.6, 19.9, 17.8, 17.2, 14.4, 11.8.


20 **Example 45 – Epoxidation of (20*R*)-20-(1-cyanomethyl)-pregna-4,6-dien-3-one to form (6 α , 7 α , 20*R*)-20-(1-cyanomethyl)-6,7-epoxy-pregn-4-en-3-one**



(20*R*)-Cyanomethyl-4,6-pregnadien-3-one (5.1 g, 15.1 mmol) was dissolved in HFIP (20 mL) and EtOAc (10 mL) and was cooled to 10 °C. MTO (38 mg, 1 mol%), 3-methylpyrazole (73 μ L, 6 mol%) and UHP (1.6 g, 16.6 mmol) were added and the mixture stirred at 10 °C. After 4 h, MTO (38 mg, 1 mol%), 3-methylpyrazole (73 μ L, 6 mol%) and UHP (0.28 g, 3.0 mmol) were added and the mixture stirred at 10 °C. After a further 17 h, MTO (38 mg, 1 mol%), 3-methylpyrazole (73 μ L, 6 mol%) and UHP (0.28 g, 3.0 mmol) were added and the mixture stirred at 10 °C. After a further 72 h the mixture was quenched with 5% aq. sodium bisulfite (20 mL). The mixture was diluted with EtOAc (80 mL), 5% aq. sodium bisulfite (50 mL) and 5% aq. sodium chloride (50 mL). The aqueous phase was extracted with EtOAc (80 mL), and the combined organics washed with 5% aq.

sodium chloride (50 mL), dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (heptane-EtOAc) to give the desired product (3.9 g, 73%) as an off-white solid. ¹H NMR (700 MHz, CDCl₃): δ = 6.11 (1H, s, C4-CH), 3.46 (1H, d, J = 3.9, C6-CH), 3.33 (1H, d, J = 3.8, C7-CH), 2.55 (1H, ddd, J = 5.6, 14.2, 18.1, C2-CH_aH_b), 2.48-2.45 (1H, m, C2-CH_aH_b), 2.39 (1H, dd, J = 3.8, 16.7, C22-CH_aH_b), 2.23 (1H, dd, J = 7.6, 16.8, C22-CH_aH_b), 2.01-1.91 (4H, m, C1-CH_aH_b, C12-CH_aH_b, C15-CH_aH_b, C16-CH_aH_b), 1.88 (1H, td, J = 10.9, 1.3, C8-CH), 1.84-1.80 (1H, m, C20-CH), 1.72 (1H, td, J = 5.2, 13.9, C1-CH_aH_b), 1.56-1.49 (2H, m, C11-CH_aH_b, C14-CH), 1.38-1.21 (6H, m, C9-CH, C11-CH_aH_b, C12-CH_aH_b, C15-CH_aH_b, C16-CH_aH_b, C17-CH), 1.18 (3H, d, J = 6.8, C21-CH₃), 1.10 (3H, s, C19-CH₃), 0.77 (3H, s, C18-CH₃); ¹³C NMR (176 MHz, CDCl₃): δ = 198.3, 162.5, 131.2, 118.9, 54.6, 54.5, 52.5, 51.2, 43.2, 40.5, 38.9, 35.5, 34.6, 34.1, 33.8, 33.7, 28.2, 24.8, 23.6, 19.8, 19.3, 17.2, 11.9.


Example 46 – Epoxidation of (20S)-azidomethyl-pregna-4,6-dien-3-one to form (6 α , 7 α , 20S)-6,7-epoxy-20-azidomethyl-pregna-4-en-3-one



15

To a solution of (20S)-azidomethyl-pregna-4,6-dien-3-one (203 mg, 0.598 mmol) and 3-methylpyrazole (3 μ L, 0.04 mmol) in HFIP (0.8 mL) under argon atmosphere at 10 °C, MTO (3.2 mg, 0.013 mmol) and UHP (64 mg, 0.68 mmol) were added. The reaction was stirred at 10 °C for 2 h, and quenched with 5% aq. sodium bisulfite solution (1.0 mL). The reaction was diluted with ethyl acetate (10 mL) and washed with water (10 mL) and 10% aq. sodium bicarbonate solution (10 mL). The organic phase was separated and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (heptane-EtOAc, R_f in 3:2 heptane:EtOAc = 0.42) to the desired product (99 mg, 47%) as a white powder. ¹H NMR (700 MHz, CDCl₃): δ = 6.11 (1H, s, C4-CH), 3.46 (1H, d, J = 3.7, C6-CH), 3.39 (1H, dd, J = 11.9, 3.3, C22-CH_aH_b), 3.34 (1H, d, J = 3.7, C7-CH), 3.06 (1H, dd, J = 11.9, 7.5, C22-CH_aH_b), 2.55 (1H, ddd, J = 18.0, 14.3, 5.5, C2-CH_aH_b), 2.48-2.44 (1H, m, C2-CH_aH_b), 2.00 (1H, dt, J = 11.9, 3.3), 1.97-1.90 (3H, m), 1.87 (1H, td, J = 10.8, 1.4, C8-CH), 1.74-1.63 (2H, m), 1.53 (1H, dq, J = 12.7, 3.5), 1.49-1.45 (1H, m), 1.41-1.23 (5H, m), 1.22 (1H, td, J = 12.7, 3.5), 1.10 (3H, s, C18-CH₃), 1.06 (3H, d, J = 6.6, C21-CH₃), 0.78 (3H, s, C19-CH₃). ¹³C NMR (140 MHz, CDCl₃): δ = 198.3, 162.6, 131.1, 57.9, 54.6, 52.9, 52.5, 51.2, 43.2, 40.6, 39.1, 36.9, 35.6, 34.6, 34.1, 33.9, 28.0, 23.7, 19.9, 17.7, 17.2, 11.9.

Example 47 – Epoxidation of *N*-(*(22E*)-3,24-dioxo-4,6,22-cholatrien-24-yl)cyclopropylsulfonamide to form *N*-(*(6α, 7α, 22E*)-3,24-dioxo-6,7-epoxy-4,22-choladien-24-yl)cyclopropylsulfonamide




5

The product was prepared according to the general procedure for MTO catalysed epoxidation on 1 g scale, isolated in 68% yield (697 mg) as an off white solid.

δH (400 MHz, CDCl₃); 8.69 (1H, brs, NH), 6.93 (1H, dd, J 15.4, 9.6, C23-CH), 6.12 (1H, s, C4-CH), 5.83 (1H, m, C22-CH), 3.47 (1H, d, J 14.7, C6-CH), 3.36-3.32 (1H, m, C7-CH), 3.00 (1H, dddd, J 12.8, 9.5, 8.1, 4.8, SO₂CH), 2.67-2.40 (2H, m), 2.39-2.27 (1H, m), 2.09-1.64 (7H, m), 1.62-1.18 (11H, m), 1.11 (3H, d, J 6.1, C21-CH₃), 1.10 (3H, s, C19-CH₃), 0.78 (3H, s, C18-CH₃); δC (100 MHz, CDCl₃); 198.6, 164.0, 162.8, 156.6, 131.1, 119.3, 54.6, 54.5, 52.6, 51.2, 43.4, 40.6, 39.8, 39.1, 35.6, 34.6, 34.1, 33.9, 31.5, 28.2, 23.7, 19.9, 19.1, 17.2, 12.1, 6.3, 6.3.

15

Example 48 – Epoxidation of *N*-(*(22E*)-3,24-dioxo-4,6,22-cholatrien-24-yl)-4-(trifluoromethoxy)benzenesulfonamide to form *N*-(*(6α, 7α, 22E*)-3,24-dioxo-6,7-epoxy-4,22-choladien-24-yl)-4-(trifluoromethoxy)benzenesulfonamide




20 The product was prepared according to the general procedure for MTO catalysed epoxidation on 1 g scale, isolated in 5% yield (50 mg) as a colourless solid.

δH (400 MHz, MeOD); 8.17-8.09 (2H, m, ArH), 7.52-7.46 (2H, m, ArH), 6.82 (1H, dd, J 15.4, 8.9, 3.7, C23-CH), 6.07 (1H, s, C4-CH), 5.84 (1H, dd, J 15.4, 0.7, C22-CH), 3.49 (1H, d, J 3.8, C6-CH), 3.37-3.33 (1H, m, C7-CH), 2.62 (1H, ddd, J 18.2, 14.6, 5.6, C2-CH_aH_b), 2.44-2.27 (2H, m), 2.08-1.88 (3H, m), 1.85-1.60 (2H, m), 1.60-1.49 (1H, m), 1.48-1.17 (9H, m), 1.12 (3H, s, C19-CH₃), 1.07 (3H, d, J 6.6, C21-CH₃), 0.80 (3H, s, C18-CH₃);


δ C (100 MHz, MeOD); 201.0, 166.2, 166.1, 156.5, 153.9, 139.8, 131.8, 131.4, 122.0, 121.7 (q, J 256), 120.8, 55.9, 55.7, 53.6, 52.8, 44.6, 42.3, 41.0, 40.5, 36.9, 35.9, 35.2, 35.0, 29.2, 24.6, 21.0, 19.5, 17.3, 12.4.

5 **Example 49 – Epoxidation of (20S)-(N-phthalimidomethyl)-pregna-4,6-dien-3-one to form (6 α ,7 α ,20S)-6,7-epoxy-20-(N-phthalimidomethyl)-pregna-4,6-dien-3-one**



To a solution of (20S)-(N-phthalimidomethyl)-pregna-4,6-dien-3-one (100mg, 0.22 mmol) in EtOAc (200 μ L, 2 vol) and HFIP (400 μ L, 4 vol) under argon was added 3-methylpyrazole (2.1 μ L, 0.12 eq) and MTO (5mg, 10 mol%) and the reaction mixture cooled to 5°C. UHP (23mg, 1.2 eq) was added. After 20 hours the reaction mixture was quenched with the addition of aqueous 10% NaHSO₃ (300 μ L, 3 vol) then partitioned between H₂O (10 mL) and EtOAc (10 mL). The organic phase was washed with aqueous 5% w/v NaHCO₃ (10 mL) and H₂O (10 mL). The organic phase was dried over Na₂SO₄ and concentrated *in vacuo*. Purification by column chromatography on silica gel gave (6 α ,7 α ,20S)-6,7-epoxy-20-(N-phthalimidomethyl)-pregna-4,6-dien-3-one (62 mg, 60%) as a mixture with the β -epoxide (7.4:1 α : β), R_f 0.37 (1:1, EtOAc: Heptane); ¹H NMR (700 MHz, CDCl₃): 7.84 (2H, dd, J 5.4, 3.0), 7.72 (2H, dd, J 5.5, 3.0), 6.12 (1H, s), 3.65 (1H, dd, J 13.5, 3.7), 3.48–3.36 (3H, m), 2.60–2.51 (1H, m), 2.50–2.43 (1H, m), 2.16–1.87 (6H, m), 1.76–1.62 (2H, m), 1.55–1.20 (7H, m), 1.10 (3H, s), 0.90 (3H, d, J 6.6), 0.78 (3H, s); ¹³C NMR (175 MHz, CDCl₃): 198.6, 168.8, 163.0, 133.9, 132.0, 131.0, 123.2, 54.7, 54.3, 52.5, 51.1, 43.6, 43.5, 40.5, 39.1, 36.2, 35.6, 34.6, 34.0, 33.8, 27.9, 23.8, 19.8, 17.2, 17.0, 11.8.

25 **Example 50 – Epoxidation of (20S)-20-(5-tosyltetrazol-1-yl)methyl-pregna-4,6-dien-3-one to form (6 α , 7 α , 20S)-20-(5-tosyltetrazol-1-yl)methyl-6,7-epoxy-pregna-4-en-3-one**




The product was prepared according to the general procedure for MTO catalysed epoxidation on 300 mg scale, isolated in 33% yield (103 mg) as a colourless solid.

δ H (400 MHz, CDCl₃); 8.00-7.94 (2H, m, ArH), 7.47-7.41 (2H, m, ArH), 6.10 (1H, s, C4-CH), 4.77 (1H, dd, *J* 13.4, 3.9, C22-CH_aH_b), 4.42 (1H, dd, *J* 13.4, 3.9, C22-CH_aH_b), 3.46 (1H, d, *J* 3.7, C6-CH), 3.37-3.33 (1H, m, C7-CH), 2.61-2.37 (3H, m), 2.48 (3H, s, ArCH₃), 2.37-2.24 (1H, m), 2.11-1.80 (3H, m), 1.76-1.61 (2H, m), 1.58-1.17 (8H, m), 1.09 (3H, s, C19-CH₃), 0.85 (3H, d, *J* 7.0, C21-CH₃), 0.81 (3H, s, C18-CH₃); δ C (100 MHz, CDCl₃); 198.2, 162.5, 153.3, 147.5, 134.4, 131.1, 130.4, 129.3, 55.1, 54.5, 53.8, 52.5, 51.2, 43.6, 40.6, 39.1, 37.7, 35.5, 34.6, 34.1, 33.9, 27.6, 23.8, 21.9, 19.9, 17.2, 16.4, 11.9.

CLAIMS

1. A process for preparing a compound of general formula (Ia):



5 or a salt or isotopic variant thereof

wherein:

R² is H, halo, OH or a protected OH group;

Y is a bond, or a C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene linker group any of which is optionally substituted with one or more R³;

10 wherein each R³ is independently H, halo, OH, a protected OH group or NR⁸R⁹;

wherein each of R⁸ and R⁹ is independently H, C₁₋₆ alkyl, C(O)Ph, benzyl, phthalimide, *tert*-butyloxycarbonyl or carboxybenzyl;

15 R⁴ is C(O)OR¹⁰, OC(O)R¹⁰, C(O)NR¹⁰R¹¹, OR¹⁰, OSi(R¹³)₃, S(O)R¹⁰, SO₂R¹⁰, OSO₂R¹⁰, SO₃R¹⁰, halo, CN, C(O)R¹⁰, NR¹⁰R¹¹, BR¹⁰R¹¹, C(O)CH₂N₂, -CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, CH(BR¹⁰R¹¹)₂, azide, NO₂, NR¹⁰C(O)NR¹⁰SO₂R¹¹, NR¹⁰C(O)NR¹⁰SO₂N R¹⁰R¹¹, NR¹⁰SO₂R¹¹, C(O)NR¹⁰SO₂R¹¹, CH(XR¹⁰)(XR¹¹), CH(R¹⁰)(XR¹¹), phthalimide or a carboxylic acid mimetic group such as tetrazole;

wherein each X is independently O, S or NR⁸;

wherein each R¹⁰ and R¹¹ is independently:

20 a. hydrogen;

or

b. C₁₋₂₀ alkyl, C₃₋₇ cycloalkyl, C₂₋₂₀ alkenyl or C₂₋₂₀ alkynyl, any of which is optionally substituted with one or more substituents selected from:

25 C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹,

C(O)N(R¹⁹)₂, SO₂R¹⁹, OSO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

30 or

c. a 6- to 14- membered aryl, 5- to 14-membered heteroaryl group or 3- to 10- membered heterocyclic ring, any of which is optionally substituted with one or more substituents selected from:

C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , $C=O$, $C(O)C_{1-4}alkyl$, SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} , $N(R^{19})_2$, phenyl, 5- to 14-membered heteroaryl, 3- to 10-membered heterocyclic ring, methylenedioxy and ethylenedioxy;

5 or

d. a polyethylene glycol residue;

or

e. when R^4 is $C(O)NR^{10}R^{11}$, $CH(XR^{10})(XR^{11})$, $CH(R^{10})(XR^{11})$, $NR^{10}R^{11}$, $BR^{10}R^{11}$, $CH[C(O)OR^{10}]_2$ or $CH(BR^{10}R^{11})_2$ an R^{10} and an R^{11} group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring; wherein each R^{19} is independently:

10 H, C_{1-6} alkyl, C_{1-6} haloalkyl, or a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from halo, C_{1-6} alkyl and C_{1-6} haloalkyl;

15 and wherein each R^{13} is independently:

a. C_{1-20} alkyl, C_{2-20} alkenyl or C_{2-20} alkynyl, any of which is optionally substituted with one or more substituents selected from:

20 halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} , OSO_3R^{19} , $N(R^{19})_2$ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C_{1-6} alkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , SO_2R^{19} , SO_3R^{19} and $N(R^{19})_2$;

25 or

b. a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from: C_{1-6} alkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} and $N(R^{19})_2$;

30 wherein each R^{19} is independently:


H, C_{1-6} alkyl or C_{1-6} haloalkyl; or

Y and R^4 together form a $=CH_2$ group; and

R^5 is H, OH or a protected OH group;

35 the process comprising:


oxidation of a compound of general formula (IIa) using an oxidant and methyltrioxorhenium as catalyst;



or a salt or isotopic variant thereof

wherein R², R⁴, R⁵ and Y are as defined for compounds of general formula (Ia).

5 2. A process according to claim 1 for preparing a compound of general formula (I):



or a salt or isotopic variant thereof

wherein:

R² is H, halo, OH or a protected OH group;

10 Y is a bond, or a C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene or C₂₋₂₀ alkynylene linker group any of which is optionally substituted with one or more R³;

wherein each R³ is independently halo, OR⁸ or NR⁸R⁹;

wherein each of R⁸ and R⁹ is independently H or C₁₋₄ alkyl;

R⁴ is C(O)OR¹⁰, OC(O)R¹⁰, C(O)NR¹⁰R¹¹, OR¹⁰, OSi(R¹³)₃, S(O)R¹⁰, SO₂R¹⁰, OSO₂R¹⁰,

15 SO₃R¹⁰, OSO₃R¹⁰, halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹), CH(R¹⁰)(OR¹¹), CH(SR¹⁰)(SR¹¹), NR¹⁰R¹¹, BR¹⁰R¹¹, C(O)CH₂N₂, -CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, CH(BR¹⁰R¹¹)₂, azide or a carboxylic acid mimetic group such as tetrazole;

wherein each R¹⁰ and R¹¹ is independently:

a. hydrogen;

20 or

b. C₁₋₂₀ alkyl, C₂₋₂₀ alkenyl or C₂₋₂₀ alkynyl, any of which is optionally substituted with one or more substituents selected from:

halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to

25 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂;

or

30 c. a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of

which is optionally substituted with one or more substituents selected from:

C_{1-6} alkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} and $N(R^{19})_2$;

or

5 d. a polyethylene glycol residue;

or

e. when R^4 is $C(O)NR^{10}R^{11}$, $CH(OR^{10})(OR^{11})$, $CH(R^{10})(OR^{11})$, $CH(SR^{10})(SR^{11})$, $NR^{10}R^{11}$, $BR^{10}R^{11}$, $CH[C(O)OR^{10}]_2$ or $CH(BR^{10}R^{11})_2$ an R^{10} and an R^{11} group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring;

10 wherein each R^{19} is independently:

H , C_{1-6} alkyl, C_{1-6} haloalkyl, or a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from halo, C_{1-6} alkyl and C_{1-6} haloalkyl;

15 and wherein each R^{13} is independently:

a. C_{1-20} alkyl, C_{2-20} alkenyl or C_{2-20} alkynyl, any of which is optionally substituted with one or more substituents selected from:

halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} , OSO_3R^{19} , $N(R^{19})_2$ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C_{1-6} alkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , SO_2R^{19} , SO_3R^{19} and $N(R^{19})_2$;

or

25 b. a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group either of which is optionally substituted with one or more substituents selected from:

C_{1-6} alkyl, C_{1-6} haloalkyl, halo, NO_2 , CN, OR^{19} , SR^{19} , $C(O)OR^{19}$, $C(O)N(R^{19})_2$, SO_2R^{19} , SO_3R^{19} and $N(R^{19})_2$;

wherein each R^{19} is independently:


30 H , C_{1-6} alkyl or C_{1-6} haloalkyl; or

Y and R^4 together form a $=CH_2$ group; and

R^5 is H , OH or a protected OH group;

the process comprising:

35 oxidation of a compound of general formula (II) using an oxidant and methyltrioxorhenium as catalyst:



or a salt or isotopic variant thereof

wherein R², R⁴, R⁵ and Y are as defined for compounds of general formula (I).

- 5 3. A process according to claim 1 or claim 2, wherein the methyltrioxorhenium is present in the reaction at 0.1-10 mol%, such as 0.1-5 mol%, 0.2-3 mol%, 0.5-1.5 mol%, about 1-2 mol% or about 1 mol%.
- 10 4. A process according to any one of claims 1 to 3, wherein the oxidant is hydrogen peroxide, a hydrogen peroxide adduct such as urea-hydrogen peroxide, or sodium percarbonate.
- 15 5. A process according to any one of claims 1 to 4, wherein up to 3 equivalents (per mole of compound of general formula (II)) of oxidant are typically used, for example up to 2 equivalents, such as up to 1.8 equivalents, up to 1.5 equivalents or up to 1.2 equivalents.
6. A process according to any one of claims 1 to 5, wherein the reaction is carried out in the presence of a ligand.
- 20 7. A process according to claim 6, wherein the ligand is a Lewis base.
8. A process according to claim 6, wherein the ligand is a moiety which is bound to the rhenium via 1 to 3 atoms of at least one element selected from oxygen and nitrogen, such that the 5- to 7- valency of rhenium is fulfilled.
- 25 9. A process according to any one of claims 6 to 8, wherein the ligand is 3-cyanopyridine, 4-cyanopyridine, 2-hydroxypyridine, 3-methyl pyridine, or 3-methyl pyrazole; especially 3-methyl pyrazole.
- 30 10. A process according to any one of claims 1 to 9, wherein the reaction solvent is selected from CH₂Cl₂, CHCl₃, toluene, CH₃CN, EtOAc, IPA, MIBK, nBuOAc and fluorinated solvents, and mixtures thereof.

11. A process according to claim 10, wherein the reaction solvent is selected from CH₂Cl₂, CH₃CN, EtOAc, IPA, MIBK, nBuOAc and a fluorinated solvent, and a mixture thereof.

5 12. A process according to any one of claims 1 to 11, wherein the reaction solvent comprises fluorinated solvent.

10 13. A process according to any one of claims 10 to 12, wherein the fluorinated solvent is selected from HFIP (hexafluoroisoproanol), TFE (2,2,2-trifluoroethanol), hexafluorobutanol, trifluorotoluene, hexafluorobenzene and the solvents sold under the trade mark Vertrel®.

14. A process according to any one of claims 10 to 13, wherein the fluorinated solvent is HFIP.

15

15. A process according to any one of claims 10 to 13, wherein the reaction solvent is a mixture of a fluorinated solvent and a non-fluorinated solvent, e.g. a mixture of HFIP and ethyl acetate or toluene.

20

16. A process according to any one of claims 1 to 15, wherein the reaction is carried out in the temperature range of about -10 °C to about 50 °C, such as about -5 °C to about 25 °C, about 0 °C to about 10 °C, about 0 °C to about 5 °C, about 0 °C to about 4 °C, about 0 °C to about 3 °C, about 0 °C to about 2 °C, about 0 °C to about 1 °C or about 0 °C.

25

17. A process according to claim 16, wherein the reaction is carried out in the temperature range of about 2 °C to about 8 °C.

18. A process according to any one of claims 1 to 17, wherein R² is H.

30

19. A process according to any one of claims 1 to 18, wherein Y is a bond or a C₁₋₃ alkylene or C₂₋₃ alkenylene linker group, either of which is optionally substituted with one or two R³ groups, wherein R³ is as defined in claim 1 or claim 2.

20. A process according to claim 19, wherein Y is -CH₂CH₂- or -CH=CH-.

35

21. A process according to any one of claims 1 to 19, wherein R³ is H, halo, OH, OC(O)R¹⁴, OSi(R¹⁶)₃, or NR⁸R⁹; wherein R¹⁴ is C₁₋₆ alkyl or phenyl; each R¹⁶ is

independently C₁₋₆ alkyl or phenyl; and each R⁸ and R⁹ is independently H, methyl, ethyl or *tert*-butoxycarbonyl.

22. A process according to any one of claims 1 to 21, wherein R⁴ is C(O)OR¹⁰, OR¹⁰,

5 C(O)NR¹⁰R¹¹, SO₃R¹⁰, or OSO₃R¹⁰.

23. A process according to any one of claims 1 to 21, wherein R⁴ is halo, CN, C(O)R¹⁰, CH(XR¹⁰)(XR¹¹), CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, BR¹⁰R¹¹ or Y and R⁴ together form a =CH₂ group.

10

24. A process according to claim 23, wherein R⁴ is halo, CN, C(O)R¹⁰, CH(OR¹⁰)(OR¹¹), CH=CH₂, -C≡CH, CH[C(O)OR¹⁰]₂, BR¹⁰R¹¹ or Y and R⁴ together form a =CH₂ group.

25. A process according to any one of claims 1 to 21, wherein R⁴ is C(O)OR¹⁰,

15 OC(O)R¹⁰, OR¹⁰, OSi(R¹³)₃, OSO₂R¹⁰, halo, CN, C(O)R¹⁰, NR¹⁰R¹¹, CH[C(O)OR¹⁰]₂, azide, C(O)NR¹⁰SO₂R¹¹ CH(XR¹⁰)(XR¹¹); phthalimide, tetrazole or substituted tetrazole.

26. A process according to any one of claims 1 to 25, wherein each R¹⁰ and R¹¹ is independently:

20 a. hydrogen; or

b. C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl, any of which is optionally substituted with one or more substituents selected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, OSO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂; or

25 c. a 6- to 10- membered aryl, 5- to 10-membered heteroaryl group or 3- to 10 membered heterocyclic ring, any of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹,

30 C=O, C(O)C₁₋₄ alkyl, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂, phenyl, 5- to 14- membered heteroaryl, 3- to 10- membered heterocyclic ring, methylenedioxy and ethylenedioxy; or

d. a polyethylene glycol residue; or

35 e. when R⁴ is C(O)NR¹⁰R¹¹, CH(XR¹⁰)(XR¹¹), CH(R¹⁰)(XR¹¹), NR¹⁰R¹¹ or BR¹⁰R¹¹, an R¹⁰ and an R¹¹ group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring.

27. A process according to any one of claims 1 to 25, wherein each R¹⁰ and R¹¹ is independently:

a. hydrogen; or

b. C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl, any of which is optionally substituted with 5 one or more substituents selected from:

halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹, OSO₃R¹⁹, N(R¹⁹)₂ and a 6- to 14- membered aryl or 5- to 14-membered heteroaryl group, either of which is optionally substituted with one or more substituents selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂; or

10 c. a 6- to 10- membered aryl or 5 to 10-membered heteroaryl group either of which is optionally substituted with one or more substituents one or more substituents selected from:

C₁₋₆ alkyl, C₁₋₆ haloalkyl, halo, NO₂, CN, OR¹⁹, SR¹⁹, C(O)OR¹⁹, C(O)N(R¹⁹)₂, SO₂R¹⁹, SO₃R¹⁹ and N(R¹⁹)₂; or

15 d. a polyethylene glycol residue; or

e. when R⁴ is C(O)NR¹⁰R¹¹, CH(OR¹⁰)(OR¹¹), CH(R¹⁰)(OR¹¹), CH(SR¹⁰)(SR¹¹), NR¹⁰R¹¹ or BR¹⁰R¹¹, an R¹⁰ and an R¹¹ group, together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring.

20 28. A process according to any one of claims 1 to 27, wherein R¹⁰ is hydrogen; or C₁₋₆ such as C₁₋₃ alkyl or C₂₋₆ such as C₂₋₃ alkenyl, either of which is optionally substituted with 6- to 14-membered aryl such as phenyl, especially C₁₋₆ alkyl or benzyl.

29. A process according to any one of claims 1 to 21, wherein R⁴ is C(O)OR¹⁰, OR¹⁰,

25 SO₃R¹⁰, OSO₃R¹⁰, halo, CN, C(O)R¹⁰, CH(XR¹⁰)(XR¹¹), CH[C(O)OR¹⁰]₂ or BR¹⁰R¹¹; and each R¹⁰ and R¹¹ is independently H, C₁₋₆ alkyl or benzyl; or,

when R⁴ is CH(OR¹⁰)(OR¹¹) or BR¹⁰R¹¹, R¹⁰ and R¹¹ together with the atom or atoms to which they are attached, may combine to form a 3- to 10-membered heterocyclic ring; or R⁴ is C(O)NR¹⁰R¹¹ substituted with C(O)OR¹⁹, OR¹⁹, SO₃R¹⁹, or OSO₃R¹⁹ and R¹⁹ is H.

30

30. A process according to claim 29, wherein X is O.


31. A process according to any one of claims 1 to 30, wherein R⁵ is H.

35 32. A process according to claim 1, wherein the compound of general formula (I) is: compound (IA): (6 α , 7 α , 22E)-6,7-epoxy-3-oxo-4,22-choladien-24-oic acid ethyl ester and

the compound of general formula (II) is compound (IIA): (22*E*)-3-oxo-4,6,22-cholatrien-24-oic acid ethyl ester, or

the compound of general formula (I) is compound (IB): (6 α , 7 α)-6,7-epoxy-3-oxo-4-cholen-24-oic acid ethyl ester and the compound of general formula (II) is compound (IIB): 3-oxo-4,6-choladien-24-oic acid ethyl ester.

33. A process for the preparation of a compound of general formula (XVIIia):



(XVIIIa)

10 wherein R¹ is C₁₋₄ alkyl, C₂₋₄ alkenyl or C₂₋₄ alkynyl optionally substituted with one or more substituents selected from halo, OR⁶ and NR⁶R⁷;

wherein each of R⁶ and R⁷ is independently H or C₁₋₄ alkyl;

R² is H, halo or OH;

R^{5a} is H or OH; and


15 Y¹ is a bond, or a C₁₋₂₀ alkylene linker group which is optionally substituted with one or more R³;

or Y^1 and R^4 together form a $=CH_2$ group;

wherein R³ and R⁴ are as defined for compounds of general formula (Ia) in claim 1;


20 the process comprising:

i. preparing a compound of general formula (Ia):



wherein Y , R^2 , R^4 and R^5 are as defined in claim 1;


25 by oxidation of a compound of general formula (IIa) using an oxidant and methyltrioxorhenium as catalyst:



wherein Y, R², R⁴ and R⁵ are as defined for compounds of general formula (Ia) in claim 1;

ii. selective alkylation of a compound of general formula (Ia) with an organometallic


5 reagent to give a compound of general formula (XIXa):



wherein R¹ is as defined for compounds of general formula (XVIIia) and Y, R², R⁴ and R⁵ are as defined for compounds of general formula (Ia) in claim 1;


10

iii. reducing a compound of formula (XIXa) using a suitable reducing agent to give a compound of general formula (XXa):



15 wherein R¹ and Y¹ are as defined for compounds of general formula (XVIIia) and R², R⁴ and R⁵ are as defined for compounds of general formula (Ia) in claim 1;


iv. oxidising the compound of general formula (XXa) using a suitable oxidizing agent to give a compound of general formula (XXIa):



20 wherein R¹ and Y¹ are as defined for compounds of general formula (XVIIia) and R², R⁴

and R⁵ are as defined for compounds of general formula (Ia) in claim 1;

v. epimerisation of the compound of general formula (XXIa) to give a compound of general formula (XXIIa):



5

(XXIIa)


wherein R¹ and Y¹ are as defined for compounds of general formula (XVIIia) and R⁴ is as defined for compounds of general formula (Ia) in claim 1;

R² is H or OH or a protected OH group which is stable under basic conditions; and

10 R^{5b} is H or OH or a protected OH group which is stable under basic conditions; and

vi. reduction of the compound of general formula (XXIIa) using a suitable reducing agent and, where R² and/or R^{5b} is a protected OH, removal of the protecting group(s), to give a compound of general formula (XVIIia), wherein removal of the protecting group can 15 take place before or after the reduction.

34. A process for the preparation of a compound of general formula (XVII):



(XVII)

20 wherein R¹ is C₁₋₄ alkyl optionally substituted with one or more substituents selected from halo, OR⁶ and NR⁶R⁷;

wherein each of R⁶ and R⁷ is independently H or C₁₋₄ alkyl;

R² is H, halo or OH;

R^{5a} is H or OH; and


25 Y¹ is a bond, or a C₁₋₂₀ alkylene linker group which is optionally substituted with one or more R³;

or Y¹ and R⁴ together form a =CH₂ group;

wherein R³ and R⁴ are as defined for compounds of general formula (I) in claim 2;

the process comprising:


- i. preparing a compound of general formula (I):



wherein Y, R², R⁴ and R⁵ are as defined in claim 2;

5


by oxidation of a compound of general formula (II) using an oxidant and methyltrioxorhenium as catalyst:



wherein Y, R², R⁴ and R⁵ are as defined for compounds of general formula (I) in claim 2;


10

- ii. selective alkylation of a compound of general formula (I) with an organometallic reagent to give a compound of general formula (XIX):



15 wherein R¹ is as defined for compounds of general formula (XVIII) and Y, R², R⁴ and R⁵ are as defined for compounds of general formula (I) in claim 2;


- iii. reducing a compound of formula (XIX) using a suitable reducing agent to give a compound of general formula (XX):



20 wherein R¹ and Y¹ are as defined for compounds of general formula (XVIII) and R², R⁴ and


R⁵ are as defined for compounds of general formula (I) in claim 2;

iv. oxidising the compound of general formula (XX) using a suitable oxidizing agent to give a compound of general formula (XXI):



wherein R¹ and Y¹ are as defined for compounds of general formula (XVIII) and R², R⁴ and R⁵ are as defined for compounds of general formula (I) in claim 2;

10 v. epimerisation of the compound of general formula (XXI) to give a compound of general formula (XXII):



wherein R¹ and Y¹ are as defined for compounds of general formula (XVIII) and R⁴ is as defined for compounds of general formula (I) in claim 2;

R² is H or OH or a protected OH group which is stable under basic conditions; and

R^{5b} is H or OH or a protected OH group which is stable under basic conditions; and

20 vi. reduction of the compound of general formula (XXII) using a suitable reducing agent and, where R² and/or R^{5b} is a protected OH, removal of the protecting group(s), to give a compound of general formula (XVIII), wherein removal of the protecting group can take place before or after the reduction.

35. The process according to claim 33, wherein the process further includes one or 25 more steps of converting compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) or (XVIIia) to other compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) or (XVIIia).

36. The process according to claim 34, wherein the process further includes one or

more steps of converting compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) or (XVIII) to other compounds of general formulae (I), (XIX), (XX), (XXI), (XXII) or (XVIII).

37. The process according to claim 35, wherein the one or more optional steps consist

5 of reacting the side chains of the compounds of general formulae (Ia), (XIXa), (XXa), (XXIa), (XXIIa) and (XVIIIA) to arrive at compounds with alternative Y and/or R⁴ moieties.

38. The process according to claim 37, wherein the one or more optional steps consist

of reacting the side chains of the compounds of general formulae (I), (XIX), (XX), (XXI),

10 (XXII) and (XVIII) to arrive at compounds with alternative Y and/or R⁴ moieties.

39. A compound of general formula (IIa) or formula (II) selected from:

(20S)-20-acetoxymethyl-pregna-4,6-dien-3-one (Example 20);

(20S)-20-hydroxymethyl-pregna-4,6-dien-3-one (Example 21);

15 (20S)-20-tertbutyldimethylsilyloxyethyl-pregna-4,6-dien-3-one (Example 22);

(20S)-20-formyl-pregna-4,6-dien-3-one (Example 23);

(20S)-20-(ethylenedioxymethyl)-pregna-4,6-dien-3-one (Example 24);

(20S)-20-(1-mesyloxymethyl)-pregna-4,6-dien-3-one (Example 25);

(20S)-20-(1-bromomethyl)-pregna-4,6-dien-3-one (Example 26);

20 23-carboxy-3-oxo-4,6-choladien-24-oic acid diethyl ester (Example 27);

3-oxo-4,6-choladieno-24-nitrile (Example 28);

(20S)-20-(1-aminomethyl)-pregna-4,6-dien-3-one (Example 29);

(20R)-20-(1-cyanomethyl)-pregna-4,6-dien-3-one (Example 30);

23-carboxy-3-oxo-4,6-choladien-24-oic acid dimethyl ester (Example 31);

25 (22E)-3-oxo-4,6,22-cholatrien-24-oic acid (Example 32);

N-((22E)-3,24-dioxo-4,6,22-cholatrien-24-yl)cyclopropylsulfonamide (Example 33);

N-((22E)-3,24-dioxo-4,6,22-cholatrien-24-yl)-4-(trifluoromethoxy)benzenesulfonamide

(Example 34);

(20S)-20-(5-Tosyltetrazol-1-yl)methyl-pregna-4,6-dien-3-one (Example 35); and

30 (20S)-(N-phthalimidomethyl)-pregna-4,6-dien-3-one (Example 36);

or a salt or isotopic variant thereof.

40. A compound of general formula (Ia) or formula (I) selected from:

(6 α , 7 α , 20S)-6,7-epoxy-20-hydroxymethyl-pregn-4-en-3-one (Example 37);

35 (6 α , 7 α , 20S)-20-(1-bromomethyl)-6,7-epoxy-pregn-4-en-3-one (Example 38);

(6 α , 7 α , 20S)-20-(1-mesyloxymethyl)-6,7-epoxy-pregn-4-en-3-one (Example 39);

(6 α , 7 α , 20S)-20-(1-tertbutyldimethylsilyloxyethyl)-6,7-epoxy-pregn-4-en-3-one

(Example 40);

(6 α , 7 α , 20S)-20-acetoxymethyl-6,7-epoxy-pregn-4-en-3-one (Example 41);

(6 α , 7 α , 20S)-6,7-epoxy-20-(ethylenedioxymethyl)-pregn-4-en-3-one (Example 42);

(6 α , 7 α)-23-carboxy-6,7-epoxy-3-oxo-4-cholen-24-oic acid dimethyl ester (Example 43);

5 (6 α ,7 α)-6,7-epoxy-3-oxo-4-cholen-24-nitrile (Example 44);

(6 α , 7 α , 20R)-20-(1-cyanomethyl)-6,7-epoxy-pregn-4-en-3-one (Example 45);

(6 α , 7 α , 20S)-6,7-epoxy-20-azidomethyl-pregna-4-en-3-one (Example 46);

N-((6 α , 7 α , 22E)-3,24-dioxo-6,7-epoxy-4,22-choladien-24-yl)cyclopropylsulfonamide (Example 47);

10 N-((6 α , 7 α , 22E)-3,24-dioxo-6,7-epoxy-4,22-choladien-24-yl)-4-

(trifluoromethoxy)benzenesulfonamide (Example 48);

(6 α ,7 α ,20S)-6,7-epoxy-20-(*N*-phthalimidomethyl)-pregna-4,6-dien-3-one (Example 49);

and

(6 α , 7 α , 20S)-20-(5-tosyltetrazol-1-yl)methyl-6,7-epoxy-pregna-4-en-3-one (Example 50);

15 or a salt or isotopic variant thereof.




FIG. 1
PART 1




FIG. 1
PART 2




FIG. 1
PART 3

4 / 4




FIG. 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2017/051389

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07J9/00 C07J71/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TOCHTROP G P ET AL: "Synthesis of [3,4-(13)c(2)]-enriched bile salts as NMR probes of protein-ligand interactions", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY ETC., vol. 67, no. 19, 20 September 2002 (2002-09-20), pages 6764-6771, XP002260968, ISSN: 0022-3263, DOI: 10.1021/J00259109 page 6768, scheme 5 -----	1-38
A	EP 1 985 621 A1 (MITSUBISHI CHEM CORP [JP]) 29 October 2008 (2008-10-29) page 65; example 30 ----- -----	1-38 -/-

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 June 2017	07/09/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Watchorn, Peter

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2017/051389

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-38

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-38

A process for the 6,7-epoxidation of steroidal 4,6-dien-3-one compounds using methyl rhenium trioxide as a catalyst.

2. claim: 39

Specific chemical intermediates being steroidal 4,6-diene-3-one compounds (claim 39)

3. claim: 40

Specific chemical intermediates being steroidal 6,7-alpha-epoxy-4-ene-3-one compounds (claim 40)

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2017/051389

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2006/122977 A2 (ERREGIERRE SPA [IT]; FERRARI MASSIMO [IT]; PELLICCIARI ROBERTO [IT]) 23 November 2006 (2006-11-23) cited in the application example 1 -----	1-38
A	SAROJ RANJAN DE ET AL: "Regio- and Stereoselective Monoepoxidation of Dienes using Methyltrioxorhenium: Synthesis of Allylic Epoxides", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 79, no. 21, 7 November 2014 (2014-11-07), pages 10323-10333, XP055383720, ISSN: 0022-3263, DOI: 10.1021/jo501958d entries 5,6; page 10327; table 4 -----	1-38
A,P	WO 2016/079517 A1 (DEXTRA LAB LTD [GB]) 26 May 2016 (2016-05-26) examples 12-17 -----	1-38

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/GB2017/051389
--

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 1985621	A1 29-10-2008	EP 1985621 A1 JP 2007210888 A KR 20080082980 A TW 200736271 A US 2010063272 A1 WO 2007080951 A1		29-10-2008 23-08-2007 12-09-2008 01-10-2007 11-03-2010 19-07-2007
WO 2006122977	A2 23-11-2006	AT 453657 T AU 2006248906 A1 CA 2608539 A1 CN 101203526 A DK 1888614 T3 EP 1888614 A2 ES 2338698 T3 JP 5127700 B2 JP 2008540612 A US 2008214515 A1 WO 2006122977 A2		15-01-2010 23-11-2006 23-11-2006 18-06-2008 10-05-2010 20-02-2008 11-05-2010 23-01-2013 20-11-2008 04-09-2008 23-11-2006
WO 2016079517	A1 26-05-2016	CA 2968309 A1 EP 3221331 A1 KR 20170086604 A TW 201632537 A WO 2016079517 A1		26-05-2016 27-09-2017 26-07-2017 16-09-2016 26-05-2016